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ABSTRACT
Diabetic neuropathy is characterised by neurodegeneration of peripheral sensory nerves, 
resulting in acute pain, sensory loss, and an increased risk of limb amputation. A clearer 
understanding of the mechanisms underlying the development and progression of diabetic 
neuropathy are likely to indicate new directions for the treatment of this complication of 
diabetes. A neuronal target for investigation is the endocannabinoid system. The aims of this 
project were to investigate whether the expression of cannabinoid (CB^ receptors was 
decreased under hyperglycaemic conditions, which may contribute to the pathogenesis and 
progression of diabetic neuropathy, and whether altered CB, expression led to a decrease in 
CBi signalling.
In a rat pheochromocytoma (PC12) cell line in vitro model of diabetic neuropathy, we found a 
reduction in total neurite length induced by nerve growth factor (50ng/ml) at 20-50mM glucose 
on day 6 (P<0.01 versus 5.5mM; n=70-79 from 6 independent cultures). This effect was due to 
raised glucose levels, used to mimic diabetic conditions, rather than any hyperosmolality 
effects since mannitol (50mM) gave similar results to that of the physiological 5.5mM glucose 
control (P=0.79). High glucose was associated with increased oxidative stress and a dose- 
dependent increase in IL-6 production (P<0.05).
The expression of CB! receptors significantly decreased in PC12 cells cultured in 
hyperglycaemic conditions (P<0.05; n=5 for each) which corroborated with the results from an 
in vivo model showing a similar decline in CB-i receptors in dorsal root ganglion neurons from 
diabetic rats (P<0.01; n=3 for immunohistochemistry, and n=5 for Western blot). Cell viability 
assays conducted in parallel on day 6 confirmed that the total cell numbers were not 
significantly different between the various glucose concentrations (P=0.50; n=6). These results 
suggest that high glucose concentrations are associated with decreased expression of CBi 
receptors in nerve cells.
We assessed CBi receptor function by measuring the inhibitory effect of the CB! receptor 
agonist HU210 on capsaicin-induced calcium influx in PC12 cells cultured in physiological and 
high glucose conditions. In fluo-4-loaded cells, capsaicin evoked an increase in fluorescence 
(«[CaHi) in a concentration-dependent manner. Application of the CB, agonist HU210 (1pM) 
significantly inhibited capsaicin-induced calcium influx (P<0.01), and this inhibitory effect of 
HU210 was reversed by co-application of the CB-i antagonist AM251 (1pM) but not the CB2 
receptor antagonist AM630 (1pM). At concentrations of HU210 below 1pM we observed a 
blunted inhibition of capsaicin-evoked calcium influx in cells cultured in high glucose. However, 
at concentrations >1pM HU210, the function of the CBi receptor was preserved, as evidenced 
by a similar degree of inhibition of capsaicin-evoked calcium influx in 5.5 and 50mM glucose 
conditions (61% versus 59%, respectively, n=30-50, from four independent cultures).
The synthetic CBi agonist, HU210 (0.03-30pM), was used in order to investigate CBi receptor- 
mediated ‘neurite rescue’ in PC12 cells. Addition of HU210 (0.03-3pM) had no significant effect 
on the total neurite length in PC12 cells cultured in 5.5mM glucose (P=0.168 versus the 
control/vehicle; n=148-220) while an increased total neurite length was found in cells cultured in 
50mM glucose in a concentration-dependent manner. The HU210 (IpM)-mediated rescue of 
neurite outgrowth could be blocked by AM251 (1pM) (P<0.05) but not by AM630 (1pM), 
confirming the role of CB-i receptors (n=131-208). In addition, HU210 significantly reduced high 
glucose-induced oxidative stress in PC12 cells via a CB^independent mechanism.
These results suggest that high glucose concentrations are associated with decreased 
expression, but preserved function of CB! receptors in nerve cells. Given the neuroprotective 
effect of cannabinoids, CB-i receptors may be an appropriate therapeutic target in preventing 
the neurodegenerative process in diabetes.
DECLARATION
I hereby declare that this submission is my own work and that, to the best of my 
knowledge and belief, it contains no material previously published or written by 
another person nor material which has been accepted for the award of any 
other degree or diploma of the university or other institute of higher learning, 
except where due acknowledgment has been made in the text.
Fan Zhang
ACKNOWLEDGEMENTS
First of all, I would like to offer my deep and sincere gratitude to my supervisor Dr 
Paula Smith for her guidance, patience and inspiration. Paula has supported me 
throughout my PhD study, and her wide knowledge and logical thinking have been of 
great value for me.
I would like to thank my second supervisor Professor Vicki Stone for her valuable 
advice, understanding and encouragement. I wish to thank Dr David Mincher for his 
review and advice for my transfer and progression reports.
A special thanks goes to all the people in the Biomedicine Research Group. They 
provided a welcome environment to make me never feel away from home. Dr David 
Brown’s technical help certainly facilitated my project. A warm thanks goes to my 
colleagues, especially Min Zhao and Helina Johnston, for their listening and 
understanding at good and bad times.
I would also like to thank Dr Shuangsong Hong at Michigan University for providing 
DRG samples and the advice for immunostaining, Dr David Wyllie and Dr Keith 
Finlayson at The University of Edinburgh for the use of an osmometer and the 
donation of PC12 cells, and Dr Edward Rowan at University of Strathclyde for the 
training of DRG dissection.
Finally, I would like to express my deep thanks to my family and friends, in particular, 
my parents for their never-ending support. I owe my loving thanks to my wonderful 
husband Haoying for always being there for me and believing in me. Without his 
encouragement and support, it would have been impossible to finish this work.
The financial support of Napier University and the Overseas Research Students Award 
Scheme is acknowledged.
LIST OF FIGURES i
LIST OF TABLES v
LIST OF ABBREVIATIONS . vi
CHAPTER 1: INTRODUCTION 1
1.1 Diabetes mellitus 2
1.1.1 The prevalence of diabetes 2
1.1.2 Types of diabetes 2
1.2 Diabetic neuropathy 4
1.2.1 Types of diabetic neuropathy 4
1.2.2 Diabetic Neuropathy and Sensory Neurons 7
1.2.3 Models of diabetic neuropathy 8
1.2.4 Potential Mechanism of Diabetic Neuropathy 10
1.3 The role of cytokines (lnterleukin-6) 14
1.4 The role of vanilloid receptors (TRPV1) 18
1.4.1 General introduction of TRPV1 receptors 18
1.4.2 The role of TRPV1 receptors in diabetic neuropathy 22
1.5 History of cannabis in medical use 24
1.6 The molecular biology of cannabinoid receptors 28
1.6.1 The discovery of cannabinoid receptors 28
1.6.2 The structure of CBi receptors 29
1.6.3 The distribution of CBt receptors 30
1.6.4 The mechanism of G protein-coupled CBi receptor action 31
1.6.5 The signal transduction of CBt receptors 32
1.6.6 The neuroprotective role of CBt receptor in nerve injury 36
1.7 Cannabinoids and pain control 38
1.7.1 The evidence of therapeutic effects of cannabinoids 38
1.7.2 Commercially available cannabinoids 45
CONTENTS
1.8 Regulation of the CE  ̂ receptor expression in neurodisorders 47
1.9 The role of CBi and its regulation with TRPV1 49
1.10 Aims and Hypothesis 50
CHAPTER 2: MATERIALS AND METHODS 51
2.1 Introduction 52
2.2 PC12 53
2.3 Experimental Animals 53
2.4 Preparation of varying glucose solution 54
2.5 Preparation of NGF solution 54
2.6 Plating PC12 cells 54
2.7 Morphology study (measurement of neurite length) 55
2.8 Oxidative stress study (GSH/GSSG estimation) 56
2.8.1 Introduction 56
2.8.2 Cell extraction 56
2.8.3 GSH assay 57
2.8.4 GSSG assay 57
2.9 Lactase Dehydrogenase (LDH) assay 58
2.10 MTT assay 58
2.11 Measurement of osmolality 59
2.12 Measurement of glucose concentration 59
2.13 Bradford protein assay 60
2.14 Enzyme Linked-lmmuno-Sorbent Assay (ELISA) 60
2.14.1 Introduction 60
2.14.2 Sample preparation 61
2.14.3 IL-6 examination 61
2.15 RT-PCR for detection of mRNA expression 62
2.15.1 RNA extraction 62
2.15.2 Two step RT-PCR reaction 63
2.15.3 Examination of PCR products 66
2.16 Real time PCR LightCycler 66
2.16.1 Introduction 66
2.16.2 Real time PCR reaction 67
2.17 Detection of expressed CE  ̂and TRPV1 receptor protein
in cultured PC12 cells 69
2.18 Detection of CB-i receptor protein associated with C/A5 fibres
in diabetic and control DRG samples 70
2.19 Ca2+ influx study 71
2.19.1 Introduction 71
2.19.2 Detection of intracellular Ca2+ increase 71
2.20 Western blotting: Preparation of cell lysate 75
2.21 Immunoprécipitation 76
2.22 Sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS PAGE) 78
2.23 Western Blotting 79
2.24 Immuno-detection of CBi receptors in Rat DRG 80
2.25 CB^mediated neuroprotection 80
2.26 Statistical analysis 81
CHAPTER 3: VALIDATION OF AN IN VITRO CELL MODEL
OF DIABETIC NEUROPATHY 82
3.1 Introduction 83
3.2 Determination of the time length for optimum
neurite outgrowth of PC12 cells 84
3.3 Validation of Metamorph™ methods on measuring neurite length 87
3.4 Effects of glucose on neurite outgrowth in PC12 cells 88
3.5 Effects of glucose on oxidative stress in PC12 cells 93
3.6 Effects of glucose on cell viability in PC12 cells 94
3.7 Effects of glucose on cell proliferation in PC12 cells 96
3.8 Effects of glucose on interleukin-6 (IL-6) production 98
3.9 Discussion 99
CHAPTER 4: AN INVESTIGATION OF THE CANNABINOID
CB-, RECEPTOR EXPRESSION IN HYPERGYCAEMIC 
PC12 CELLS AND DIABETIC RATS 105
4.1 Introduction 106
4.2 CBi mRNA down-regulation induced by high concentration of KCI 107
4.3 The effect of glucose on CBt gene expression in an in vitro cell model 109
4.3.1 Conventional RT-PCR 109
4.3.2 Real time-PCR 113
4.4 The cannabinoid CBt protein expression in
hyperglycaemic PC12 cells and DRG neurons from diabetic rats 116
4.4.1 In vitro cell model 116
4.4.1.1 Immunocytochemistry 116
4.4.1.2 Western blotting and immunoprecipitate 118
4.4.2 In vivo model 121
4.4.2.1 Optimisation of immunohistochemistry on
formalin fixed paraffin embedded tissue samples 121
4.4.2.2 Immuno-detection of CBi protein expression
in DRG neurons from control and diabetic rats 123
4.4.2.3 Immuno-detection of the co-expression of CBi receptors
and C fibres in DRG neurons from control and diabetic rats 126
4.5 Discussion 128
CHAPTER 5: AN INVESTIGATION OF THE EFFECT OF GLUCOSE
ON CANNABINOID RECETPOR FUNCTION 132
5.1 Introduction 133
5.2 Optimization of parameters for Ca2+ imaging assay
with confocal microscopy 135
5.3 Ca2+ influx triggered by Capsaicin (1pM) 137
5.4 Capsaicin concentration-response curve 140
5.5 Ca2+ influx triggered by capsaicin (300pM) 142
5.6 The inhibitory effect of capsazepine on Ca2+ influx induced by capsaicin 144
5.7 Inhibitory effect of cannabinoid agonist HU210 on calcium influx
is mediated by CBt receptors, not by CB2 receptors 146
5.7.1 Concentration-response curve of inhibitory effect
of HU210 on Ca2+ influx 146
5.7.2 The effect of a selective CBt receptor antagonist
on HU210 responses 147
5.7.3 The inhibition of Ca2+ influx by HU210 (1 pM) 150
5.7.4 The effect of a selective CB2 antagonist on HU210 responses 154
5.8 Discussion 156
CHAPTER 6: THE NEUROPROTECTIVE EFFECT OF A
CANNABINOID CBA RECEPTOR AGONIST IN VITRO 160
6.1 Introduction 161
6.2 The treatment of PC12 cells with a cannabinoid receptor agonist 163
6.2.1 Concentration response - relationship of HU210 on cell growth 163
6.2.2 The effect of HU210 on neurite outgrowth 166
6.2.3 The protective effect of HU210 on oxidative stress
caused by high glucose 168
6.3 The co-application of a selective cannabinoid
CB ì receptor antagonist 170
6.3.1 Concentration-response relationship of
AM251 (3pM) on cell growth 170
6.3.2 Neurite outgrowth affected by the co-application
of AM251 (3pM) and HU210 173
6.3.3 The effect of the co-treatment of AM251 and HU210
on oxidative stress induced by high glucose 176
6.4 The co-application of a cannabinoid CBt antagonist
AM251 (1pM) or/and a CB2 antagonist AM630 (1pM) 178
6.4.1 Cell viability following treatment with AM251 (1pM)
and/or AM630 (1pM) with HU210 178
6.4.2 Neurite outgrowth following the co-application with
AM251 (1 pM) and/or AM630 (1 pM) 179
6.5 Discussion 182
CHAPTER 7: GENERAL DISCUSSION 186
7.1 General discussion 187
7.2 Conclusions 203




Figure 1.1 Metabolic pathways of hyperglycaemia underlying oxidative stress 12
Figure 1.2 The effects of neuroprotection and neurodegeneration
induced by IL-6 signal transduction in synergism with NGF 17
Figure 1.3 Vanilloid structures: capsaicin, resiniferatoxin and anandamide 
are TRPV1 receptor agonists; capsazepine is a TRPV1 
receptor antagonist 21
Figure 1.4 TRPV1 functions as an integrator of noxious stimuli 21
Figure 1.5 Cannabis sativa which contains chemicals called
cannabinoids which produce the "high" effect / mental 
+ physical effects when utilized 25
Figure 1.6 Two-dimensional structure of the human hCBi receptor 30
Figure 1.7 The mechanism of G protein-coupled receptor action 32
Figure 1.8 The signalling pathways emanating from CBi/Gai/0 35
Figure 1.9 Cannabinoid structures: A9-THC, CBD, WIN 55, 212-2,
HU-210, ACEA, CP-55,940, SR141716A, 0-1057, AA-DA, CT-3 44
Figure 2.1 Flow diagrams showing the procedure of Ca2+ imaging study used
to investigate the inhibitory effect of CBt agonists on Ca2+ influx 74
Figure 2.2 Flow diagram showing the immunoprécipitation method used prior
to western blotting to detect CBï receptor expression in PC12 cells 77
Figure 3.1 The effect of glucose on neurite outgrowth in PC12 cells in the
presence of nerve growth factor (50ng/ml) on day 4, 6, 8 86
Figure 3.2 The correlation between manual measurement and digital
quantitative analysis software measurement on neurite outgrowth
in PC12 cells growth in the presence of nerve growth
factor (50ng/ml) on day 6 87
Figure 3.3 Representative photomicrographs showing the effect of
increasing glucose concentration on neurite outgrowth in PC12
cells grown in the presence of nerve growth factor (50ng/mL) 89
Figure 3.4 The effect of glucose on neurite outgrowth in differentiated PC12 cells 90
Figure 3.5 Measurements of glucose concentrations in the aspirated
medium following 2 days in culture, either in plates containing
no cells, or those plated with 1x105 PC12 cells/ml 92
Figure 3.6 The effect of glucose on oxidative stress in differentiated PC12 cells 93
Figure 3.7 Mean concentration of lactase dehydrogenase release from PC12 
cells stimulated with NGF (50ng/ml) and in the absence/presence of
high glucose (30 and 50mM) on day 2, 4 and 6 of culture 95
Figure 3.8 Cell viability of PC12 cells cultured in an increasing
concentration of glucose (5.5, 10, 20, 30, 40, 50mM) under
the stimulation of NGF (50ng/ml) for 6 days 95
Figure 3.9 The effect of glucose on cellular protein levels in PC12 cells 97
Figure 3.10 The effect of glucose on cell density in PC12 cells 97
Figure 3.11 The effect of glucose on interleukin-6 production 98
Figure 4.1 Reverse transcription-PCR analysis of the effect of potassium
choride on CBi cannabinoid receptor mRNA expression in PC12 cells 108
Figure 4.2 Reverse transcription-PCR analysis of the effect of glucose
on CBi cannabinoid receptor mRNA expression in PC12 cells 110
Figure 4.3 Reverse transcription-PCR analysis of the effect of glucose
on CBi receptor mRNA expression in PC12 cells 112
Figure 4.4 Real time-PCR analysis of the CBi receptor
mRNA expression in rat brain 114
Figure 4.5 Representative real time-PCR analysis of the
CBt receptor mRNA expression in PC12 cells 115
Figure 4.6 Confocal and Western analysis of CBi receptor expression in
differentiated PC12 cells cultured in variable glucose concentrations 117
Figure 4.7 Western blot analysis confirmed the reduction of CBi
receptor protein in cells cultured in high glucose 119
Figure 4.8 Immunoprecipitate analysis of phosphorylation of CBi receptors
in PC12 cells cultured in 50mM glucose versus controls (5.5mM) 120
Figure 4.9 Confocal detection of the colocalisation of cannabinoid CBi
receptors, and A or C fibres in human mid-brain 122
Figure 4.10 Confocal analysis of CBi protein expressed in rat DRG 124
Figure 4.11 Western blot analysis of CBt receptor expression in rat DRG 125
Figure 4.12 Confocal analysis of co-localisation of CQ̂  protein and
C fibre in rat DRG neurons 127
Figure 5.1 Ca2+ influx induced by the addition of KCI and Thapsigargin 136
Figure 5.2 Inhibition of the response of Ca2+influx to capsaicin in the presence
of HU210 in PC12 cells cultured in 50mM glucose for 6 days 139
Figure 5.3 Concentration-response curve to the TRPV1 receptor
agonist capsaicin 141
Figure 5.4 Representative traces showing changes in fluo-4 fluorescence induced
by capsaicin (Cap, 300 pM) and potassium chloride (KCI, 70mM) 143
Figure 5.5 Capsazepine blocks capsaicin evoked Ca2+entry in PC12 cells 145
Figure 5.6 Concentration-response curves of the inhibitory effect of
HU210 on capsaicin evoked Ca2+ influx in PC12 cells 146
Figure 5.7 Representative traces showing changes in fluo-4 fluorescence 
induced by capsaicin (Cap, 300pM) and potassium chloride 
(KCI, 70mM), in the presence of HU210 (30pM) or with 
the co-application of AM251 (30pM) 148
Figure 5.8 HU210 inhibits capsaicin-evoked responses in PC12 cells
in the presence of HU210 (30pM) 149
Figure 5.9 Representative traces showing changes in fluo-4 fluorescence induced 
by capsaicin (Cap, 300pM) and potassium chloride (KCI, 70mM), 
in the presence of HU210 (1pM) or with the co-application 
of AM251 (1 pM), for 5.5mM glucose and 50mM glucose 152
Figure 5.10 HU210 inhibits capsaicin-evoked responses in PC12 cells 153
Figure 5.11 The CB2 antagonist AM630 is unable to reverse the inhibitory
effect of HU210 on Ca2+ influx triggered by capsaicin 155
Figure 6.1 Mean concentration of lactate dehydrogenase release from 
PC12 cells stimulated with NGF (50ng/ml) and in the 
absence/presence of high glucose (50mM) when treated with 
HU210 (0 -  30pM) on day 2, 4 and 6 of culture 164
Figure 6.2 Cell viability of PC12 cells treated with HU210 (0 -  3pM) 165
Figure 6.3 CBt agonist treatment promotes neurite outgrowth in PC12 cells 168
Figure 6.4 A CBi agonist has no significant impact on oxidative stress
in differentiated PC12 cells 169
Figure 6.5 Mean concentration of lactase dehydrogenase
release from PC 12 cell 171
Figure 6.6 Cell viability of PC12 cells treated with the combination of a selective
CBt antagonist AM251 (3pM) with a CBt agonist HU210 (0 -  3pM) 172
Figure 6.7 The representative pictures showing the neurite outgrowth in 
PC12 cells cultured in combination of AM251 and HU210 in 
the presence of high glucose 175
Figure 6.8 The co-application of AM251 and HU210 affects
neurite outgrowth in PC12 cells 176
Figure 6.9 The effect of CBi antagonists on oxidative stress in differentiated
PC12 cells with/without HU210 177
Figure 6.10 Cell viability of PC12 cells treated with the combination of
HU210 (0.3pM) with AM251 (1 pM) or/and AM630 (1 pM) 178
Figure 6.11 The representative photomicrographs show the neurite outgrowth 
in PC12 cells cultured in control medium, vehicle medium and 
the medium supplemented with HU210 180
Figure 6.12 HU210 promotes neurite outgrowth in a CBr dependent manner 181
Figure 7.1 The route of the experimental design 189
Figure 7.2 Mechanisms involved in development and progression
of diabetic neuropathy 194
Figure 7.3 Representative traces showing the increase in sensory
discharge from perivascular nerves in response to capsaicin
(c; 0.3 nmoles i.a.) in an anaesthetised rat 206
IV
LIST OF TABLES
Table 1.1 Cannabinoids as novel therapeutic agents 46
Table 2.1 The volume of reagents required to prepare one reaction and
master mix for reverse transcription 64
Table 2.2 The volume of reagents required to prepare one reaction and
master mix for PCR amplification 64
Table 2.3 Time and temperature scale for PCR thermal cycle reaction 65
Table 2.4 The volume of reagents used to prepare one reaction and a master
mix for real time PCR 67
Table 2.5 Time and temperature scale for PCR light cycler reaction 68







AGE Advanced glycosylation end product
ATP Adenosine-5'-triphosphate
ATPase Adenosine triphosphatase
BSA Bovine serum albumin
+CMCOO Calcium
cAMP Cyclic adenosine monophosphate
CB-i Cannabinoid receptor 1
CBD Cannabidiol
cDNA Cyclic deoxyribonucleic acid
CGRP Calcitonin gene related peptide
CNTF Ciliary neurotrophic factor
Cpu Caudate putamen
CPZ Capsazepine
CT-3 T, T-dimethylheptyl-A8-tetrahydrocannabinol-11-oic acid
CTLA-4 Cytotoxic T lymphocyte antigen 4
dH20 Distlled water




DRG Dorsal root ganglion
DTT Dithiothreitol
ECL Enhanced Chemiluminescence


































Enzyme Linked-lmmuno-Sorbent Assay 
Extracellular signal-regulated kinase 
Fluorescein isothiocyanate 
Guanine nucleotide binding proteins 
Glyceraldehyde-3-phosphate dehydrogenase 
Guanosine diphosphate 
L-y-glutamyl-L-cysteinylglycine, reduced from 
L-y-glutamyl-L-cysteinylglycine, oxidised form 














Mitogen activated protein kinase
Messenger ribonucleic acid
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Nicotinamide adenine dinucleotide (reduced)









PBS Phosphate buffered saline
PBST PBS Tween
PC12 Pheochromocytoma cells
p g i2 Prostacyclin
PKC Protein kinase C
PPAR Peroxisome proliferator-activated receptor alpha
RAGE AGE receptors
RIPA Radiolmmuno precipitation assay
ROS Reactive oxygen species
RPMI Roswell Park Memorial Institute medium
RT-PCR Reverse transcription-polymerase chain reaction
RTX Resiniferatoxin
SDS PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
STAT Signal transducer and activators of transcription
STZ Streptozotocin
TBE Tris-Borate-EDTA
a 9-th c Delta 9-tetrahydrocannabinol
TMB Tetramethylbenzidine
TNF-a Tumour necrosis factor-a
UV Ultraviolet-Visible
VMH Entromedial hypothalamus





1.1.1 The prevalence of diabetes
Over past few decades, diabetes has become one of the major public health 
burdens worldwide. The enormous economic growth in developing countries is 
associated with the greatest increase in the occurrence of diabetes (Amos, 
1997; King and Rewers, 1993). Globally, the number of adults with diabetes is 
estimated to rise from 171 million in 2000 to 366 million in 2030, and men and 
woman are at equal risk of diabetes (Wild et al., 2004). Surprisingly, in 
developing countries, the number of young people with diabetes (24-44 years) 
is estimated to increase to more than double in the next 30 years, which is the 
same as the growth rate in older people with diabetes (45-64 and >65 years). 
In contrast, in developed countries, the diabetic prevalence is mainly in people 
> 45 years old, and the majority of those with diabetes are >64 years of age 
(Wild et al., 2004). In the UK, at least 2.3 million people have been diagnosed 
with diabetes (Diabetes UK website http://www.diabetes.org.uk).
1.1.2 Types of diabetes
Diabetes mellitus is a group of metabolic disorders characterized by a high
blood glucose level (hyperglycemia), which results from absent or insufficient
production of, or response to, insulin. Insulin is the principal hormone produced
by beta cells in the pancreas in response to rising levels of glucose in the blood,
as occurs after a meal. Under normal conditions, insulin regulates uptake of
glucose from blood into cells by promoting the translocation of glucose
transporter proteins (e.g. GLUT4) into the plasma membrane, which facilitate
the diffusion of glucose into the insulin-responsive cells of muscle, liver and
adipose tissue (Watson and Pessin, 2001). Once inside the cell, glucose
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undergoes cellular respiration to produce ATP, or is converted to other useful 
molecules, such as glycogen. If the pancreas no longer produces insulin, or 
cells stop responding to insulin, the excessive glucose cannot be removed from 
blood, resulting in persistent hyperglycemia, poor protein synthesis and 
metabolic disarrangement (Mathur etal., 2005).
There are two types of diabetes mellitus, type 1 and type 2. Type 1, also called 
juvenile diabetes mellitus, is most commonly diagnosed in childhood and 
adolescence with a fairly abrupt onset. In this type of diabetes, the pancreas 
produces little or no insulin because the insulin-producing p cells in the islet of 
Langerhans are destroyed by an autoimmune response. These patients may 
require several insulin injections during the day to keep blood glucose level 
normal (Campbell et al., 2005). The genetic susceptibility is associated with 
human leukocyte antigen (HLA) on chromosome 6, shorter forms of a variable 
number tandem repeat of insulin gene on chromosome 11, and cytotoxic T 
lymphocyte antigen 4 (CTLA-4) (Ueda et al., 2003). All these important 
susceptibility genes for type 1 diabetes facilitate the presentation of pro-insulin 
antigen to T cells and result in T cell activation (Gillespie, 2006). In addition, 
increasing environmental pressure is also identified to impact on genetic 
susceptibility for type 1 diabetes. For instance, virus infection could put infants 
at very high risk of type 1 diabetes, exposure to microbes and other pathogens 
in early life has been shown to promote innate immune response and 
development of atopic and autoimmune disorders (Gillespie, 2006).
Type 2 is the most common form of diabetes mellitus, typically affecting adults 
over 40 years. The symptoms are milder than that of type 1 because of its slow
onset, so that type 2 may not be noticed for years in patients before diagnosis
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(Votery et al., 2005). This form of diabetes mellitus is characterized by ‘insulin 
resistance’ as cells respond inappropriately to the insulin produced, combined 
with reduced insulin secretion. The level of insulin receptors expressed on cell 
membranes is certainly related to the defective responsiveness of body tissue 
to insulin (Michael et al., 2000, Trischitta et al., 1997). Since insulin is still 
produced at the early stage, type 2 diabetes can be controlled by improving 
insulin sensitivity and reducing glucose production by the liver, using drugs 
such as thiazolidinediones and metformin (Bolen et al., 2007). However, as a 
consequence of uncontrolled type 2 diabetes, insulin injection becomes 
necessary. Central obesity is a common cause of insulin resistance: 90% of 
type 2 diabetics have the problem of obesity (McTernan et al., 2002). Although 
both type 1 and type 2 diabetes are partially inherited, those with type 2 family 
histories are believed to have a higher chance of developing type 2 diabetes 
(Stumvoll et al., 2005).
1.2 Diabetic neuropathy
1.2.1 Types of diabetic neuropathy
Diabetic neuropathy is a common complication of diabetes, resulting from 
sustained hyperglycaemia. It virtually affects every type of neuron fibre in the 
body, including sensory, autonomic and motor neurons, and causes significant 
morbidity and mortality in diabetic patients (Duby et al., 2004). A 
comprehensive collection of epidemiological studies reveals that diabetic 
neuropathy affects 50% of diabetic patients and occurs at same frequency in 
type 1 and type 2 diabetes; this percentage approaches 100% if subclinical 
non-symptomatic neuropathy is included (Vinik et al., 2006).
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Diabetic neuropathy is classified by the nerve fibre affected, and includes 
peripheral sensory neuropathy, autonomic neuropathy and focal neuropathy 
(Vinik, 2004; Duby et al., 2004). Distal symmetrical sensory polyneuropathy is 
the most common form of diabetic neuropathy, affecting both large and small 
afferent nerve fibres. It is characterized by neurodegeneration of peripheral 
sensory nerve endings (“dying-back” of distal axons), which results in acute 
pain and eventual sensory loss, impairment of warm thermal perception, and 
attenuated skin blood flow in diabetic patients (Said et al., 1983; Said, 2007). 
Sensory impairment can result in injurious tissue damage, for example to the 
sole of the foot, which, when coupled with peripheral vascular disease and 
reduced blood flow, creates an ulcer which easily becomes infected. 
Gangrenous foot ulcers are associated with a high risk of limb amputation 
(Jeffcoate and Harding, 2003). In the UK, more than 5000 people with diabetes 
have amputation per year and people with diabetes are 15% more likely to 
have amputation than those without diabetes (NHS Diabetes foot guide 
http://www.diabetes.nhs.uk/downloads/NDST_Diabetic_Foot_Guide.pdf).
Diabetic autonomic neuropathy is a serious and key cause of morbidity and
mortality in diabetes. Cardiovascular autonomic neuropathy occurs in 15% of
type 1 and 20% of type 2 diabetic patients (Vinik et al., 2006). The mortality
rate in diabetic patients with cardiovascular complications is 22% higher than
those without cardiovascular complications in 10 years scope (Ziegler, 1999).
Cardiovascular autonomic neuropathy affects both the sympathetic and
parasympathetic innervation of the heart and coronary vessels, resulting in
cardiovascular dysfunction, myocardial infarction, orthostatic hypotension and
sudden death. In addition, diabetic autonomic dysfunction also affects the
entire gastrointestinal and genitourinary system. The people with these two
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types of autonomic neuropathy may suffer sever constipation, diarrhoea, faecal 
incontinence, sexual dysfunction and urinary incontinence, which significantly 
influence quality of life (Duby et al., 2004).
Focal and multifocal neuropathy is less common compared to other forms of 
neuropathy in diabetic patients, and is usually seen in elderly people with type 
2 diabetes (Vinik et al., 2006). It is characterized by sensorimotor deficit in 
territories of one or several nerve trunks, roots and plexus, leaving the muscle 
weak or in pain. Diabetic focal neuropathy affects cranial, limb, truncal and 
proximal nerves, causing inability of focus, double vision, aching behind the eye, 
limit of mobility, paralysis and pain throughout the body (Said, 2007; Vinik et al., 
2006).
Diabetic neuropathy is associated with high risk factors for macrovascular and 
microvascular complications, such as poor metabolic control, dyslipidaemia, 
smoking, microalbuminuria and retinopathy, due to their physiological co­
dependency. Blood vessels depend on neural regulation to maintain their 
functions, and neurons depend on blood vessels to obtain nutrients. Early in 
diabetic neuropathy, the balance between vasodilatation and vasoconstriction 
is altered in favour of the latter, resulting in decreased blood flow and increased 
vascular permeability. This is reflected by the vulnerable vascular endothelium 
and deficit of major vasodilators, nitric oxide (NO), endothelium-derived 
hyperpolarising factor (EDHF) and prostacyclin (PGI2). Hyperglycaemia may 
also cause decreased neurotrophic support. Taken together, all these changes 
lead to hypoxia, reduced nerve blood flow and ischaemia in the nervous system, 
contributing to the progression of diabetic neuropathy (Cameron et al., 2001; 
Brownlee, 2001).
6
1.2.2 Diabetic Neuropathy and Sensory Neurons
Among these diabetic complications, sensory neurons are likely to be involved 
first. Unfortunately, loss of sensory neurons may become irreversible at later 
stages of the complication. The early sign of sensory neuropathy is pain in the 
toes and in the fingers, which are innervated by the longest sensory nerves in 
the body; the longer the nerve axon, the more likely it, and its terminals, will be 
targeted by hyperglycemic insults. In addition, the damaged perikaryon (the cell 
body of a neuron) fails to supply structural components to the most distal 
terminals (Toth etal., 2004).
Sensory nerves can be divided into several subpopulations based on their 
neurochemistry, anatomy, and physiology. The majority of small diameter 
unmyelinated C-fibres and thinly myelinated AS-fibres are nociceptive, and 
constitutively express the neuropeptides, calcitonin gene related peptide 
(CGRP) and substance P, as well as the nerve growth factor (NGF) receptors, 
trkA and p75 (Lawson, 2002). The cell bodies of these fibres are located in the 
dorsal root ganglion (DRG), with central terminals in laminae I and II of the 
superficial dorsal horn and peripheral terminals in tissues (e.g. muscle, joint 
and skin). In diabetic patients small fibre (C and A5) neuropathy is responsible 
for the early hyperalgesia (excessive sensitivity to pain caused by noxious 
stimuli) and allodynia (exaggerated pain caused by non-noxious stimuli), and 
the late hypoalgesia (decreased sensitivity to pain stimuli), impairment of warm 
thermal perception and skin blood flow. C-fibres are thought to be the initial 
class of nerves to be affected in diabetic neuropathy: a study in patients with 
type 2 diabetes found axon-reflex mediated vasodilatation to be impaired at an 
earlier stage of diabetes than autonomic nerve and endothelial dysfunction 
(Stansberry et a!., 1999).
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1.2.3 Models of diabetic neuropathy
Intensive research has focused on studying the pathogenesis of diabetic 
neuropathy using in vivo models. Experimental diabetes is commonly induced 
by injecting adult rats or mice with the beta-cell toxins, alloxan or streptozotocin, 
to destroy the function of insulin production, thus creating a hyperglycaemic 
condition (Calcutt, 2004). In non-diabetic human, normal blood glucose levels 
are between 4 and 7mM before meals (fasting levels), and less than 10mM 
after meals. Diabetes is typically diagnosed when fasting blood glucose levels 
are 7mM or higher (www.netdoctors.co.uk). In contrast, the rat diabetic model 
showed a 5-fold elevation in plasma glucose compared to controls, and these 
levels would fluctuate throughout the animals’ lives. Others have reported 
plasma glucose levels in the STZ-diabetic rat range from 25 - 50mM (mean 
34.5 ± 3.05mM) compared to controls (5.91 ± 0.54mM) (Purves etal., 2001).
The sustained blood glucose level eventually triggers the occurrence of 
peripheral neuropathy, which is expressed as hypersensitivity to painful or non- 
painful sensory stimuli (Cole, 2007). Behavioural tests are the most commonly 
used screening methods: e.g., measuring the time for withdrawal of a limb, 
such as the tail or a paw, from a noxious heat or a non-noxious light touch by 
von Frey filaments (Calcutt, 2004). A shorter latency in the diabetic models 
illustrates hyperalgesia or allodynia, which is manifest in diabetic patients. In 
these in vivo models of diabetic neuropathy, hyperglycaemia is demonstrated 
to slow nerve conduction velocity (Malone et al., 1996), decrease axonal 
transport of structure protein (Jakobsen and Sidenius, 1980) and initiate 
neuronal apoptosis (Barber et al., 1998; Russell and Feldman, 1999; Vincent et 
al., 2002).
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Numerous in vitro cell models have been previously used to study the cellular
mechanisms involved in the pathophysiology of diabetes, such as cultured
vascular endothelial cells (Baumgartner-Parzer et a i; 1995; Doyle et al., 1997),
fibroblasts (Reenstra et al., 1999; Atkin et al., 1996) and kidney cells (Ortiz et
al., 1997). In these cell models of diabetes, hyperglycemia is simulated by
addition of glucose to the culture medium. Most notably, cultured DRG is one of
few neuronal cell models which have been used to study the effect of
hyperglycaemia on neuronal functions. Some studies have reported that
hyperglycaemia (0-300mM above controls 25-30mM) reduces neurite extension
in cultured rat DRG neurons which is correlated with increased oxidative stress
and apoptosis (Russell and Feldman, 1999, Sotelo et al., 1991; Vincent et al.,
2005 ). Human neuroblastoma SH-SY5Y cells have also been used as an in
vitro model to test the effect of hyperglycaemia on nerve function. Li et al.
(2003) reported that administration of insulin/C-peptide can significantly
stimulate cell proliferation and prevent apoptosis in SH-SY5Y cells cultured in
the presence of high glucose (100mM versus control 25mM) (Li et al., 2003).
Recently, the neural-crest derived pheochromocytoma cells (PC12) was
established as an in vitro cell model of diabetic neuropathy by Lelkes and
colleagues (Lelkes et al., 2001). With the most similarity to primary neurons,
undifferentiated PC12 cells proliferate like embryonic neurons. However, in the
presence of nerve growth factor (NGF), the attached PC12 cells cease their
proliferation and start extending neurite branches like adult neurons. In addition,
the nature of neurotransmitter secretion such as catecholamines makes PC12
cells an ideal neuronal cell model to study neuronal differentiation and
neurotransmitter release. In the study by Lelkes et al. (2001) the high glucose
(25mM versus the control 5mM) treated PC12 cells reproduced some of the
phenomena of diabetic neuropathy: impaired neurite extension, increased
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oxidative stress, apoptosis and upregulated neurotransmitter release, which are 
all implicated in contributing to the pathogenesis of diabetic neuropathy.
1.2.4 Potential Mechanism of Diabetic Neuropathy
The pathogenesis of diabetic neuropathy is complex and involves multiple 
pathways (Skundric and Lisak, 2003). The oxidative stress resulting from 
hyperglycaemia is believed to be a major factor involved in the development 
and progression of macro- and micro-vascular complications associated with 
diabetes, including peripheral neuropathy (Feldman, 2003).
Oxidative stress occurs in a cell or tissue when antioxidants such as 
glutathione (GSH) fail to deplete excessive free radicals generated. Free 
radical species are normally produced in the body during metabolic activity, 
such as superoxide (O2'), hydrogen peroxide (H2O2) and nitric oxide (NO). 
These three reactive oxygen species (ROS) are essential for maintaining 
normal physiology. However, they are also believed to be the mediators of 
aging and cellular degeneration in diabetic and other diseased states by 
producing highly active singlet oxygen (0-), hydroxyl radicals (HO-), and 
peroxynitrite (ONOO-) (Lee et a/., 2003; Vincent et at., 2004). The products of 
these ROS can damage protein, lipid and DNA, resulting in decreased 
biological functions including loss of energy metabolism, transport, cell 
signalling and other major functions. Accumulation of such injuries eventually 
leads to cell loss through necrotic or apoptotic pathways (Vincent et at., 2004). 
For example, the individual O2' and NO can attack iron-sulphur centres of 
enzymes and other proteins, and consequently inhibit protein/enzyme activity. 
Furthermore, when they interact, the product of the highly reactive peroxynitrite 
attacks and inhibits proteins and lipids. Many proteins involved in the
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mitochondrial electron transport chain, aconitase of the trichloroacetic acid 
cycle, and biotin synthase are extremely sensitive to this type of inhibition 
(Brown and Borutaite, 1999; Andersson et al., 1998 ). End products of lipid 
peroxidation (malondialdehydes) can be toxic to cells and require removal by 
GSH that has dramatically decreased under chronic hyperglycaemic conditions 
(Hayes and McLellan, 1999; Dave and Kalia, 2007). In addition, accumulation 
of modified protein accounts for the decreased axonal transport, leading to 
impaired delivery of nerve growth factor and intermediates from tissue to cell 
bodies, resulting in induction of nerve degeneration and apoptosis (Metodiewa 
and Koska, 2000). Gene expression is tightly regulated in healthy cells. 
Oxidative modification of transcription factors can cause the imbalance 
between control protein and stress protein expression, leading to decreased 
apoptosis inhibition factors such as complex I, and increased apoptotic proteins 
such as c-Jun N-terminal kinase (JNK kinase) (De La Monte et al., 2000; Conn 
et al., 2001; Paschen et al., 2001; Pugazhenthi etal., 2003 ).
Recent studies on measurement of oxidative stress in sensory neurons as well 
as neuronal protection by antioxidants provide evidence that increased cellular 
oxidative stress mediated by hyperglycaemia is a unifying mechanism of 
nervous system injury in diabetes (Russell et al., 2002). Animal and in vitro 
studies have suggested four pathways of glucose metabolism are implicated in 
the development of diabetic neuropathy (Feldman, 2003). These include 
increased polyol pathway activity; H-redox imbalances; increased formation of 
advanced glycation end-products (AGEs); protein kinase C (PKC) activation; 
and increased hexosamine pathway flux. ROS are overproduced through the 
hyperglycaemia-mediated pathways (Feldman, 2003). Figure 1.1 outlines the 
details of each pathway, which accounts for burdens of ROS.
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Figure 1.1 Metabolic pathways of hyperglycaemia underlying oxidative stress. 
(Adapted from Feldman, 1999)
The first derivation of oxidative stress by glucose is via the polyol pathway. 
Under normal conditions the enzyme aldose reductase converts toxic 
aldehydes to inactive alcohols. Despite glucose being a poor substrate for 
aldose reductase, at high concentrations this enzyme converts glucose to 
sorbitol, initiating the polyol pathway of glucose conversion to fructose. NADPH 
is an essential factor to coordinate aldose reductase as well as GSH reductase 
enzyme. Therefore, excessive activation of the polyol pathway depletes 
cytosolic NADPH and subsequently inhibits GSH formation. With a deficit of 
antioxidant, the cell becomes vulnerable to ROS produced during normal 
cellular functions such as electron transfer. In addition, accumulation of sorbitol 
itself causes osmotic stress that also generates oxidative stress (Vincent et al., 
2004). Recent human genetic and biochemical data suggest polymorphisms of 
the aldose reductase gene and elevated tissue levels of this enzyme strongly 
increase risks for diabetic complications (Obara et al., 2004).
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The second pathway is advanced glycosylation end product (AGE)-mediated 
ROS formation. Glucose at elevated concentrations undergoes non-enzymatic 
reaction to form glycated residues called Amadori products that subsequently 
are converted to stable covalent adducts known as AGEs. These reactions are 
catalysed by transition metal ions. Reduced ability in diabetic patients to 
chelate transition metals may exacerbate AGE formation (Thornalley, 2002). 
AGE receptors (RAGE) are then activated by binding of AGE, initiating a 
cascade of signal transduction events involving p44/p42 microtubule affinity 
regulating kinases (MARKs), nuclear factor-xBrn p21 Ras, and other 
intermediates (Lander et al., 1997; Wautier et al., 1994). Interaction of AGEs 
with RAGE induces the production of ROS through a mechanism involving a 
key role for activated NADPH oxidase. In neuronal cell lines, application of 
AGEs depletes GSH and alters intracellular protein function (Feldman, 2003; 
Vincent et al., 2004).
The next fate of glucose is activation of PKC pathway. PKC has several unique 
structural features that facilitate its regulation according to redox status. 
Prooxidants can stimulate PKC activity by reacting with its regulatory domain, 
but antioxidants inhibit its activity by the reaction with the catalytic domain of 
PKC. PKC becomes activated either directly by glycolytic intermediates or 
indirectly by stress hormones, which contribute to diabetic neuropathy through 
the effect of increased vascular disease, inflammation, and oxidative stress. 
Once activated, PKC stimulates the phosphorylation of transcription factors and 
alters the balance of gene expression, such as NF-kB and NADPFI oxidase, 
inducing ROS (Feldman, 2003; Vincent et al, 2004). This is evidence for the 
role of PKC in hyperglycaemia. In endothelial cells, NF-xB was activated by
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high glucose, leading to ROS formation and cellular activation; this effect was 
prevented in the presence of PKC inhibitor (Srivastava, 2002).
The final pathway involved in ROS generation is increased hexosamine 
pathway flux and impaired mitochondrial respiration. Overloaded glucose 
causes the accumulation of glycolytic intermediates and leads to escape of 
fructose-6-phosphate undergoing hexosamine pathway. The increased 
hexosamine pathway leads to vascular disease and formation of ROS. In 
addition, overloading and slowing of the election transport chain causes escape 
of reactive intermediates to produce ROS in mitochondria and activation of 
NADH oxidase generating ROS (Feldman, 2003).
These metabolic pathways induced by hyperglycaemia directly or indirectly 
produce ROS. In the nervous system, the oxidative stress triggers decreased 
blood flow, protein and lipid oxidation, and inflammation, leading to impaired 
neurotropism, axonal transport and gene expression, and loss of neural 
function. In the long term, oxidative stress can mediate apoptosis of neurons 
and supporting cells including Schwann cells, the glial cells of the peripheral 
nervous system (Brownlee, 2001; Feldman, 2003).
1.3 The role of cytokines (lnterleukin-6)
Oxidative stress stimulates transcription of proinflammatory cytokines, such as 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumour necrosis factor-a (TNF-a), 
resulting in an inflammatory response. Cytokines possess multifunctional 
protein modulating activities on individual cells and tissues have been found to 
modulate neurological function (Viviani et al., 2004). The precise of these 
cytokines in the nervous system is complex and incompletely understood.
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IL-6 for example, which is secreted by e.g. macrophages, lymphocytes and 
epithelial cells, is an important cytokine displaying diverse biological functions 
(Jain et al., 2003). In addition to modulation of inflammatory and immune 
response in the periphery, it also induces growth and differentiation of cells in 
the immune and hematopoietic systems (Gruol and Nelson, 1997). IL-6 belongs 
to the neuropoietic class of cytokines which include ciliary neurotrophic factor 
(CNTF), leukaemia inhibitory factor (LIF), oncostatin M (OM) and interleukin-11 
(IL-11). This cytokine family shares a common tertiary structure giving rise to a 
very similar three-dimensional shape. Most importantly, they all act via 
receptors linked to gp130 signal transducing units to stimulate a kinase­
signalling cascade (Alonzi et al., 2001; Taga and Kishimoto, 1997).
IL-6 displays both neurotrophic and neurodegenerativo effects in the nervous 
system: low concentrations of IL-6 are neuroprotective, however, sustained or 
excessive IL-6 causes neuron degeneration (Gadient and Otten, 1996; Gruol 
and Nelson, 1997). IL-6 has been found to be expressed in sympathetic and 
sensory ganglia of adult rats (Gadient and Otten, 1996) and rapidly 
accumulates following nerve injury, which exacerbates functional nerve 
regeneration (Marz et al., 1999). On the other hand, elevated levels of IL-6 in 
the central nervous system have been found in several neurological disorders, 
such as Alzheimer’s disease (Gruol and Nelson, 1997). Therefore, the 
disrupted IL-6 signalling might contribute the development and progression of 
diabetic neuropathy.
IL-6 can promote the progression of diabetic neuropathy through interaction 
with nerve growth factor (NGF). As seen in Figure 1.2, IL-6 binds to the water- 
soluble IL-6 receptor linked to gp130 signal transducing unit, stimulating a
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cytoplasmic signalling cascade to activate Janus kinases (JAK)/signal 
transducer and activators of transcription (STAT) pathway, leading to the IL-6 
specific element transcription (Heinrich et al., 2003 ). IL-6 in synergism with 
NGF can promote completely opposite actions on neurons, triggering neuron 
survival, or neuron degeneration and death (Otten et al., 2000). At low 
concentrations of IL-6, NGF acts on trkA (high-affinity tyrosine kinase receptor), 
stimulating extracellular signal-regulated kinase (ERK)/mitogen activated 
protein kinase (MAPK) kinase cascade. This activation leads to neuroprotection. 
At high concentrations of IL-6, NGF binds to p75 (low-affinity glycoprotein) 
(Averill et al., 1995)), activating JNK kinase cascade. This activation leads to 
neurodegeneration. Diabetic patients have already elevated blood levels of 
cytokines (Hussain et al., 1996; Targher et al., 2001) and further increases in 
circulating cytokines could exacerbate neurological complications in persons 
with pre-existing neuropathy.
Thus, IL-6 is a critical mediator in diabetic neuropathy since elevated levels 
could contribute to nerve degeneration and death. Although the mechanism of 
IL-6 and the correlation with other factors is complex, it is very important in 
understanding the pathogenesis of diabetic neuropathy.
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Figure 1.2 The effects of neuroprotection and neurodegeneration induced by 
IL-6 signal transduction in synergism with NGF. (Adapted from Heinrich et al., 
2003)
17
1.4 The role of vanilloid receptors (TRPV1)
1.4.1 General introduction of TRPV1 receptors
Before the discovery of the vanilloid receptor (VR1 or transient receptor 
potential vanilloid 1, TRPV1), capsaicin (Figure 1.3 A), a main ingredient of 
chilli pepper, was found to excite a subset of primary sensory neurons in dorsal 
root ganglia (DRG) DRG or trigeminal ganglia. These capsaicin-sensitive 
neurons are generally peptidergic, small diameter neurons giving rise to 
unmyelinated C fibres (Holzer, 1991). However, not all small diameter neurons 
response to capsaicin, and, actually, the large diameter A5 fibre neurons are 
also capsaicin-responsive (Ikeda et at., 1997). Summarising from much 
research focused on capsaicin activity, three strong evidences indicate the 
existence of a specific capsaicin recognition site: capsaicin-mediated activity 
requires strict structure-activity relations (Szolcsanyi et at., 1975; Szolcsanyi 
and Jancso-Gabor, 1976); only specific neuron tissues are sensitive to 
capsaicin (Holzer, 1991); and response to capsaicin is species-selective (Buck 
and Burks, 1986). In 1990, Szallasi and Blumberg demonstrated a specific 
binding of resiniferatoxin (RTX) (Figure 1.3 B), a capsaicin analogue, at rat 
DRG membrane (Szallasi and Blumberg, 1990), providing the first direct 
evidence for the existence of TRPV1 receptors. In 1997, Caterina and 
colleagues first cloned rat TRPV1 receptors which contain 838 amino acids 
with a molecular mass of 95KDa (Caterina et at., 1997). The development of 
capsazepine (Figure 1.3 C) provides the first and only commercially available 
competitive TRPV1 antagonist (Walpole and Wrigglesworth, 1993). 
Capsazepine has been found to effectively inhibit both capsaicin (Lee and 
Lundberg, 1994; Lalloo et at., 1995) and RTX responses (Ellis and Undem,
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1994; Wardle et al., 1996; Wardle et a!., 1997), and it has become an essential 
tool for studying neuronal functions.
The TRPV1 receptor, present on small diameter C- and A5- sensory nerve 
fibers, is defined as a non-selective cation channel, with high permeability of 
Ca2+, sensitive to the pungent vanilloid capsaicin (Caterina et al., 1997). 
Structurally, it spans six transmembrane domains and contains a possible pore- 
loop between the fifth and sixth membrane-spanning regions (Figure 1.4). The 
fact that the capsaicin binding site is intracellular comes from Humphrey H. 
Rang’s study (Spring Pain Conference, Grand Cayman, BWI, 1998) showing 
that lower capsaicin concentrations are required to activate the cells from inside. 
This concept was further confirmed by Jung and co-workers in 1999 (Jung et 
al., 1999).
It has been found TRPV1 exists in various brain regions and is highly 
expressed in DRG (Sanchez et al., 2001). In addition to capsaicin, TRPV1 
receptors are also activated endogenously by noxious heat (>42°C), acidic PH 
(<6.0), and the endocannabinoid, anandamide (arachidonoylethanolamide; 
AEA; Figure 3D), (Smith and McQueen, 2001; Zygmunt et al., 1999). 
Inflammatory mediators including bradykinin, histamine, serotonin, and 
prostaglandin E2 (Kress et al., 1997), and proinflammatory cytokines such as 
TNF-a, IL-1 and IL-6 (Nicol et al., 1997) have also been demonstrated to be 
able to enhance capsaicin sensitivity of rat DRG neurons.
When pungent vanilloids, like capsaicin, bind to TRPV1 receptors, the channel 
pore opens, leading to massive Ca2+influx (Marsh et al., 1987). The Ca2+ influx 
generates an action potential which is propagated along the entire length of the
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excited neurons, causing central and peripheral release of the neuropeptides 
substance P and calcitonin gene-related peptide (CGRP). As well as giving rise 
to the perception of pain, these neuropeptides are important mediators of 
neurogenic inflammation, and induce production of proinflammatory cytokines 









Figure 1.3 Vanilloid structures: capsaicin, resiniferatoxin and anandamide are 
TRPV1 receptor agonists; capsazepine is a TRPV1 receptor antagonist.
Figure 1.4 TRPV1 functions as an integrator of noxious stimuli. 
(Adapted from Cortright and Szallasi, 2004)
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There is some evidence suggesting the activation of TRPV1 receptors plays a 
role in painful neuropathy. Hyperalgesia (excessive sensitivity and pain 
response to noxious stimuli) and allodynia (pain evoked from non-noxious 
stimuli) are two common types of neuropathic pain occurring frequently in 
diabetic patients. Kamei and colleagues have reported that the thermal 
hyperalgesia and allodynia observed in diabetic mice is due to sensitisation of 
TRPV1 receptors (Kamei et al., 2001). Also, Hong and Wiley (2005) have 
shown that the TRPV1 receptor is highly sensitised on DRG from diabetic rats 
(Hong and Wiley, 2005)
As a cation channel, TRPV1 is regulated by phosphorylation and
dephosphorylation processes. This sensitisation can occur via protein kinase C
(PKC)-mediated phosphorylation of TRPV1, which lowers the activation
threshold for proton and heat-induced currents (Premkumar and Ahern, 2000;
Hong and Wiley, 2005; Numazaki et al., 2002). Indeed, a PKC activator has
been shown to block TRPV1 desensitisation on DRG neurons from diabetic
rats; this effect is reversed by a PKC inhibitor (Hong and Wiley, 2005). PKC
activation in diabetes could result from the enhanced release of chemical
mediators under ischaemic conditions, following hyperglycaemia-induced
oxidative stress as described earlier: bradykinin is one such example (Walker
et al., 1995). Bradykinin-induced sensitisation of TRPV1 occurs not only
through PKC-mediated phosphorylation, but also via the displacement of
membrane lipids from an inhibitory site on TRPV1 (Sugiura et al., 2002). In
addition to PKC, the activation of Erk/MAPK may also be involved in the
sensitisation of TRPV1 receptors (Dai et al., 2002). Taylor and colleagues have
shown capsaicin prevents retrograde axonal transport in rat sensory neurons
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1.4.2 The role of TRPV1 receptors in diabetic neuropathy
by depriving sensory nerves of nerve growth factor (Taylor et al., 1985), and 
excess TRPVR1 stimulation may therefore lead to axonal degeneration in 
diabetic neuropathy.
Capsaicin-evoked CGRP release from sensory neurons is inhibited by 
anandamide (Richardson et al., 1998a). This effect is mediated by cannabinoid 
CBi receptors. Cannabinoid receptors (CE^), belonging to the G protein- 
coupled receptor superfamily, are co-expressed with TRPVR1 in DRG neurons, 
and central and peripheral terminals of nociceptive afferents (Hohmann and 
Herkenham, 1999; Ahluwalia et ai, 2002).
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Cannabis sativa (cannabis) (Figure 1.5) has been recorded in medical use in 
China, India and Africa for thousands of years. The archeological and historical 
evidence shows that the earliest use of the cannabis plant was found in China. 
The ancient Chinese cultured cannabis for its fibres since 4,000 B.C., which 
can be made into strings, ropes, textiles and even paper (Li and Lin, 1974). The 
cannabis fruits were used as food until the beginning of the Christian Era when 
the new cultures were introduced (Touw, 1981; Zuardi, 2006).
More importantly, the seeds of cannabis were recorded in the world’s oldest 
pharmacopoeia of China, as the main piece utilized in medicine to cure a 
variety of diseases, such as rheumatic pain, intestinal constipation, disorders of 
the female reproductive system and malaria (Touw, 1981). About 2000 years 
ago, Hua T’o, a famous Chinese physician, discovered the anaesthetic function 
of cannabis, and soon after performed the surgery with the aid of its 
anaesthesia (Li and Lin, 1974; Zuardi, 2006).
In India, the utilization of cannabis in surgery appeared around 1000 years B.C. 
(Mikuriya, 1969). Since the religion assigned sacred virtues to the plant, 
cannabis was applied both as a medicine and a recreational drug. As a 
significant extension, more parts of the cannabis plant, such as dry leaves, 
hairs and solitary resin glands, were found to have pharmacological activities, 
and subsequently adopted as remedies in the clinic. Probably due to the better 
preparation method of cannabis that was believed to effectively protect the 
activities of cannabinoid compounds, the psychoactive effects of the cannabis 
were well-known in India. Meanwhile, the medical use of the plant in India was
1.5 History of cannabis in medical use
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r
Figure 1.5 Cannabis sativa which contains chemicals called cannabinoids which 
produce the "high" effect / mental + physical effects when utilized.
(Downloaded from http://www.cannabis.com/faqs/about_cannabis_FAQ/index.html)
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numerous, such as analgesic (neuralgia, headache, and toothache), 
anticonvulsant (epilepsy, tetanus, and rabies), hypnotic, tranquilizer (anxiety, 
mania, and hysteria), anaesthetic, anti-inflammatory (rheumatism and other 
inflammatory diseases), and antibiotic (topical use on skin infections, erysipelas, 
tuberculosis) (Aldrich, 1997; Mikuriya, 1969; Touw, 1981; Zuardi, 2006). In the 
15th century, cannabis was introduced into Africa by Arab traders, and the 
connection with India was evidenced by the similarity of the term for preparing 
the plants in Africa and in India (Du Toit, 1980). Today, we know the female 
flowers contain the highest concentration of psychoactive chemicals, the leaves 
less, and the seeds none.
In the 19th century, William B. O’Shaughnessy, an Irish physician, and 
Jacques-Joseph Moreau, a French psychiatrist, effectively brought cannabis 
into western medicine. O’Shaughnessy described various successful human 
experiments using cannabis in his book titled “On the Preparations of India 
Hemp, or Gunjah” (Mikuriya, 1969; Fankhauser, 2002). Moreau systematically 
experimented different cannabis preparations on himself and his students, and 
found the remarkable therapeutic effects of cannabis, especially on mental 
diseases which were recorded in his book titled “Du Hachisch et de I'Alienation 
Mentale: Etudes Psychologiques” (Brill and Nahas, 1984; Moreau, 1845). 
Because of their great contributions on improving the applications of cannabis, 
the use of this plant in medical fields spread rapidly from England and France 
to all other European countries. In the late 19th century and early 20th century, 
the applications of cannabis in medical fields reached a climax, which was 
mainly in three areas: sedative or hypnotic; analgesic; other uses to improve 
appetite and digestion (Fankhauser, 2002; Brill and Nahas, 1984). However, 
later on, in the 20th century, the use of cannabis experienced decline and
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rediscovery- In the first decades, the active component of cannabis had not 
been isolated and the raw extracts were used to make drugs. Due to the 
varying efficacy of different samples of the plant, it was very difficult to obtain 
replicable effects (Fankhauser, 2002). In addition, the registration and tax 
payment were required for using cannabis. All these factors restricted the 
therapeutic exercises and experimentation of cannabis in western countries 
(Fankhauser, 2002; Zuardi, 2006).
With better knowledge of cannabis including identifying the chemical 
compositions and separating the pure active compounds, for instance, A9- 
tetrahydrocannabinol (A9-THC) was isolated in 1964 (Gaoni and Mechoulam, 
1964), cannabis was once again brought back into scientific interest. In the 
early 1990’s, cannabinoid receptors and an endocannabinoid system were 
discovered in the nervous system, stimulating extensive research activity into 
the relevant therapeutic effects (Martin et at., 1999). Currently, more accurate 
scientific methods have been developed to elucidate the structures of chemical 
compounds extracded from cannabis, to clarify the mechanisms of the 
pharmacological functions, and to prove the effectiveness, efficacy and safety 
(Zuardi, 2006). A cannabimemetic drug, Sativex, containing A9-THC together 
with cannabidiol, was approved in UK in November 2005.
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1.6 The molecular biology of cannabinoid receptors
1.6.1 The discovery of cannabinoid receptors
A9-tetrahydrocannabinol (THC) is the main constituent responsible for the 
psychoactive effects of Cannabis sativa. In terms of chemical structures, (-)-A9- 
THC produced more psychoactive effect by interacting more potently with 
artificial membrane containing only cholesterol and phospholipid than its 
nonpsychotropic enantiomer, (+)-A9-THC (Pertwee, 1988). It was initially 
believed that the psychoactivity of cannabinoids was through disordering 
neuronal cell membrane lipids by fitting into asymmetric components of the 
hydrocarbon matrix rather than binding into specific receptors (Pertwee, 1988).
In 1990, Matsuda and colleagues first cloned cannabinoid receptors (CBi) from 
rat cortex (Matsuda et at., 1990). Radioligand-binding studies showed that the 
brain distribution of CBi mRNA was highly overlapped with radio-labelled 
cannabinoids, which revealed the CBi receptor as the specific binding site for 
cannabinoids (Devane etal., 1988; Herkenham et a!., 1990).
A few years later, a second type of the cannabinoid receptor (CB2) was 
identified and cloned from rat spleen (Munro et a!., 1993). Compared to the CBi 
receptor which has been found to be widely present in the central nervous 
system, peripheral nervous system and haematopoietic cells (Munro et al., 
1993), the CB2 receptor is mainly expressed on immune cells. In addition, CBi 
receptors are highly conserved in mice, rat and human, The CB2 receptor, 
however, is more divergent. Rat CB2 receptors have only 93% homology with 
mice and 81% with human (Griffin et al., 2000; Shire et al., 1996a; Munro et al., 
1993). Although the overall homology between human CBi and CB2 receptor is
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only as low as 42%, most of the plant-derived, endogenous, synthetic 
cannablnoids have similar affinities for both of the receptors (Showalter et al., 
1996).
As mentioned above, the CBi receptor is extensively expressed in central and 
peripheral nervous systems, and is believed to be the analgesic receptor 
responsive to cannabinoids. Whilst CB2 receptors were thought to have 
immunosuppressive and anti-inflammatory activity due to their primary 
expression on immune cells, recent studies have revealed additional 
localization of CB2 receptors in the pain pathway including A/C fibres, DRG and 
the dorsal horn, indicating a possible analgesic role involved in pain control 
(Beltramo et a!., 2006). Additional receptor types have been identified for 
cannabinoids, for example peroxisome proliferator-activated receptor alpha 
(PPARa) (Sun et a!., 2007)and the orphan receptor GPR55 (Ryberg et a/., 
2007). In this thesis, the CBi receptor is the major target, to be studied regards 
its neuroprotective role in diabetic neuropathy.
1.6.2 The structure of CBi receptors
The diagrammatical structure of the human CBi receptor is illustrated in Figure 
1.6. The CBi receptor was recognized by translated cDNA as a 473-amino-acid 
protein, and similarly to other members of G protein coupled receptors, has 
seven hydrophobic domains, and contains numerous residues which are highly 
conserved residues (Mukhopadhyay et at., 2002; Matsuda et al., 1990). The 
extracelluar loops of CBi receptors have high affinity for ligands such as A9- 
THC and anandamide, and subsequently trigger signal transduction. The 
intracellular loops are there to mediate G protein signalling (Joy et al., 1999).
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Figure 1.6 Two-dimensional structure of the human hCB1 receptor. Three 
extracellular and intracellular regions are represented. (Adapted from 
Mukhopadhyay et al., 2002)
1.6.3 The distribution of CB1 receptors
The CBi receptor is believed to be the most abundant receptor in the brain and 
has been investigated by use of various bio-techniques including receptor 
autoradiography, immunohistochemistry, and in situ hybridization 
histochemistry (Walker and Huang, 2002). Its existence has been 
demonstrated in the brain of rat (Egertova and Elphick, 2000; Hajos et al., 2000; 
Moldrich and Wenger, 2000), mouse (Marsicano and Lutz, 1999; Hermann et 
al., 2002), bird (Söderström and Johnson, 2000), primate (Ong and Mackie, 
1999), and, most importantly, human (Katona et al., 2000; Mailleux and 
Vanderhaeghen, 1992).
The high densities of CBi in the central nervous system, such as basal ganglia, 
cerebellum, neocortical and hippocampus, account for the effect of CB-i 
agonists on locomotor activity, cognition and memory performance. In other 
parts of the central nervous system, the expression of CBi receptors was found 
in spinal cord and DRG subpopulations, mostly on medium and small DRG 
neurons (Farquhar-Smith et al., 2000; Hohmann and Herkenham, 1998), from 
which it is transported and assembled on central and peripheral terminal
30
afferents in the peripheral nervous system. This fact may be connected to the 
analgesic effect produced by spinal and/or peripheral administration of 
cannabinoid agonists (Herkenham et al., 1991; Hohmann and Herkenham, 
1998; Hohmann and Herkenham, 1999). Further evidence revealed the 
localization of CBi receptors on nerve endings, indicating the presynaptic 
inhibition of neurotransmitter release (Herkenham et al., 1991; Mailleux and 
Vanderhaeghen, 1992; Tsou et al., 1997). This presynaptic inhibition can 
directly cut the output of a neuron and subsequent communication to other 
neurons, by which the signal transduction is preliminarily hindered and 
analgesia is produced (Reviewed in Walker and Huang, 2002). These brains, 
spinal, and peripheral distributions of CBi receptors provide the strong anatomy 
basis to the CBr mediated antinociception.
1.6.4 The mechanism of G protein-coupled CBi receptor action
As a member of the G protein coupled receptor superfamily, the CBi receptor 
activates signal transduction through an adapter guanine nucleotide binding 
protein, G protein (Figure 1.7). The interaction of an agonist-stimulated CBi 
receptor and G protein causes the replacement of guanosine diphosphate 
(GDP) by guanosine triphosphate (GTP), via phosphate exchange, which 
subsequently stimulates the dissociation of the a, p and y subunits. These 
subunits realize the signal transduction by regulating effectors of proteins 
including adenylyl cyclases, ion channels, phosphoinositide 3-kinase, and 
phospholipases (Diaz-Laviada and Ruiz-Llorente, 2005). The activated signal 
transduction returns to a resting state by the hydrolysis of GTP to GDP, and 
then the three subunits become reassociated (Feldman and Quenzer, 1984).
31
Ca2+ ChannelCB, Receptor
Figure 1.7 The mechanism of G protein-coupled receptor action. (Adapted from 
Sinauer association Inc. Feldaman Fundamentals of Neuropsychopharmacology 
Figure 6.23)
1.6.5 The signal transduction of CBi receptors
The binding of a CBi agonist to the CBi receptor generates a series of signal
transduction events. CBi receptors are linked to Gj/0 proteins, resulting in the
inhibition of adenylyl cyclase, leading to decreased level of cAMP. As a second
messenger, cAMP transmits information originating from the cell membrane to
the cell’s interior, so that the reduction of cAMP significantly hinders the cell
response to exterior stimulation, for example, reduced Ca2+ entry into
noradrenergic nerve terminals, leading to decreased neurotransmitter release.
Also, the decreased adenylyl cyclase influences the activity of protein kinase A,
causing the reduction of phosphorylation of potassium channels which
eventually increases the efflux of potassium (Azad et al., 2001). Thus, the
activation of the CBi receptor inhibits N and Q-type of Ca2+ channels, and
activates K+ conductance via Gi/0. This cAMP-dependent mechanism eventually
decreases Ca2+ entry and increase K+ efflux (Mackie and Hille, 1992; Mackie et
al., 1995; Twitchell et al., 1997). Considering the findings that CBi receptors
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al., 1995; Twitchell et al., 1997). Considering the findings that CBi receptors 
localize on presynaptic terminals (see above), neurotransmitter-positive 
neurons and nerve fibres (Hohmann and Herkenham, 1999; Dvorak et al., 
2003), these signalling pathways modulated by the CBi receptor may all 
account for the general inhibition of neuropeptide release.
The activities of the CBi receptor can also be desensitized by phosphorylation. 
Like other G protein-coupled receptors, the CB! receptor is primarily 
desensitized by phosphorylation of serine/threonine kinases and by interaction 
with beta-arrestins, a family of uncoupling proteins, which can form a complex 
to mediate the desensitization (Ferguson, 2001; Pierce et al., 2001). 
Stimulation of protein kinase C was also found to disrupt cannabinoid- 
mediated activation of an inwardly rectifying potassium current (Kir current) and 
depression of P/Q-type calcium channels in CBi receptor-transfected AtT-20 
cells, by phosphorylating a single serine (S317) of a fusion protein 
incorporating the third intracellular loop of CBi (Diaz-Laviada and Ruiz-Llorente, 
2005; Garcia et al., 1998).
The activation of CBi receptors also promotes the process of neurite outgrowth 
through the Gj/0 protein-mediated signal transduction. The regulation of neurite 
outgrowth is a tightly controlled process and requires the coordination of 
signals coming from outside and inside of cells. This function is based on the 
growth cone at the elongation of axonal and dendrites, which is believed to 
recognize and transduce such information into directed movement (Strittmatter 
and Fishman, 1991). Ga0 protein is highly expressed in growth cone membrane 
(Strittmatter et al., 1990). The evidence of its functional significance comes
from the study showing that the expression of constitutively active Ga0 results
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in better neurite outgrowth in both neuroblastoma and PC12 cells (Strlttmatter 
et al., 1994).
The CBi receptor/Go/i signalling network in the regulation of neurite outgrowth 
(Figure 1.8) has been intensively studied in Neuro2A cells. Jordan and 
colleagues first demonstrated that the endogenous Ga0/i-coupled CBi receptor 
in Neuro2A cells activated a small G protein, Rap1, to induce neurite outgrowth 
by regulating the proteosomal degradation of RapIGAPII, a GTPase activating 
protein for Rap1. HU210, a CBi agonist, indeed, stimulated neurite outgrowth 
in Neuro2A cells, which was reversed by the inhibition of Rap1 and 
proteasomal degradation (Jordan et al., 2005). Ral was later reported by He 
and coworkers (2005) to be activated by HU210 via Rap1 and involved in the 
signalling transduction of neurite outgrowth (He et al., 2005). Furthermore, Ga0/i 
was proved to activate the Src-Stat pathway though Rap1 and Ral. The 
evidence showed that Rap1 and Ral activated CBrinduced Src phosphrylation 
was inhibited by dominant negative of Rap1 and Ral. The dominant negative of 
Ral was observed to block Ga0-induced Stat3 activation, but not to Src-induced 
activation, indicating that CBi receptor, through Ga0/i, mediates sequential 
activation of Rap1-Ral-Src-Stat3 in Neuro-2A cells (He et al., 2005). Stat3 is 
indicated to be a key molecule in signalling neurite outgrowth through CBt 
receptors. The Rac-JNK pathway was also demonstrated to stimulate CB-i- 
mediated Stat3 activation by the evidence showing that the phosphorylation of 
JNK by HU210 was blocked by dominant negative of Rac, and the application 
of the JNK inhibitor (SB-202190) significantly inhibited HU210-induced Stat3 
activation (He et al., 2005).
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It was found that the CBi receptor stimulates both the tyrosine and 
serine/threonine phosphorylation of Stat3. Based on the two divisions of 
signalling pathways, Src is likely to mediate the tyrosine phosphorylation and 
Rac-JNK is involved in the serine/threonine phosphorylation of Stat3. Therefore, 
the CBi receptor, through Ga0/i, triggers neurite outgrowth via the activation of 
two signalling pathways: Src and JNK that converge at Stat3 (He et al., 2005).
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Figure 1.8 The signalling pathways emanating from CB^GOi/o. 
(Adapted from He et al, 2006)
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The abundant distribution of CBi receptors throughout the whole nervous 
system has indicated its neuroprotective role in neuropathic diseases. In 
peripheral large myelinated fibres and small unmyelinated fibres, CBi receptors 
exist on CGRP-positive neurons (Stander et al., 2005). Domenici revealed CBi 
receptors are expressed on presynaptic axon terminals of glutamatergic 
neurons (Domenici et at., 2006). This evidence provides a molecular basis 
which contributes to the inhibition of neuropeptide release by CBi receptors. 
This theory is further verified in an animal study, which reported a significant 
increased in levels of substance P, dynorphin, enkephalin, and glutamic acid 
decarboxylase in CBrknockout mice (Steiner et at., 1999).
Overloaded intracellular Ca2+ breaks homeostasis in cells, causing excitotoxcity
and leading to neuronal cell death. The deregulated intracellular homeostasis
has been implicated in the pathogenesis of central nervous disorders, such as
Alzheimer’s and Parkinson’s diseases (Annunziato et at., 2003). Oxidative
stress can be one of the causes of increased intracellular Ca2+ concentration.
Some studies have shown that free radicals cooperate with Ca2+ ion to induce
cell injury in glutamate induced cell death (Bridges et al., 1991), or induces
intracellular Ca2+ concentration leading to the activation of endonucleases
which degrades DNA, and eventually causing cell death (Cantoni et al., 1989).
Other findings have demonstrated that the overproduced free radicals can
prevent Ca2+-ATPase, causing imbalanced homeostasis and cell death (Chan
and Mattson, 1999). Although oxidative stress does not always induce cell
injury by the mechanism of deregulating intracellular Ca2+ concentration, for
instance, Rata and colleagues (1994) have reported that oxidative stress can
directly induce immature cortical neurons (Ratan et al., 1994), the evidences
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1.6.6 The neuroprotective role of CBi receptor in nerve injury
have supported that the Ca2+ dependent mechanism can be still significant 
when considering neuron injury. Furthermore, other evidence suggests that the 
activation of Ca2+ channels/TRPV1 receptors can also cause imbalance of 
intracellular homeostasis by generating excessive Ca2+ influx, leading to 
neuronal cell death. It was reported that capsaicin can kill cultured adult 
sensory neurons in a TRPV1 receptor-dependent pathway (Winter, 1987). This 
action can be prevented when removing extracelluar calcium, or blocking the 
calcium influx by ruthenium red (Chard eta!., 1995; Winter et al., 1990).
The enhancement of intracellular Ca2+ is suggested to cause thermal allodynia 
and hyperalgesia in diabetic mice, from the behavioural studies in which 
increased tail-flick latencies were found after increasing intracellular Ca2+ in 
non-diabetic mice (Ohsawa and Kamei, 1999b). As mentioned before, the 
activation of CBi receptors results in a decrease in Ca2+ influx, which well 
correlates with the therapeutic aspect of CBi receptors in pain relief. 
Consistently, synthetic and endogenous CBi receptor agonists (WIN 55212-2 
and anandamide) have shown dose-dependent inhibition of Ca2+ uptake in rat 
synaptosomes, which was reversed by a CBi receptor antagonist (SR 
141716A). This study suggests that CBi receptor activation and the opening of 
voltage-sensitive K+ channels inhibit Ca2+ uptake of rat brain nerves (Yoshihara 
et al., 2006). In some studies, stimulation and/or blockage of CBi receptors 
have been used to examine the function of the CBi receptor in models of 
neuropathic pain. Agonist stimulation of CBi receptors decreases the response 
to noxious stimuli in nociceptive neurons (Martin et al., 1996). The reverse 
study showed blockage of CBi with selective antagonists produces 
hyperalgesia, and also blocks the analgesia produced by electrical stimulation 
in rats (Strangman et al., 1998). Taken together, these data strongly suggest
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that the activated CBi receptor is a neuroprotective mediator of neuropathic 
pain prevention and relief, and its activators, cannabinoid receptor agonists, act 
as antinociceptive agents through stimulation of CBi receptors.
1.7 Cannabinoids and pain control
1.7.1 The evidence of therapeutic effects of cannabinoids
Anandamide (N-arachidonoylethanolamide) was identified as an endogenous 
agonist at the CBi receptor in 1992 (Devane et al., 1992) (Fig 1.3D). 
Anandamide can either inhibit or stimulate sensory neurotransmission, via the 
CB1 or TRPV1 receptor respectively. These two receptors are highly co­
expressed. These opposing actions of anandamide are concentration- 
dependent: low dose of anandamide inhibits the release of neurotransmitter via 
CBi receptors, while high dose increases the release of peptides via TRPV1 
(Morisset et at., 2001; Ralevic, 2003). As the TRPV1 binding site is intracellular 
(Kamei et at., 2001b), anandamide firstly has to be taken up into the neuron via 
a membrane transporter before it can activate the TRPV1 receptor, thus 
providing a further level of discrimination between CB1 versus TRPV1 
activation. In untreated mice, intrathecal injection of a CBi antagonist, 
SR141716A, evoked a significant thermal hyperalgesia (Strangman et al., 
1998). Anandamide also attenuated hyperalgesia induced by the chemical 
damage in peripheral tissue through activating CB-i receptors (Calignano et al., 
1998; Richardson et al., 1998). These results suggest that endocannabinoids 
naturally modulate endogenous pain. The unbalanced endogenous system 
could trigger certain types of chronic.
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With the isolation and structure-elucidation of pure cannabinoid compounds, 
many synthetic cannabinoids have also been used into animal studies to prove 
the antinociceptive effect both in central and peripheral nervous systems. It is 
recognised that cannabinoids relieve chronic pain both via CBHndependent 
and CBrdependent mechanisms.
Oxidative stress has been implicated in the pathogenesis of neurodegenerativo 
diseases, including diabetic neuropathy (Cameron et al., 1993; Kamei et al., 
2001a; Karasu et al., 1995; Van Dam et al., 1995), and peripheral neurons are 
particularly vulnerable (Romero et al., 1991). The phenolic moiety of the 
Cannabis sativa derivatives, A9-THC (Fig 1.9A) and cannabidiol (CBD; Fig 
1.9B), acts as an electron donor and direct free-radical scavenger. This 
antioxidant property is fully independent of the CBi activation and confers 
neuroprotective properties to cannabinoids against oxidative stress (Chen and 
Buck, 2000; Hampson et al., 1998; Marsicano et al., 2002).
In addition to non-CBr mediated antioxidant effects, cannabinoids evoke
neuroprotective effects via CBi receptor activation. The application of
cannabinoid receptor agonists has an inhibitory effect on glutamatergic
responses from forebrain presynaptic neurons (Domenici et al., 2006). The
inhibition by WIN55, 212-2 (Fig 1.9C) is absent in mice lacking CBi receptors in
forebrain neurons (Domenici et al., 2006). In brain injury, WIN55, 212-2
prevents neuron loss from global and focal ischaemia in rats through CBi
activation (Nagayama et al., 1999). These studies strongly suggest that
cannabinoid suppresses excitatory synaptic transmission and vasodilatation by
activating CBi receptors expressed on presynaptic axon terminals in the brain
(Domenici et al., 2006; Nagayama et al., 1999). The cannabinoid HU210
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(Dexanabinol, Sinnabidiol; Fig 1.9D) showed attenuation of capsaicin- 
stimulated Ca2+ influx and substance P release in rat DRG cells (Oshita et al., 
2005). In a rat model of chronic neuropathic pain, WIN55, 212-2 effectively 
produced a CBi-dependent reversal of mechanical and thermal hyperalgesia, 
and tactile allodynia (Herzberg et al., 1997; Fox et al., 2001). In the same 
model, another two cannabinoids HU210 and CP-55,940 (Fig 1.9E) were also 
studied and the inhibitory effect on mechanical hyperalgesia was similarly 
displayed (Fox et al., 2001).
In an in vitro study, ACEA (arachidonyl-2-chloroethylamide; Fig 1.9F), a CB-i 
agonist, significantly attenuated capsaicin evoked Ca2+ response in DRG 
neurons from neuropathic rats, and this response was reversed by pre­
treatment with the selective CBi antagonist, SR141716A (Fig 1.9G) (Kelly and 
Chapman, 2001). A subsequent in vivo study further proved that spinal 
administration of ACEA significantly inhibited the mechanically evoked 
responses of dorsal horn neurons, which was also antagonised by SR141716A 
(Kelly and Chapman, 2001). These studies have demonstrated the inhibitory 
effect of CBi agonists on evoked response of DRG neurons and dorsal horn 
neurons in neuropathic rats and strongly suggest cannabinoids are likely to 
attenuate chemical and mechanical-evoked hyperalgesia in rats and also cause 
anti-hyperalgesia in a model of neuropathic pain via a CBi-mediated 
mechanism.
Peripherally, ACEA and WIN55, 212-2 both showed the CBi receptor-mediated 
therapeutic effects. The injection of peripheral ACEA inhibited innocuous and 
noxious mechanically evoked responses of spinal neurons, which was reversed
by co-administration of SR141716A (Kelly et al., 2003). These results suggest
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peripheral CB  ̂ receptors mediate both innocuous (Ap fibre) and noxious (A5 
and C fibres) stimulation. Dogrul and colleagues (2004) have firstly reported 
that topical administration of cannabinoid WIN 55,212-2 showed an anti­
nociceptive effect through peripheral CBi receptors (Dogrul et al., 2004). Also, 
an antinociceptive synergy between peripheral and spinal cannabinoid action 
was suggested by the findings that combining topical with spinal administered 
WIN 55,212-2 potentiated the analgesic effect (Dogrul et al., 2003). This study 
indicates that topically administrated cannabinoids could avoid side effects 
mediated by actions in the central nervous system, such as hypoactivity, motor 
dysfunction and hypotermia hypothermia (Dogrul et al., 2003)
There are a number of recent papers reporting the generation of novel 
cannabinoid receptor ligands with antinociceptive properties. Different from the 
hydrophobic nature of other cannabinoids, the newly synthesised 0-1057 (A8- 
tetrahydrocannabinol hydrochloride; Fig 1.9H) is a water soluble cannabinoid 
receptor agonist (Pertwee et al., 2000). 0-1057 has shown the ability to 
suppress cAMP production in vitro, reduce mouse spontaneous activity and 
rectal temperature, and induce antinociceptive activity in the tail flick test when 
given intravenously or even through inhalation, all of which were blocked by 
SR141716A (Pertwee et al., 2000; Lichtman et al., 2000). Two well established 
cannabinoid receptor agonists, A9-THC and CP-55,940, were compare with O- 
1057, and the more potent cannabimimetic properties of 0-1057 were shown in 
the in vivo study, indicating the great clinical potential as an analgesic (Pertwee 
et al., 2000). Another novel cannabinoid, AA-DA (N-arachidonyl-dopamine; Fig 
1.91) behaves as a CBi agonist and exhibits the analgesic effect along with 
other actions including hypothermia, hypo-locomotion, catalepsy in mice 
(Bisogno et al., 2000).
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With the high demand on producing analgesic agents with reduced side effects, 
a novel analogue of metabolites of A9-THC, CT-3 (V, 1’-dimethylheptyl-A8- 
tetrahydrocannabinol-11-oic acid; Fig 1.9J), has shown the potential to achieve 
this goal, which is under development by Atlantic Pharmaceuticals as an anti­
inflammatory and analgesic drug (Dajani et al., 1999). CT-3 induces marked 
analgesia both in rat and mice as assessed by tail flick and hot plate tests 
(Dajani et al., 1999). Furthermore, in behavioural models of chronic 
neuropathic pain in the rat, CT-3 produced up to 60% reversal of mechanical 
hyperalgesia and allodynia by activating the CBi receptor, and was devoid of 
cannabis-like adverse events that usually develop in other cannabinoid 
treatment (Dyson et al., 2005). This finding is in agreement with results from 
clinical trials of CT-3 in patients with neuropathic pain (Karst et al., 2003; 
Mitchell et al., 2005). With its superior therapeutic index, CT-3 shows promise 
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Figure 1.9 Cannabinoid structures: A9-THC, CBD, WIN 55, 212-2, HU-210, ACEA, 
CP-55,940, SR141716A, 0-1057, AA-DA, CT-3.
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1.7.2 Commercially available cannabinoids
As the therapeutic value of cannabinoids is controversial, most of these 
cannabinoid agents have not broken through the limitation for marketing. 
Currently, three cannabinoid agonists are available on the international market, 
however, under tight regulation. They are dronabinol, nabilone, and a cannabis 
medicinal extract (Sativex™). Dronabinol, a synthetically manufactured THC, is 
available in the US as a Schedule III controlled substance which is mainly use 
to stimulate appetite in patients with HIV or suppress chemotherapy-induced 
nausea and vomiting (Burns and Ineck, 2006). Nabilone is available in 
Switzerland, the UK, and Canada. This THC analogue is indicated only for 
themotherapy-induced nausea and vomiting, but its successful use for multiple 
sclerosis-associated pain and spasticity has been reported (Hamann and di 
Vadi, 1999). However, these older cannabinoid drugs have considerable 
drawbacks of producing adverse effects, such as anxiety, confusion, dizzy, and 
sleepless. Most recently, Sativex™ received the approval (unlicensed) of its 
medical use in the UK as adjunctive treatment for symptomatic relief of 
neuropathic pain in adults with multiple sclerosis (Perras, 2005). It is a 1:1 
THC:CBD sublingual whole-plant extract. CT-3, or ajulemic acid, is currently 
under development (Burns and Ineck, 2006). The dramatic therapeutic effects 
on anti-inflammation and analgesia with tolerable side effects, as discussed 
above, have made it a promising cannabinoid drug on the near future market.
TM
In July 2006, the cannabinoid antagonist Acomplia (rimonabant, also known 
as SR141716) was approved for use as an anti-obesity drug (Pi-Sunyer et al., 
2006). Cannabinoid agonists and antagonists are currently being examined as 
potential treatments for a plethora of additional clinical conditions (Table 1.1).
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agonists:
-  suppression of muscle spasm in MS (Smith, 2002; Vaney et al., 2004; Williamson 
and Evans, 2000)
-  relief of chronic pain (Herzberg eta!., 1997; Tsou et at., 1996)
-  glaucoma (Porcella et al., 2001 ; Stamer et al., 2001 )
-  asthma (Kasserra et al., 2004, Lunn et al., 2006)
-  anxiety (Moreira et al., 2007; Pacher et al., 2006)
-  anti-emetic (Sanger and Andrews, 2006; Sharkey et al., 
2007)
-  anti-cancer (Gustafsson et al., 2006; Joseph et al., 2004)
antagonists:
-  appetite suppressants/obesity treatment (Bronander and Bloch, 2007, Sink et al., 2008)
-  schizophrenia (Meltzer et al., 2004)
-  disorders of cognition and memory (Wise et al., 2007)
-  addiction (Filip et al., 2006; Le Foil and Goldberg, 2005)
Table 1.1 Cannabinoids as novel therapeutic agents.
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Mounting evidence demonstrates cannabinoids act as CBi agonists to produce 
neuroprotective effects. Attention has been focused on the changes of CE  ̂
receptor expression in various neurodisorders which may vary the expected 
therapeutic effect of cannabinoids. CBi receptor regulation caused by 
pharmacological treatment, pathological condition, and/or genetic modification 
does not necessarily follow a similar pattern.
In glucocorticoid-deprived rats, the CBi level was up-regulated by 50% in the 
caudate putamen(Mailleux and Vanderhaeghen, 1993). Increased CBi mRNA 
was observed in a rat model of chronic neuropathic pain (Siegling et at., 2001). 
Intestinal inflammation has been found to upregulate CBi mRNA levels (Izzo et 
at., 2001). Furthermore, cerebral artery occlusion-induced experimental stroke 
was found to enhance the CBi protein level in the ischemic tissue within a short 
term (Jin et at., 2000). In a human study, patients with schizophrenia showed 
increased levels of CBi mRNA in the dorsolateral prefrontal cortex (Hakak et at., 
2001). From these findings the expression of CBi is likely enhanced in an effort 
to deal with degenerated biological function.
However, a down-regulation of CBi expression has been demonstrated in other 
cases. Chronic alcohol exposure leads to decreased CBi level in mice, 
indicating the involvement of CBt in alcohol tolerance and dependence 
(Basavarajappa et at., 1998). Studies in patients diagnosed with Huntington’s 
disease which is characterised by motor dysfunction, personality changes, 
dementia and premature death showed a reduction in cannabinoid receptor 
ligand binding in basal ganglia output nuclei and the substantia nigra pars 
reticulata compared to the neurologically normal controls prior to the
1.8 Regulation of the CBi receptor expression in neurodisorders
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development of other identifiable neuropathology (Richfield and Herkenham, 
1994; Glass et al., 1993; Glass et al., 2000). Consistent with the findings from 
human studies, mouse models of Huntington’s disease exhibit reduced CBi 
receptor in basal ganglia (Glass et al., 2004) and decreased CBimRNA in the 
subset of neurons, the lateral striatum, cortex and hippocampus (Denovan- 
Wright and Robertson, 2000). The observation of the loss in CBimRNA was 
also extended to another neurological disorder in the striatum of a rat model of 
Parkinson's disease (Silverdale et al., 2001). In nitric oxide synthase (NOS)- 
knockout animals, a low level of CBimRNA was found in the ventromedial 
hypothalamus (VMH) and the caudate putamen (Cpu) which are the regions 
involved in cannabinoid-induced thermoregulation and decrease of locomotion 
(Azad et al., 2001). These findings suggest that decreased CBi receptors may 
account for the pathogenesis and progression involved in neurodegenerative 
diseases.
At the outset of this thesis, no-one had previously examined the level of CB1
receptor expression in diabetes. Two studies published in 2004 demonstrated 
the anti-nociceptive action of a mixed cannabinoid CB1/CB2 receptor agonist is 
preserved in diabetic mice (Dogrul et al., 2004) and rats (Ulugol et al., 2004). A 
clearer understanding of the role of CBi receptor in a model of diabetic 
neuropathy would be valuable for potentially relieving and reversing this 
complication of diabetes.
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There is some evidence to suggest that the balance of C Br versus TRPV1- 
mediated responses is tipped unfavourably towards TRPV1 in diabetes. As 
described earlier, several studies have shown that TRPV1 is sensitised by PKC 
in diabetics. Interestingly, PKC disrupts K+ current to downregulate CBi 
activation, while it sensitises TRPV1 receptors (Garcia et al., 1998). Ellington 
and colleagues (2 0 0 2 ) examined anandamide-induced inhibition of capsaicin- 
evoked CGRP release in rat paw skin from control and diabetic rats (Ellington 
et al., 2002). They found anandamide inhibited CGRP release only in skin from 
non-diabetic animals, and furthermore, actually stimulated CGRP release in 
skin from diabetic rats when tested at higher concentrations. These data 
suggest anandamide action at TRPV1 receptors overcomes the inhibitory 
action mediated by CBi receptors in diabetes. Even if TRPV1 activation evokes 
synthesis and release of anandamide, as has been demonstrated in cultured 
DRG (Ahluwalia et al., 2003), this will only serve to enhance TRPV1 signalling 
under conditions where CBi receptors are down-regulated. A differential 
regulation of TRPV1 versus CBi receptors remains to be determined, but there 
are clear implications of a decreased CBi action and/or increased TRPV1 
action in the pathogenesis of neuropathy.
Therefore, the actions of TRPV1 and CBi receptors are relevant to 
mechanisms of neurodegeneration and neuroprotection, and their regulation 
needs to be explored, the understanding of which will be helpful for 
improvement of analgesic drugs.
1.9 The role of CBi and its regulation with TRPV1
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At the outset of this thesis it was hypothesised that, firstly, a decline in CBi 
receptor expression contributes to the neurodegenerative process observed in 
diabetic neuropathy. Secondly, a decrease in CE  ̂ receptor expression could 
result in attenuated nerve cell responses to a CBi agonist under 
hyperglycaemic conditions.
The specific aims arising from the above hypotheses were:
1. To validate PC12 as an in vitro cell model of diabetic neuropathy;
2. To examine CBi receptor expression in the in vitro model of diabetic 
neuropathy, at the mRNA and protein level, and compare this to 
expression in neurons from diabetic rats.
3. To investigate the function of CBt receptors and CBrmediated 
neuroprotective effects in the in vitro model of diabetic neuropathy.






This chapter details all the methods and materials which have been used in this 
project. A variety of molecular biology and toxicology techniques were carried 
out in order to investigate the effect of hyperglycemia on expression and 
function of cannabinoid CBi receptors, and the neuroprotective effect of 
cannabinoid CBi receptor agonists.
In this project, the rat pheochromacytoma PC12 cell line was validated and 
used as an in vitro model of diabetic neuropathy to study the expression and 
function of CB-i receptors regulated by high glucose. Diabetic rat doorsal root 
ganglion (DRG) neurons obtained from Michigan University in USA were used 
as in vivo model to confirm the findings from PC12 cells.
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2.2 PC12
PC12 (purchased from European Collection of Animal Cell Cultures) is a rat cell 
line derived from pheochromacytoma which is a tumour of the adrenal gland. 
PC12 is a commonly used neuronal model in terms of its ability to differentiate 
into a neuronal phenotype with nerve growth factor (NGF) stimulation. PC12 
cells were grown as non-adherent cells in RPMI 1640 medium (Sigma) 
supplemented with 1 0 % foetal calf serum, 1 % penicillin/streptomycin antibiotic 
mixture and 1% L-glutamine solution (all purchased from Invitrogen, UK). They 
were maintained at 37°C in a humidified atmosphere of 5% carbon dioxide in 
air, and split once or twice per week. The cells were collected by centrifugation 
at 2500g for 5 minutes and the pellet was then suspended in fresh medium.
2.3 Experimental Animals
Male Sprague-Dawley rats were housed in the animal facility of the University 
of Michigan Unit for Laboratory Animal Medicine, which was maintained at 22 
°C, 55% relative humidity, with an automatic 12-h light/dark cycle. The animals 
received a standard laboratory diet and tap water ad libitum. All experiments 
were approved by the University of Michigan Committee on Use and Care of 
Animals according to the National Institutes of Health guidelines. Diabetes 
mellitus was induced by a single intraperitoneal injection of streptozotocin (STZ, 
45 mg/kg) to 180-200g rats that had been fasted overnight to maximize the 
effectiveness of STZ treatment. STZ solution was prepared fresh by dissolving 
it in 0.1 M citrate buffer, pH 5.5. Age matched control rats were injected with 
citrate buffer alone. The diabetic condition was assessed by glucose levels 
greater than 300mg/dl (16.7mM). Rats meeting this criterion were used 
experimentally 4-8 weeks after STZ induction. (Performed by Dr Shuangsong 
Hong, University of Michigan).
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2.4 Preparation of varying glucose solution
As an in vitro model of diabetic neuropathy, glucose (Sigma, UK) was used to 
simulate hyperglycaemic conditions. Glucose solution stocks of 
45,145,245,345,445mM were prepared in sterilised water, and then autoclaved. 
1 0 % of these glucose solutions were added to supplement dulbecco’s modified 
eagles medium (DMEM; Sigma, UK) containing 5.5mM glucose (Sigma, UK) to 
achieve final glucose concentrations of 5.5 (physiological glucose level), 
10,20,30,40,50mM.
2.5 Preparation of NGF solution
NGF (0.1 mg; Sigma, UK) was diluted to 5ng/pl in DMEM medium and stored in 
aliquots at -20°C.
2.6 Plating PC12 cells
Prior to use, 6 -well or 24-well plates were coated with poly-L-lysine (0.02%;
Sigma, UK) which creates an adhesion surface for cells. Poly-L-lysine was left
for 30 minutes and removed. The plates were then rinsed by dH20  and left to
dry overnight under UV light. The following day, PC12 cells were seeded in 6 -
well or 24-well plates at density of 1x105 cells/ml (2ml or 1ml per well in total,
respectively). The cells were quantified by haemocytometer counts and the
viability was determined using 2% trypan blue solution (Sigma, UK). With the
exception of glucose 5.5mM (achieved by DMEM medium only), 10% of each
glucose concentration (2 0 0 pl) was added to each well and then supplemented
by 10% FCS (200pl) and 50ng/ml NGF (20cl of 5ng/pl NGF). DMEM medium
was finally added to bring the total volume to 2ml in each well. The plates were
labelled as shown below and then incubated at 37°C in a humidified
atmosphere of 5% carbon dioxide in air.
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The medium and factors were changed every two days.
2.7 Morphology study (measurement of neurite length)
Neurite outgrowth of PC12 cells was examined at increasing glucose 
concentrations 5.5 to 50mM and osmotic controls (mannitol 30 and 50mM). The 
neurite outgrowth of PC 12 cells was apparent after 4 days of treatment with 
NGF. Photographs were taken from three random fields from each well using a 
digital camera (SONY) installed to a light microscope (Zeiss Axiovert 25). The 
neurite length and cell body diameter in each picture was measured using the 




The total neurite length was expressed as sum (length of each individual 
neurite) / cell body diameter to exclude the influence of magnification. The
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longest neurite length was expressed as length of longest neurite of individual 
cell / cell body diameter.
2.8 Oxidative stress study (GSH/GSSG estimation)
2.8.1 Introduction
The method of Akerboom and Sies (1981) was adopted to examine oxidative 
stress in the cell model. Reduced glutathione (GSH) is a major natural 
antioxidant in human tissues, protecting the body by reduction of free radicals. 
Oxidised glutathione (GSSG) is then recycled into GSH by glutathione 
reductase and NADPH. However, excessive oxidative stress will disturb the 
balance and result in decreased GSH/GSSG ratio as a consequence of GSSG 
accumulation. Therefore, GSH/GSSG ratio is a significant indicator to estimate 
oxidative stress (Hissin and Hilf, 1976). PC12 treated with 5.5-50mM glucose, 
as described in section 2 .6 , were used to investigate the oxidative stress 
introduced by hyperglycaemia.
2.8.2 Cell extraction
Medium was removed from wells, which were then washed with 2ml of ice cold 
PBS before adding 250ml of 9mM ice cold EDTA/perchloric acid (75.2mg 
Na2EDTA dissolved in 20ml 14% perchloric acid). After the cells were lifted 
using a scraper, the plates were then incubated on ice for 15 minutes. The 
mixture from each well was transferred to separately labelled eppendorf tubes 
and centrifuged at 10,000g for 5 minutes at 4°C; 170pl of supernatant was 
transferred to clean eppendorfs and then filled up with 125pl neutralizing 
solution (1M KOH+1M KHCO3). Extensive foam was formed by tapping the
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bottom of the tubes. After full neutralization, the eppendorfs were centrifuged 
at 10,000g for 5 minutes at 4°C. The supernatant was transferred to clean 
eppendorfs and then placed on ice for assay on same day or stored at -80°C.
2.8.3 GSH assay
GSH stock (0.5mM; Sigma, UK) was made up in sodium phosphate/EDTA 
buffer (0.1 M sodium dihydrogen orthophosphate (NaH2P0 4 .2 H20 ) 0.005M 
EDTA pH8 ), from which a series of GSH standards were achieved: 0, 1.5625, 
3.125, 6.25, 12.5, 25pM.
After 100pl of the samples were mixed with 1.8ml NaH2P04.2H20/EDTA buffer, 
100pl O-phthaldehyde (1mg/ml OPT in methanol; Sigma, UK) was added to the 
mixture. Following an incubation for 15 minutes at room temperature, 200pl of 
the mixture was then transferred into a white wall/clear bottom 96-well plate 
(Porvair, UK), in triplicate, which was read immediately in a fluorescence plate 
reader (BMG Lab Technologies, UK) at an excitation of 350nm and emission 
420nm. The unknown samples were calculated from the constructed standard 
curve.
2.8.4 GSSG assay
In a similar procedure to the GSH assay, 0.5mM GSSG (Sigma, UK) was made 
up in 0.1 M NaOH as the stock, from which GSSG standards were achieved: 0, 
1.5625, 3.125, 6.25, 12.5, 25pM.
Different from the GSH method, 100pl of the samples were first mixed with 40pl 
prepared 0.04M N-ethyl-maleimide ((NEM) 0.05g NEM dissolved in 10ml 
NaH2P0 4 - EDTA buffer; Sigma, UK). Following 30 minutes of incubation at
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room temperature, 100pl of the NEM treated extract was mixed with 1.8ml 
NaOH (0.1 M) before adding 100pl of OPT. After a further 15 minutes incubation 
at room temperature, the samples were transferred and read immediately as 
described in GSH detection.
2.9 Lactase Dehydrogenase (LDH) assay
The LDH assay assesses cellular toxicity which is based on the theory that the 
soluble cytosolic enzyme (LDH) is released from cells into culture medium 
following loss of membrane integrity. Culture medium collected every two days 
from PC12 cells cultured in the presence of glucose (5.5, 30 and 50mM) with 
NGF (50ng/ml) was used to test LDH activities. After loading 10pl of the test 
supernatants to a 96-well plate in triplicate, 50pl of 1mg/ml NADH (diluted in 
0.75mM sodium pyruvate; Sigma, UK) was added to the supernatant- 
containing wells, whilst 60pl of standard solutions with LDH activity (0- 
2000units/ml) were also included in the separate wells. Following exactly 30 
minutes-incubation at 37°C, 50pl of 2,4-dinitrophenylhydrazine was added to 
each well and incubated for a further 20 minutes at room temperature. Diluted 
NaOH (4N) was finally added to all wells, and after 5 minute-incubation, the 
plate was read immediately at 540nM in a plate reader (Dynex 
spectrophotometer Revelation 4.25). The supernatant from Triton-X (0.1%)- 
treated cells was used as a positive control and considered as 1 0 0 % cell lysis.
2.10 MTT assay
MTT assay measures cell viability and it is based on enzyme reduction of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in living cells, 
since yellow MTT can be reduced to purple formazan only when mitochondrial
reductase enzymes are active. The purple-coloured solution in DMSO is
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PC12 cells (1*105 cells/ml) were cultured in 24-well plates in the presence of 
glucose (5.5-50mM) and mannitol (30,50mM) under the stimulation of NGF for 
6  days prior to this assay. MTT stock (5mg/ml; Sigma, UK) was prepared in 
PBS and filtered before use. To a 24-well plate, 100pl of the stock solution was 
added to each well containing cells and 1 .0 ml medium (final 
concentration^.5mg/ml). Following a 4.5 hour incubation at 37°C, the wells 
were aspirated before 500pl of DMSO was added to each well and mixed to 
dissolve crystals. The mixture was incubated for 5 minutes at 37°C for a 
complete dissolution, from which 250 pi of the solution per well was finally 
transferred to a 96-well plate, and read in Dynex spectrophotometer at 550nm.
2.11 Measurement of osmolality
The increase in osmolality in PC12 culture medium caused by high glucose 
was assessed. A series of glucose/mannitol stocks was diluted 10 fold in 
DMEM to give a range of glucose concentrations (5.5, 10, 20, 30, 40, 50mM) 
and mannitol concentrations (30, 50mM). The osmolality was measured in an 
osmometer (model 3D3, Advanced Instruments Inc., USA; provided by Dr. 
David Wyllie, University of Edinburgh)
2.12 Measurement of glucose concentration
The glucose consumed by PC12 cells after 2 days of culture was determined 
by measuring the glucose concentration from aspirated culture medium from 
various glucose/mannitol treatments using a Glucose (GO) Assay Kit (Sigma; 
performed by Dr. Paula Smith, Napier University).
m easured  co lou rim etrica lly , w h ich  is re la ted  to  the  v iab le  cells.
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2.13 Bradford protein assay
The Bradford protein assay is a colourimetric assay based on the observation 
that the absorbance maximum for an acidic solution of Coomassie Brilliant Blue 
G-250 shifts from 465 nm to 595 nm when bound to arginine and hydrophobic 
amino acid residues present in protein. The absorbance is proportional to the 
protein concentration present in samples, so that the unknowns can be easily 
calculated according to standards set up in parallel.
The protein concentration was measured in PC12 cells cultured in various 
concentrations of glucose on day 6  of culture. After removal of culture medium, 
320pl of Triton-X 100 (0.1%) was added into each well and then incubated for 5 
minutes at room temperature. The cells were mixed into the solution and then 
transferred into eppendorfs. After centrifuging at 10,000g for 3 minutes, 10pl of 
supernatant of unknown samples was added into individual wells of a 96-well 
plate. A series of standards was made from BSA (1mg/ml; Sigma, UK) stock to 
give a range of 500, 250, 125, 62.5, 31.25, 15.6 mg/ml (i.e. 500pl of 1mg/ml 
stock and added to 500ul water, to give 500mg/ml solution, and so on). After 
10pl of prepared BSA standards was pipetted into assigned wells of the same 
96-well plate, all wells containing standard and samples were filled up with 
200pl of diluted Bradford Reagent (1 Reagent+4 distilled H20). The plate was 
read immediately in a plate reader at 595nm (Dynex 3.04).
2.14 Enzyme Linked-lmmuno-Sorbent Assay (ELISA)
2.14.1 Introduction
ELISA is a solid phase sandwich enzyme linked immuno-sorbent assay. Rat IL- 
6  is captured by the immobilized antibody that has been coated onto the wells
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provided. A biotinylated antibody specific for rat IL- 6  is added in order to bind to 
the captured rat IL-6  antigen. An enzyme is added, binding to the biotinylated 
antibody. A substrate solution is finally added to react with the enzyme, which 
produces colour. The intensity of coloured product indicates the concentration 
of rat IL- 6  (Biosource International, UK).
2.14.2 Sample preparation
Samples were collected from the medium in which the PC12 cells were 
cultured with increasing glucose concentrations (5.5-50mM). The samples were 
placed on ice for use same day or stored at -80 °C.
2.14.3 IL-6 examination
The ELISA kit was purchased from Amersham Biosciences. Standard solutions 
were serially diluted from 10,000pg/ml reconstituted standards to 0, 31.2, 62.5, 
125, 250, 500, 1000, 2000pg/ml in standard dilutant buffer.
50pl standards and samples were added to each well in duplicate after 50pl 
sample diluent buffer was added to each well. The plate was covered tightly by 
an adhesive plate cover and then incubated for 2  hours at room temperature. 
The plate was aspirated and washed three times with wash buffer (x1). Addition 
of 100pl of the biotinylated antibody reagent was applied to all wells. The plate 
was sealed again and left at room temperature for 1-hour incubation. During 
the incubation, Streptavidin-Horseradish Peroxidase Conjugate (HRP) solution 
was prepared as 3:2 dilution with streptavidin-HRP concentrate and buffer. After 
the incubation, the plate was aspirated and 100pl prepared streptavidin-HRP 
solution was then added. After 30 minutes incubation, 100pl of 
tetramethylbenzidine (TMB) substrate solution was pipetted into each well. A
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blue colour was produced at room temperature for 30 minutes without plate 
cover. After 30 minutes incubation, 100pl of stop solution was finally added to 
each well, which allowed the blue colour to turn yellow. The absorbance was 
measured using a plate reader (Dynex 3.04) at 450nm.
2.15 RT-PCR for detection of mRNA expression
Conventional reverse transcription-polymerase chain reaction (RT-PCR) was 
performed to screen the mRNA expression of TRPV1 and CBi genes. PC12 
cells were plated as described in section 2 .6 .
2.15.1 RNA extraction
RNA was extracted from differentiated PC12 cells. Hyperglycaemic cells 
(differentiated) cultured in 6 -well plates were lysed in TRI Reagent (0.5ml per 
well; Sigma, UK) for 5 minutes. The cells were lifted using a cell scraper and 
then transferred to eppendorfs for the next extraction.
The homogenate was supplemented with 0.2ml chloroform, followed by 
vigorous shaking for 15 seconds. The samples were then stored at room 
temperature for 2-15 minutes and centrifuged at 10,000g for 15 minutes at 4°C. 
After centrifugation, an upper aqueous phase was transferred and mixed with 
0.5ml isopropanol. The samples were stored at room temperature for 5-10 
minutes. A gel-like RNA precipitate was formed after centrifugation at 10,000g 
for 8  minutes at 4°C. The RNA pellet was washed with 70% absolute ethanol 
(BDH) and then sedimented by centrifugation at 7,500g for 5 minutes at 4°C. 
The washed RNA pellet was dried briefly and finally suspended in nuclease- 
free water. The RNA concentration was measured using a DU® 800 
spectrophotometer (BECKMAN COULTER) at 260nm, and the purity was
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expressed as the ratio 260/280nm. The yield of RNA was calculated using the 
equation below:
RNA (ng/pl) = Absorbance x 40ng/pl x Dilution Factor
The RNA samples were placed on ice to use on the same day or stored at - 
80°C.
2.15.2 Two step RT-PCR reaction
For the RT reaction, AMV reverse transcriptase, deoxynucleotides (dNTPs), 
Random Nonamer oligodeoxyribonucleotides and 2xAMV Buffer (final 
concentration, 50mM Tris-HCI (pH 8.3 at 25°C), 50mM KCI, 10mM MgCb, 
0.5mM spermidine, 10mM DTT) were all purchased from Promega. An RT 
master mix was set up as outlined in the Table 2.1 by applying 1pg of prepared 
RNA for each reaction.
For the PCR reaction, each cDNA was added to a PuReTaqTM Ready-To- 
GoTM PCR Bead containing ~2.5U PuReTaq DNA polymerase, 200pM dNTPs, 
and Reaction Buffer (10mM Tris-HCI, (pH 9.0 at room temperature), 50mM KCI, 
1.5mM MgCI2, stabilizers, and BSA), together with 125pmol specific primers for 
CBi (sense: 5’-AT GAAGT CGAT CCTAGATGGCCTT G-3’; antisense: 5’- 
GTTCTCCCCACACTGGATG-3’, Zhuang et al„ 1998) (MWG-Biotech AG, 
Germany) or rat (3-actin (R&D Systems Europe Ltd.), to a final volume of 25pl. 
All the reagents were allowed to thaw at room temperature, spun down and 
placed on ice for use. A PCR master mix was set up as outlined in the Table 2.2. 
The tubes were gently mixed, spun down and then placed into a PCR thermal 
cycler (Thermo Scientific Hybaid PCR Sprint Thermal Cyclers). The RT and 
PCR programmes were optimised as described in Table 2.3.
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^ ■ ■ 1  Reagents JH jjjH j x 1 Master Mix
Buffer 10 pi x samples+1
dNTP 1 pi x samples+1
Random Nonamers (2pM) 1 pi x samples+1
AMV Reverse Transcriptase (1U) 1 pi x samples+1
RNA 2-1 Oul
Nuclease-free H20 x pi
(adjust to 25pl)
Table 2.1 The volume of reagents required to prepare one reaction and 
master mix for reverse transcription.
.
Reagents x 1 Master Mix
Sense primer (200nM) 1 pi x samples+1
Anti-sense primer (200nM) 1 pi x samples+1
PuReTaq™ Ready-To-Go™ PCR Beads 1
cDNA 5 pi
Nuclease-free H20 18 pi
(adjust to
25pl)
Table 2.2 The volume of reagents required to prepare one reaction and 
master mix for PCR amplification.
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Two step RT-PCR thermal cycle programme:
1) RT Step for 1 cycle Incubation 00 o O for 45 minutes
2) PCR step for 30 cycles Hot start 95°C for 2 minutes
Dénaturation
O0in05 for 30 seconds
Annealing 62°C for 1 minute
Elongation
Oo00<0 for 2 minutes
3) Final elongation step 68°C for 7 minutes
4) Cooling for 1 cycle 20°C for 1 minute
4°C for 8 hours
Table 2.3 Time and temperature scale for PCR thermal cycle reaction.
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The samples were analysed using gel electrophoresis. The amplified cDNA 
fragments migrated to different distances according to the different lengths, as 
monitored by a DNA marker (Roche). A 1.5% agarose gel (Bio-Rad) was 
prepared in 50pl of TBE buffer (*1) with addition of 1mg/pl of ethidium bromide 
(Sigma). 16pl of PCR products premixed with 4pl of loading buffer were loaded 
to the gel and then left to run at 100 volts for 45 minutes. 2pl of DNA marker 
was run in parallel. After the electrophoresis completed, the DNA bands were 
visualised under UV light and photographed using a digitalised gel 
documentation and analysis system (GeneSnap and Gene Tools from 
SynGene, Cambridge UK).
2.16 Real time PCR LightCycler
2.16.1 Introduction
The LightCycler system is a fluorescence-based method. Compared to 
conventional RT-PCR, real time PCR has the great advantage of monitoring the 
formation of products throughout the reaction. The fluorescent dye SYBR 
Green I binds to the double-stranded DNA and produces a detectable 
fluorescence. However, the unbound single stranded DNA exhibits very little 
fluorescence. Therefore, the more DNA amplified, the greater fluorescence 
obtained. The fluorescence is measured at the end of the elongation step to 
monitor the increasing amount of amplified DNA. A melting curve analysis is 
able to separate the signal for specific product from unspecific product. CBi 
was detected using a Roche LightCycler® 2.0 Instrument machine. Beta-actin 
was used as the reference gene to normalise the detected CBi mRNA 
expression.
2.15.3 Examination of PCR products
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2.16.2 Real time PCR reaction
The RNA samples and cDNAwere prepared as described in section 2.15.1 and 
section 2.15.2. SYBR Green Taq ReadyMix™ containing 20mM Tris-HCI (PH 
8.3), 100mM KCI, 7mM MgCb, 0.4mM each dNTP, stabilizers, passivator, 
0.05unit/pl Taq DNA Polymerase, JumpStart Taq antibody, and SYBR Green I 
was purchased from Sigma. The specific primers for CBi and (3-actin were 
purchased from SuperArray Bioscience. A PCR master mix was set up as 
described in Table 2.4, gently mixed and spun down. Each sample was 
transferred to a glass capillary tube and then spun down using a capillary 
centrifuge (Roche). The amplification of target DNA sequences was monitored 
using a PCR LightCycler system (Roche). The programme was optimised as 
described in Table 2.5. The PCR product was analysed using Roche 
LightCycler data analysis software.
Reagents X 1 Master Mix
SYBR Green Taq ReadyMix 10|jl ^samples +1




Table 2.4 The volume of reagents used to prepare one reaction 
and a master mix for real time PCR
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PCR light cycler programme:
Dénaturation Dénaturation 94°C for 30 seconds
for 1 cycle (Température transition rate 20°C/Sec)
Followed by
PCR step for 58 cycles Dénaturation 94°C for 0 seconds
(Température transition rate 20°C/Sec)
Annealing 55/58°C for 5/10 seconds 
(for CBi and P-actin respectively) 
(Température transition rate 20°C/Sec)
Elongation 72°C for 10/13 seconds 
(for CBi and p-actin respectively) 
(Température transition rate 20°C/Sec)
95°C for 0 seconds 
(Température transition rate 20°C/Sec) 
60°C for 1 minute
(Température transition rate 20°C/Sec) 
95°C for 0 second
(Température transition rate 0.10°C/Sec)
Followed by
Melting curve for 1 cycle
Followed by
Cooling for 1 cycle 40°C for 30 seconds
(Temperature transition rate 20°C/Sec)
Table 2.5 Time and temperature scale for PCR light cycler reaction.
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2.17 Detection of expressed CBi and TRPV1 receptor protein in 
cultured PC12 cells
The expression of CBi and TRPV1 at the protein level was examined in 
differentiated PC12. Primary antibodies (rabbit anti-rat TRPV1 and goat anti-rat 
CB-i) and fluorochrome-conjugated secondary antibodies (FITC-anti-rabbit and 
Rhodamine-anti-goat) were all purchased from Santa-Cruz Biotechnology Ltd.
Confocal imaging and densitometric analysis of immunofluorescence were 
used to detect differences in protein expression between the groups with 
varying glucose concentrations. The cells were grown on sterilised glass 
coverslips at a density of 1 * 1 0 5 cells/ml in the presence of glucose as 
described in section 2 .6 .
The cultured cells were washed briefly with PBS mixture (PBS*1 with 0.3% 
BSA and 10mM EDTA) and then fixed with 4% paraformaldehyde (diluted in 
PBS*1) for 30 minutes. The specimens were incubated with 10% normal 
blocking serum (donkey serum in PBS mixture) for 20 minutes to suppress non­
specific binding of IgG. After washing with PBS once, the specimens were 
incubated with 0.3pg/ml primary antibody (200pg/ml diluted in PBS mixture) for 
2 hours, which was followed by washing with three changes of PBS mixture for 
10 minutes each. The specimens were incubated again with fluorochrome- 
conjugated 0.3pg/ml secondary antibody (200pg/ml diluted in PBS mixture) and 
then washed with three changes of PBS mixture for 10 minutes each. The 
coverslips with specimens were mounted with mowoil on glass slides. The 
slides were examined using a confocal laser-scanning microscopy (Zeiss LSM- 
510) on the next day or stored in a dark location at room temperature for up to 
one week.
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2.18 Detection of CBi receptor protein associated with C/A5 fibres in 
diabetic and control DRG samples
The protein expression of CBi receptors alone or associated with C/A8  nerve 
fibres was examined in formalin-fixed paraffin-embedded DRG tissue samples 
(supplied by Dr Shuangsong Hong, Michigan University, USA).
An antigen retrieval step was conducted prior to immunohistochemistry staining. 
The sample sections were deparaffinized in 3 changes of xylene for 5 minutes 
each, which was followed by rehydration in two changes of 1 0 0 % alcohol and 
one change of decreasing concentration of alcohol (90%, 70%, 50%, 30%) for 
5 minutes each. The sample section was kept in distilled water until the next 
step was ready.
Sodium citrate buffer comprised of tri-sodium citrate 0.294% (WA/), 0.2M 
hydrochloric acid solution 2.2% (VA/) in distilled water, and was adjusted to pH 
6.0 using sodium hydroxide and hydrochloric acid. A microwaveable vessel 
containing the buffer solution and the sample slides was heated in a microwave 
(Proline) set to full power for 15 minutes after the solution came to boil. The 
buffer solution was then allowed to cool down for 2 0  minutes before the slides 
were washed in distilled water and once in PBS.
For immunohistochemistry staining, the sections were incubated in 0.3% Triton 
X-100 in PBS Tween (0.1%; PBST) for 2 hours and then briefly washed in 
PBST. 10% donkey serum (Sigma, UK) in PBST was used to block the sections 
to suppress non-specific binding for at least 4 hours. After being washed in one 
change of PBST and 2 changes of PBS for 5 minutes each, the sections were 
incubated with primary antibodies diluted in PBST: rabbit anti-rat CBi (1:300;
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Sigma) alone or together with mouse anti-rat peripherin (1:500; Sigma), at 4°C 
overnight. The next day, the sections were washed in one change of PBST and 
two changes of PBS for 5 minutes each, and subsequently incubated with 
secondary antibodies: donkey anti-rabbit-rhodamine (1:80; Santa-Cruz 
Biotechnology Ltd) or together with goat-anti mouse-633 (1:400; Molecular 
Probes) for two hours in the dark. Again, the sections were washed in one 
change of PBST and two changes of PBS for 5 minutes each. Finally, mowoil 
and clean coverslips were mounted onto the sections to preserve fluorescence. 
The stained DRG sections were examined using a confocal microscope (Zeiss 
LCM-510) on the next day.
2.19 Ca2+influx study
2.19.1 Introduction
Fluo-3 AM/Fluo-4 AM is an acetoxymethyl ester derivative of fluo-3 which is a 
calcium probe. The AM form helps fluo-3 easily penetrate into cells by a certain 
time of incubation and then subsequently is cleaved off by hydrolysis. Fluo-3 is 
non-fluorescent in its free-ligand form, but the fluorescence increases more 
than 100 times on binding to calcium. Importantly, fluo-3 has an absorption 
spectrum compatible with excitation at 488nm by argon-ion laser sources, so 
that it has been widely used in conjunction with a confocal microscopy (Zeiss 
LCM-510).
2.19.2 Detection of intracellular Ca2+ increase
Coverslips (42 mm) were pre-coated with poly-L-lysine, washed with dH20  and 
dried in petri dishes overnight before use. PC12 cells were plated at a density 
of 1*105 cells/ml (3ml in total) with or without the treatment of high glucose
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(50m M ), un de r th e  s tim u la tion  o f N G F (50ng /m l) fo r  6 days.
As illustrated in Figure 2.1, on the 6 th day, the coverslip containing cells was 
washed using HEPEs buffer/saline three times and then incubated with 5pM 
fluo-3 AM or 3pM fluo 4-AM mixed with 0.02% pluronic F- 6 8  for 40 minutes at 
37°C.
To study TRPV1 receptor-mediated Ca2+ entry, after washing off excessive dye, 
the coverslip containing cells was transferred to a confocal live imaging 
chamber and filled up with 500pl fresh HEPEs buffer saline. A confocal 
microscope (LSM Zeiss 510) with the filter sets: 488nm for excitation and 
548nm for emission, was used for the fluorescence measurement. X-Y frame 
scan were adopted with the time series of 3.93 second intervals.
Firstly, a concentration-response curve to the TRPV1 receptor agonist 
capsaicin (1-700pM; Tocris Biosciences) was carried out in several control 
conditions. Capsaicin was added after 118 second-baseline scan and the 
capsaicin activation was monitored for a further 275 seconds. Subsequent 
experiments used a concentration of capsaicin which produced -50% of the 
maximum response. To confirm that the capsaicin-evoked Ca2+ influx was 
mediated by TRPV1 receptors, the effect of capsazepine (100pM; Tocris 
Biosciences), a competitive TRPV1 antagonist, was tested. To assess the 
potential for the CB-i receptor agonist HU210 (Tocris Biosciences) to inhibit the 
capsaicin-evoked increase in [Ca2+li, the response to capsaicin (300pM) alone 
or following 10 minutes pre-treatment with HU210 (0.03-30pM) was measured 
in separate experiments (to exclude possibility of TRPV1 desensitization) until
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the fluorescence returned to baseline. The selective CB-i- and CB2-receptor 
antagonists, AM251 (1pM) and AM630 (1pM) (both from Tocris Biosciences) 
respectively, were co-administered with HU210 in some experiments to 
establish the receptor subtype mediating the inhibitory action of HU210. KCI 
(70mM) was added at the end of each experiment to confirm cells were still 
viable. Only those cells responding to KCI were included in the analysis, and 
data expressed as a percentage of the KCI-evoked increase in fluorescence for 
each cell. All drugs were initially prepared as stock solutions in DMSO: fluo-3 
AM/fluo-4 AM 1mM, capsaicin 50mM, capsazepine 100mM, HU210 100mM, 
AM251 100mM, AM630 100mM. HEPEs buffer/saline contains 120mM NaCI, 
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Figure 2.1 Flow diagrams showing the procedure of Ca2+ imaging study used to 
investigate the inhibitory effect of CBi agonists on Ca2+ influx.
PC12 cells were cultured for 6  days as described In section 2.6. The procedure 
was carried out restrictively on ice or in a cold room as protein starts to degrade 
as soon as lysis buffer is added; low temperature can dramatically slow down 
protein degradation and kinase reactions. PBS, eppendorfs, cell scrapers and 
radiolmmuno precipitation assay (RIPA) buffer were all pre-cooled on ice before 
the experiment. The cell culture dishes containing PC12 cells were placed on 
ice and washed with PBS buffer before adding RIPA buffer and protease 
inhibitor cocktail. PC12 cells were scraped off and transferred to eppendorfs. 
The cell lysates were agitated for 30 minutes on ice, followed by a 
centrifugation at 10,000g for 20 minutes at 4°C. The supernatants were 
transferred to clean eppendorfs and placed on ice for use on the same day or 
stored at -80°C for delayed experiments. The supernatant was then assayed for 
total protein concentration using a Bradford Protein Assay (Bio-Rad, UK), with 
bovine serum albumin as a standard.
2.20 Western blotting: Preparation of cell lysate
RIPA buffer 4x:
50mM Tris HCl PH8  
150mM NaCI 
1% NP-40 buffer
(20mM Tris HCl PH8 ; 137mM NaCI; 10% glycerol; 1% nonidet P-40 and 2mM 
EDTA)







1 0 pg/ml leupeptin
1 0 pg/ml antipain
1 pg/ml pepstatin A
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2.21 Immunoprécipitation
Protein A-Sepharose beads were purchased from Sigma as a powder. One 
hundred milligrams of the powder was allowed to hydrate in 1ml PBS (0.1M) for 
1 hour, followed by a gentle centrifugation. The beads were aspirated and then 
incubated in 1ml PBS/BSA (1% w/v) for an hour to block non-specific binding. 
Following two rinses in PBS, the beads were preserved in 400pl of PBS with 
0.1% azide (50% of slurry) and stored at 4°C.
On the day of use, the protein A beads slurry (50pl slurry for 500pg protein) 
was washed with cold lysis buffer three times in eppendorfs and collected by 
centrifugation at 10,000g for 30 seconds. At the end, the beads were re­
suspended in cold lysis buffer to the original volume.
As illustrated in Figure 2.2, each protein sample with equal concentration and 
volume (1pg/pl and 500pl in total) was incubated on ice, with rabbit anti-rat CBi 
receptor antibody (1:500; Sigma) for 1 hour under agitation. The bead slurry 
was mixed well and carefully added to protein/antibody mixture. After the 
incubation at 4°C under rotary agitation overnight, the bead-protein-antibody 
complex was precipitated from solution and collected by a gentle centrifugation 
at 4°C. The sediment was washed three times in lysis buffer and then 
immersed in loading buffer (50pl for 50pl added slurry) after the supernatant 
was removed. Finally, the beads-protein-antibody complex was boiled at 95- 
100°C to release the protein from the beads and denature the protein. The 
supernatant was then collected by centrifugation and kept on ice for the use on 
same day or stored at - 80°C for a delayed experiment. The samples were run 
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Protein A sepharose was 
added to make protein- 
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Figure 2.2 Flow diagram showing the immunoprécipitation method used prior to 
western blotting to detect CB! receptor expression in PC12 cells.
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2.22 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS PAGE)
Fifteen percent acrylamide separating gel was cast in a Hoefer dual gel caster 
unit (Amersham Biosciences). After 1 hour, a 5% acrylamide staking gel was 
laid on the top and left to dry for 45 minutes. Gel cassettes were transferred to 
a Hoefer TE 260 mini-vertical electrophoresis tank and immersed in 
electrophoresis buffer. Lysate samples were diluted 1:1 with sample buffer and 
then heated at 95°C for 5 minutes to denature protein. 20pl of each 
lysate/sample buffer mixture was loaded and migrated at 300V for 45 minutes. 
Biotinylated broad range molecular weight markers (Bio-Rad) and wide range 
colour markers (Sigma, UK) were prepared according to the manufacturer’s 
instructions and run in parallel.
Separating gel in H?Q (VA/)
15% Acrylamide mix
25.3% 1.5M Tris (PH8 .8 )
1.0% 10% SDS
1.0% 10% Ammonium Persulphate (APS in H20)
0.05% (TMEM)
Staking gel in H?Q (VA/)
5.2% Acrylamide mix
12.6% 0.5M Tris (PH6 .8 )
1% SDS+bromophenol blue
1.0% 10% Ammonium Persulphate (APS in H20)
0.1% (TMEM)
Sample buffer in H?Q (VA/)










Transfer equipment was equilibrated in transfer buffer during electrophoresis. 
The protein on the gel was transferred to a nitrocellulose membrane 
(PerkinElmer) in a Hoefer TE 22 mini-tank transfer unit filled with transfer buffer. 
The transfer was completed after 90 minutes at a power of 100V. The 
membrane then was rinsed twice with washing buffer (0.25% Tween and 0.01% 
NP-40 in 1x PBS) and blocked with blocking buffer (5% non-fat milk powder or 
3% BSA, 0.05% Tween, 0.1% NP-40 in 1x PBS) overnight at 4°C. The next day, 
after rinsing twice with washing buffer, the membrane was incubated with 
primary antibody (rabbit anti-rat CBi receptor 1:1000 or mouse anti- 
phosphorylated serine 1:1000 in PBST) on an orbital shaker for one hour at 
room temperature. Following a washing step which was three repeated washes 
with 5 minutes intervals, the secondary antibodies (horseradish peroxidase 
anti-rabbit IgG/horseradish peroxidase anti-mouse IgG, 1:1500 in PBST and 
streptavidin-horseradish peroxidase conjugate 1:2500 in PBST) were applied 
for a one hour incubation period on an orbital shaker at room temperature. The 
washing step was repeated again as described above after the antibody 
detection was completed. The membrane was then immersed in Enhanced 
Chemiluminescence (ECL) detection reagents (Amersham), spot dried and 
covered in cling-film. In the dark, the membrane was then exposed to a 
Hyperfilm (Amersham, UK) for 15sec after which the film was developed and 
fixed. The picture of the protein band on the film was taken under X-ray 
chamber (Syngene, Cambridge, UK), and the bands representing CBi receptor 
protein (60kDa) or phosphorylated CBi protein (60kDa) were quantified by 
densitometry using GeneTools™ (Syngene, Cambridge, UK).
2.23 Western Blotting
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2.24 Immuno-detection of CBi receptors in Rat DRG
(Conducted by Dr Shuangsong Hong in Michigan University, USA)
Plasma membrane proteins were extracted from rat DRGs using an aqueous 
twophase polymer system of dextran-polyethylene glycol as described 
previously (Hong & Wiley, 2005). Briefly, DRGs from control and diabetic rats 
were isolated and homogenized in ice-cold lysis buffer containing 50mM Tris, 
pH 8.0, 150mM NaCI, 1mM EGTA, 50mM NaF, 1.5mM MgCI2, 10% v/v glycerol, 
1% v/v Triton X-100, 1mM phenylmethylsulfonyl fluoride, 1mM Na3V04, and 
“Complete” protease inhibitor mixture (Roche Diagnostics). The DRG 
homogenates were then centrifuged at 100,000g for 30 minutes at 4°C, and the 
pellets containing proteins from both the plasma membrane and cellular 
organelle membranes were suspended and separated by using the two-phase 
polymer solutions. The plasma membrane was finally enriched by 
centrifugation at 100,000g for 20 minutes at 4°C. The enriched DRG membrane 
protein was separated by 4-15% Tris-HCI gel and transferred to nitrocellulose 
membrane. The nitrocellulose membrane was blocked with 5% non-fat dry milk 
for 4 hours and then incubated with anti-CBi antibody (Cayman Chemicals) 
overnight. The membrane was then probed with horseradish peroxidase- 
conjugated secondary antibodies for 1 h and developed using the West Dura 
Supersignal chemiluminescence kit (Pierce). The corresponding bands were 
scanned and quantified with ImageJ software (National Institutes of Health), 
and normalised to (3-actin band intensity.
2.25 CBi-mediated neuroprotection
PC12 cells were grown as described in section 2.6 for six days ± HU210 (0.03 - 
3pM), in the presence or absence of selective CBi- or CB2- antagonists 
(AM251 and AM630, at 1 or 3pM).
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Neurite rescue study
Neurite length was determined from photomicrographs taken on day 6 from 
three random fields/well, using MetaMorph™ software (Universal Imaging 
Corporation). The total neurite length measurement was conducted as 
described in section 2.7.
The effect of HU210 on oxidative stress
Levels of oxidative stress were measured using the glutathione assay as 
described in section 2.8.
The effect of HU210/AM251/AM630 on cell viability
Cell viability was examined by using the MTT assay as described in section 
2.10, as well as the LDH assay as described in section 2.9.
All drugs were initially prepared in DMSO: HU210 100mM, AM251 100mM, 
AM630 100mM and then diluted in DMEM to achieve final concentrations.
2.26 Statistical analysis
Experiments were conducted in duplicate or triplicate. Data are presented as 
the mean ± standard error mean from at least three independent experiments, 
and analysed using MINITAB release 14. The immunoblot data were 
normalised as a percentage of control, and functional data were normalised as 
a percentage of KCI response. Multiple treatment data were analysed using 
one-way ANOVA with Fisher’s pair wise comparison, whereas data between 








Distal symmetrical polyneuropathy, the most common form of diabetic 
neuropathy, is characterized by neurodegeneration of peripheral nerve endings, 
resulting in acute pain, sensorimotor deficits, and an increased risk of limb 
amputation (Vinik et al., 2006). Given the clinical observation that controlling 
blood glucose levels delays the onset of diabetic neuropathy, the elevated 
blood glucose (hyperglycaemia) is suggested as a main trigger to diabetic 
neuropathy. Some studies have demonstrated hyperglycaemia alters the nerve 
conduction velocity and causes sensory neuron loss in diabetic mice and rat 
models (Zaruba et al., 2007; Malone et at., 1996). The mechanisms underlying 
the pathophysiology are still unclear. Oxidative stress resulting from the over­
loaded glucose metabolism is recognised as a unifying pathway, which causes 
protein and lipid oxidation in the nervous system (Russell et al., 2002; Feldman, 
2003). As consequences, mitochondrial dysfunction and apoptosis are 
preceded by the hyperglycaemia-induced oxidative injury in neurons, leading to 
neuronal dysfunction and cell death in diabetes (Schmeichel et al., 2003; 
Russell et al., 1999). The neuropoietic cytokine, IL-6, has dual functions 
contributing to either nerve degeneration or regeneration. At low levels, it 
facilitates neurite outgrowth and promotes recovery from injury, however, at 
high levels, it act as a pro-inflammatory factor. (Skundric and Lisak, 2003).
Previously, few In vitro models were established to investigate the
hyperglycaemia-mediated neuronal cell dysfunctions. Cultured ganglionic
neurons, developed as in vitro models of diabetes by Russell and colleagues,
showed a high glucose-mediated neurite retraction which was ameliorated by
the application of insulin growth factor I (Russell and Feldman, 1999; Russell et
al., 1999). PC12 cells derived from a rat adrenal pheochromacytoma were first
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established as an in vitro cellular model of diabetic neuropathy by Lelkes and 
co-workers in 2001. Their study showed that PC12 cells displayed similar 
features of diabetes- related nerve disorders: decreased neurite outgrowth, 
increased oxidative stress and accelerated apoptosis, when cultured in 
elevated glucose (Lelkes et al., 2001). The aim of this chapter was to validate 
PC12 cells as a cell culture model of diabetic neuropathy by culturing cells in 
physiological glucose (5.5mM) as well as serial elevated glucose 
concentrations (10-50mM). To exclude the possibility of increased osmolality 
causing observed differences, mannitol (30 and/or 50mM) was used as an 
osmotic control, whereby the osmolality of the solution would be the same as 
glucose, but the cells would be unable to utilize mannitol. The effect of glucose 
on morphology changes was determined by comparing neurite length in 
different glucose treatments. Oxidative stress, IL-6 production, and cell viability 
were also tested.
3.2 Determination of the time length for optimum neurite outgrowth of 
PC12 cells
To obtain the length of time for optimum neurite outgrowth, the measurement of 
neurite length in PC12 cells cultured in variety concentrations of glucose (5.5- 
50mM) and mannitol (10-30mM) was conducted on day 4, 6 and 8 of culture, 
using Metamorph™ computer software. Longest neurite length and total neurite 
length were both adopted to compare neurite outgrowth in cells, and expressed 
as percentage of cell body diameter.
As shown in Figure 3.1, both the longest neurite length (Figure 3.1 A) and total 
neurite length (Figure 3.1 B) data from all the treatment groups, including
glucose and mannitol, followed a bell-shaped pattern, showing a maximal
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neurite outgrowth on day 6 of culture. It also can be seen that the high glucose 
(20, 30, 40 and 50mM), but not mannitol (30 and 50mM), attenuated the neurite 
outgrowth compared with the control glucose (5.5mM) on day 6 and 8. In 
contrast, no clear difference on neurite outgrowth was observed among the 
treatment groups on day 4 of culture, especially from the result of total neurite 
length, which may due to the early stage of neurite outgrowth is not being 
sensitive enough to identify differences in neurite extension affected by glucose. 
Thus, day 6 of culture is suggested to be the optimal time point for neurite 
outgrowth studies, taking advantage of maximal neurite differentiation and 
sensitive identification of the effect of glucose on neurite extension.
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Figure 3.1 The effect of glucose on neurite outgrowth in PC12 cells in the presence of 
nerve growth factor (50ng/ml) on day 4, 6, 8. The neurite outgrowth In each cell was 
analysed using digital quantitative analysis software (Metamorph™), and expressed 
as percentage of cell body diameter. A represents longest neurite length and B 
represents total neurite length (n£l0 for each condition).
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3.3 Validation of Metamorph™ methods on measuring neurite length
Metamorph™ quantitative digital analysis software (Universal Imaging 
Corporation) provides a fast method of neurite outgrowth study. To validate 
Metamorph™ measurement methods, a manual measurement was conducted 
on more than 10 cells to compare with the digital measurement. Figure 3.2 
shows the correlation between the two measurement methods. It was found 
that the results of neurite length measured using Metamorph™ and manual 
measurement methods correlated highly (R2=0.9771), suggesting 
Metamorph™ is a valid method in morphology studies.
Manual
Figure 3.2 The correlation between manual measurement and digital quantitative 
analysis software measurement on neurite outgrowth in PC 12 cells growth in the 
presence of nerve growth factor (50ng/ml) on day 6 (n=24 and regression 
R2=0.9771).
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To study the effect of glucose on NGF-induced neurite outgrowth, the 
morphology study was conducted in PC12 cells cultured in DMEM 
supplemented with increasing concentrations of glucose (5.5-50mM) with the 
stimulation of NGF (50ng/ml) for 6 days.
Figure 3.3 shows the photomicrographs illustrating neurite outgrowth of PC12 
cells cultured in each condition. It was observed that cells were highly 
differentiated in 5.5 and 10mM of glucose (Figure 3.3 A and B); with increasing 
glucose concentration, the differentiation rate declined. The shortest neurite 
length was observed in cells cultured in 40 and 50mM glucose (Figure 3.3 E 
and F). Mannitol (30 and 50mM; Figure 3.3 G and H) gave a comparable 
neurite outgrowth to 5.5mM glucose in PC12 cells.
The measurements from over seventy cells were plotted in Figure 3.4 A. The 
plotter graph (Figure 3.4 A) illustrates the distribution of longest or total neurite 
length from each condition, showing the neurite length of majority cells stays in 
higher Y axis in 5.5 or 10mM glucose, and it moves downwards with the 
glucose concentration increasing (20-50mM glucose). It indicates that 5.5 or 
10mM glucose is beneficial for neurite outgrowth in PC12 cells compared to the 
higher concentrations of glucose. Statistically, glucose with the concentrations 
more than 10mM (Figure 3.4 B) significantly inhibited neurite outgrowth in 
PC12 cells (versus the control 5.5mM of glucose; P<0.01). It was ~two-fold 
decrease in total neurite length in PC12 cells cultured in 30-50mM of glucose 
compared to that in the control glucose. In contrast, mannitol (30 and 50mM) 
gave similar results to that of the physiological 5.5mM glucose control (P = 
0.79), indicating the inhibitory effect is due to raised glucose levels.
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Figure 3.3 Representative photomicrographs showing the effect of increasing glucose 
concentration on neurite outgrowth in PC12 cells grown in the presence of nerve growth 
factor (50ng/mL). A-F represent individual field observed under light microscopy (x40) in the 
increasing glucose concentration 5.5-50mM (G5.5-G50mM). G-l represent individual field 
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Figure 3.4 The effect of glucose on neurite outgrowth in differentiated PC12 cells. From 
three random fields of view per well, the total length of individual neurites per 
differentiated cell was measured using quantitative digital analysis software 
(Metamorph™), and expressed as a percentage of cell body diameter. Data shown are 
mean ± s.e.mean, where n=70-79 cells per condition from six independent experiments 
(**, P < 0.01, versus 5.5 mM glucose: one-way ANOVA-Fisher’s post-hoc analysis). 
Mannitol (30 and 50 mM) was included as an osmotic control (M30, M50). A is the 
scatter graph and B is the bar graph.
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An osmolality measurement was conducted independently (Table 3.1), showing 
no significant difference between 30 and 50mM of glucose and mannitol (P 
=1.00 and 0.37 respectively), which further confirmed no hyperosmotic effects 
were involved in the inhibition of neurite outgrowth.
Figure 3.5 shows that the cell culture model is one of maintained elevated 
glucose concentrations. The average fall in glucose levels from aspirated 
medium is 3.1 ± 0.8mM across the concentration range after 2 days in cell 
culture, but there is not a severe peak-to-trough variation in glucose (Figure 
3.5).
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Glucose (mM) Osmolality (mOsm/kgH20)
5.5 290 ±1
10 298 ±1




5.5 + Mannitol 30mM 320 ±1
5.5 + Mannitol 50mM 341 ± 0
Table 3.1 Osmolality of cell culture medium. Osmolality of culture media was measured 
in an osmometer (model 3D3, Advanced Instruments Inc., USA) (average of three 
readings). No significant differences were observed between the 30 and 50mM glucose 







Figure 3.5 Measurements of glucose concentrations in the aspirated medium following 2 
days in culture, either in plates containing no cells, or those plated with 1x105 PC12 cells/ml.
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Oxidative stress was examined in PC12 cells cultured in increasing 
concentration of glucose (5.5, 30, 50mM) on day 6. The glutathione assay 
measures the level of the reduced form of glutathione (GSH) as well as the 
oxidized form of glutathione (GSSG), identifying the level of oxidative stress in 
cells. GSH acts as a natural body defence, scavenging free radicals by 
donating a free ion whilst turning itself into GSSG. The ratio of GSSG/GSH 
indicates the oxidative stress level in cell bodies. Figure 3.6 shows the effect of 
glucose on oxidative stress in PC12 cells. It was found that glucose produced 
oxidative stress in a concentration-dependent manner. The concentration of 30 
and 50mM of glucose significantly increased oxidative stress compared with 
the control concentration (5.5mM) (P<0.05 and P<0.01) by ~two-and-three-fold, 
respectively. No significant change in oxidative stress was observed with 
mannitol treatment (50mM) (P=0.98) (versus the control 5.5mM), indicating 
there is no osmotic effect on oxidative stress levels found with high glucose 
treatment (30 and 50mM).
3.5 Effects of glucose on oxidative stress in PC12 cells
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Figure 3.6 The effect of glucose on oxidative stress in differentiated PC12 cells. An
increased ratio of GSSG/GSH represents oxidative stress in PC 12 cells cultured in
the presence of NGF (50ng/ml) and increasing concentrations of glucose (5.5, 30, 
50mM). Mannitol 50mM was used as an osmotic control (n=4; **, P<0.01; *<P0.05; 
one-way ANOVA-Fisher's post-hoc analysis).
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Cell viability was examined in PC12 cells cultured in variety concentrations of 
glucose (5.5, 30 and 50mM) with the stimulation of NGF (50ng/ml) for 6 days 
by using the lactase dehydrogenase (LDH) assay and MTT assay. LDH serves 
as a general indicator to assess cell membrane integrity and the leakage of 
LDH from plasma into cell medium suggest cytotoxicity which may result from 
chemicals and environmental changes. Figure 3.7 shows LDH levels in culture 
medium of PC12 cells cultured in the presence of glucose (5.5-50mM) and 
mannitol (50mM) on day 2, 4 and 6 with the positive control from Triton-X (0.1%) 
treated cells. A similar trend of a flat line was found in LDH levels from all of 
the three time points and in contrast to the positive control value of 1800- 
2000unit/ml, LDH levels observed from other groups all remained below 
500unit/ml. These data reveal that high glucose (30 and 50mM) did not cause 
significant LDH release in PC12 cells compared with the control LDH level 
(glucose 5.5mM) in all of the three time points. No significant change in LDH 
level was found in the mannitol (50mM) treatments when compared with the 
glucose treatments, which excludes the possibility of osmotic effects.
The MTT assay is a colourimetric method based on the ability of live cells to 
reduce a tetrazolium-based compound to a blue formazan product. Cell viability 
is expressed as absorption at 550 nm. Different from the LDH assay, the MTT 
assay was conducted in PC12 cells on day 6. As shown in Figure 3.8, there 
was no significant difference on cell viability within all the treatment groups, 
including mannitol treatments (P=0.86). The result is consistent with the finding 
from the LDH studies, suggesting glucose has no adverse impact on cell 
viability in PC12 cells.
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Figure 3.7 Mean concentration of lactase dehydrogenase release from PC12 cells 
stimulated with NGF (50ng/ml) and in the absence/presence of high glucose (30 and 
50mM) on day 2, 4 and 6 of culture. Mannitol (50mM) is the vehicle control to exclude 
an osmotic effect. +Ve is the positive control from Triton-X (0.1%)-treated cell lyses. 
Values represent mean ± SEM from 3 independent experiments (P >0.05, one-way 
ANOVA-Fisher’s post-hoc analysis).
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Figure 3.8 Cell viability of PC12 cells cultured in an increasing concentration of 
glucose (5.5, 10, 20, 30, 40, 50mM) under the stimulation of NGF (50ng/ml) for 6 
days. Mannitol (30 and 50mM) is an osmotic control. Data shown are mean ± 
s.e.mean, from n=12 independent experiments performed in duplicate (P >0.05 one­
way ANOVA-Fisher’s post-hoc analysis).
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Protein concentration and cell density were also examined, along with cell 
viability assays, to assess the effects of glucose on cell proliferation. The 
Bradford protein assay determines protein concentration in relation to a 
standard albumin curve. Figure 3.9 shows protein concentrations in PC12 cells 
cultured in increasing concentrations of glucose (5.5-50mM). No significant 
difference was found within the glucose treatment groups, although there was a 
slight increase with higher concentrations of glucose (>10mM; P=0.72). The 
results from mannitol (30 and 50mM) treatments showed no osmotic effect was 
involved in cell proliferation.
The above result was further confirmed in the cell density assay. A random cell 
count (Figure 3.10) was conducted to compare the cell density in different 
concentrations of glucose (5.5, 30 and 50mM) and mannitol (50mM). Taking 
the control (5.5mM glucose) cell density as 100%, the result revealed a 
constant cell density in all the treatment groups, including mannitol (50mM), 
with a maximal 10% of variation. The results from both studies suggest glucose 
itself has no effect on cell proliferation in PC12 cells.
3.7 Effects of glucose on cell proliferation in PC12 cells
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Figure 3.9 The effect of glucose on cellular protein levels in PC12 cells. The 
Bradford protein assay was carried out in cells cultured for 6 days with nerve growth 
factor (50 ng/ml), in the presence of 5.5 -  50mM glucose. Mannitol (30 and 50 mM) 
was included as an osmotic control (M30, M50). Protein concentration is expressed 
as pg/ml, in relation to a standard curve (albumin). All values expressed as mean ± 
s.e.mean from 3 independent experiments performed in duplicate (P >0.05, one­
way ANOVA-Fisher's post-hoc analysis).
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Figure 3.10 The effect of glucose on cell density in PC12 cells. Cells were counted 
from three random fields in each well after 6 days of culture with nerve growth factor 
(50ng/ml), in the presence of 5.5, 30 and 50mM glucose. Mannitol (50 mM) was 
included as an osmotic control (M50). The cell number is expressed as percentage 
of the control (5.5mM glucose). All values expressed as mean ± s.e.mean from 3 
independent experiments performed in duplicate (P >0.05, one-way ANOVA- 
Fisher’s post-hoc analysis).
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3.8 Effects of glucose on interleukin-6 (IL-6) production
Figure 3.11 shows the IL-6 production in PC12 cells cultured in control glucose 
(5.5mM) and high glucose (30, 50mM). The mean values from various 
treatments displayed that glucose has a tendency to increase the IL-6 
production in PC12 cells in a dose-dependent manner, however, this failed to 
reach statistical significance (P=0.427).
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Figure 3.11 The effect of glucose on interleukin-6 production. The level of IL-6 was 
measured in the culture medium of PC12 cells cultured in the absence or presence 
of high glucose (30, 50mM glucose) with the stimulation of NGF (50ng/ml) on day 6. 
All values expressed as mean ± s.e.mean from 3 independent experiments 
performed in duplicate (P >0.05, one-way ANOVA-Fisher’s post-hoc analysis).
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3.9 Discussion
Greene and Tischler first established the NGF responsive cell line, PC12, in 
1976. Upon the stimulation of NGF, PC12 cells not only cease to multiply and 
begin to extend branching varicose processes, but also synthesise and store 
neurotransmitters, such as catecholamine and noradrenaline. The high 
similarity to cultured primary neurons suggests PC12 as a useful model system 
for neurobiological and neurochemical studies (Greene and Tischler, 1976). In 
the present study, we validated PC 12 cells being an in vitro cell model of 
diabetic neuropathy, as previously established by Lelkes et at. (2001). Firstly, 
the optimum time length was investigated in the NGF stimulated PC12 cells. 
The neurite outgrowth of PC12 cells was studied at three time points: day 4, 6 
and 8, under the stimulation of NGF (50ng/ml). Day 6 was found to be the 
optimum time when maximal neurite length and a distict neurite outgrowth were 
observed with increasing concentrations of glucose (5.5-50mM). This finding is 
in agreement with a previous study showing that PC12 cell differentiation and 
neurite growth induced by a similar dose of NGF (50ng/ml) reached a plateau 
after 6 days in culture (Das et al., 2004). Ohuchi et al. (2002) compared the 
assay-based quantitative analysis (using protein and enzyme markers) with the 
neurite length measurement method to assess neurite outgrowth by stimulating 
PC12 cell differentiation with NGF for 5 days and the results showed a high 
correlation between these methods (Ohuchi et al., 2002). Lelkes et al. (2001) 
studied the effect of high glucose on neurite outgrowth on day 6 of culture in 
PC12 cells with NGF (50ng/ml) present. During the process of cell model 
selection, human neuroblastoma SH-SY5Y cells were also tested with chronic 
high glucose treatments. However, unlike PC12 cells, SH-SY5Y cells multiplied 
very rapidly during the culture, making the assessment of, particularly, the
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glucose related morphology change and the future neurite-rescue study 
impossible to carry out over a 6-day period.
The quantitative computer program, Metamorph™, provides an accurate and 
fast method for morphology studies, which has been widely used in analysing 
neurite outgrowth in many cell types, such as cultured rat hippocampal neurons 
(McCroskery et al., 2006), cultured rat doosal root ganglion neurons (Li et a!., 
2004; McCroskery et al., 2006), neuroblastoma cells (Sheehan et at., 2006) 
and PC12 cells (Shin et al., 2006). Based on its diverse uses on assessment of 
neurite degeneration and regeneration, we adopted Metamorph™ to measure 
neurite length in NGF-stimulated PC12 cells, following a validation of the semi­
automatic measurement method which proved to be highly correlated with the 
manual measurement method.
Hypersensitivity, such as hyperalgesia and allodynia, occurs in the early stages 
of diabetic neuropathy, followed by the late-stage loss of sensation (Vinik et al., 
2006). In vitro, many cell models have been used to examine the cellular 
mechanism involved in the pathophysiology of diabetic complications, such as 
endothelial cells (Baumgartner-Parzer et al., 1995; di Wu et al., 1999; Sheu et 
al., 2005), but few neuronal cell models have been studied. We, therefore, 
following Lelkes and colleagues’ (2001) study, set up PC12 cells as a neuronal 
cell model of diabetic neuropathy to investigate the effect of glucose on neurite 
outgrowth. The result from total neurite length showed glucose attenuated 
neurite outgrowth in PC12 cells in a concentration-dependent manner, and 
glucose concentrations higher than 20mM significantly inhibited neurite 
outgrowth which is in agreement with Lelkes et al. (2001) reporting 25mM 
glucose gave significant inhibitory effect on neurite outgrowth compared to the
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control (5mM glucose) in the same cell model. The osmotic control (mannitol 30 
and 50mM) gave a comparable neurite outgrowth to that of physiological 
5.5mM control, suggesting the inhibitory effect is due to high glucose, 
mimicking hyperglycaemic conditions, rather than any hyperosmotic effect. This 
result is related to the clinical study showing loss of epidermal nerve fibers in 
skin biopsies from diabetic patients (Dyck et al., 1986; Kennedy et al., 1996) 
and the recent animal study reporting axonal atrophy in sensory neurons from 
experimental diabetic animal models (Zochodne et al., 2001). In line with other 
in vitro models, high glucose was found to consistently inhibit neurite outgrowth 
in cultured sympathetic ganglion nerves (Semra et al., 2004) and induce neurite 
degeneration in dorsal root ganglion neurons (Russell et al., 1999). The 
inhibitory effect of hyperglycaemic conditions on neurite outgrowth in PC12 
cells may appropriately reflect the impaired peripheral nerve regeneration 
process observed in diabetes (Kennedy and Zochodne, 2005). Of course, due 
consideration must be made when comparing “in vitro high glucose” and “in 
vivo diabetic” states, since we had a 9-fold difference in glucose levels between 
cell-treatment groups, which remained elevated during the culture (Figure 3.5), 
whilst the rat diabetic model showed a 5-fold elevation in plasma glucose 
compared to controls, and these levels would fluctuate throughout the animals’ 
lives. Others have reported plasma glucose levels in the STZ-diabetic rat range 
from 25 - 50 mM (mean 34.5 ± 3.05mM) (Purves et al., 2001), thus making the 
concentrations used in the present in vitro study reasonable.
Oxidative stress is considered as a crucial pathogenic factor in diabetic 
neuropathy. The excessive ROS generated by hyperglycemia damages DNA, 
protein and lipid, which accompanied by disrupted natural antioxidant defence 
characterised by reduced level of glutathione (GSH), glutathione peroxides in
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peripheral nerve system, all contributing to alterations in cell signal transduction 
(Low et al., 1997; McHugh and McHugh, 2004). In the present study, we 
examined the level of GSH and GSSG in PC12 cells cultured in high glucose to 
asses the level of oxidative stress. The result revealed high glucose (30 and 
50mM) significantly induced oxidative stress in a concentration-dependent 
manner compared to the 5.5mM glucose control in this cell model system. This 
finding is consistent with other in vitro studies which demonstrated ROS was 
markedly increased by high glucose (45mM) in cultured DRG neurons, 
Schwann cells and neuroblastoma cells (Schmeichel et al., 2003; Vincent et al., 
2002; Vincent et al., 2005), which are well corroborated by in vivo studies 
showing high levels of oxidative stress are present in diabetic animals and 
human (Vincent et al., 2002).
Following the observation of high glucose-induced oxidative stress, cell viability
was also investigated in the absence or presence of high glucose by using the
MTT and LDH assays. The results from both cell viability assays suggest high
glucose did not significantly decrease cell viability in PC12 cells, which
contradicts some studies suggesting high glucose triggers apoptosis in
neuronal cells (Russell et al., 1999). Two studies conducted by Lelkes et al.
(2001) and Koshimuran et al. (2002) reported that high glucose induced
mitochondrial dysfunction and programmed cell death in PC12 cells on day 7 of
culture. In contrast, we found only a slight, non-significant decrease in
mitochondrial related-cell viability measured using the MTT assay with glucose
concentrations of 10-50mM compared to the controls (5.5mM glucose, and
mannitol 30 and 50mM), and values from the LDH assay measuring cell
membrane integrity were relatively constant before all treatments. In the view of
Toth et al. (2004) and Sullivan and Feldman, (2005), the nerve terminal loss or
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axonal atrophy is the feature of early diabetic neuropathy due to the longest 
‘exposed’ length is more vulnerable (Sullivan and Feldman, 2005; Toth et al., 
2004). The finding of the morphology study in which high glucose significantly 
inhibited neurite outgrowth on day 6 of culture shares some common pathways 
when considering regeneration of nerves.
Later, the effect of glucose on proliferation of PC12 cells was tested by using 
both protein assay and cell counting. Both of the results indicate, on day 6 of 
culture, high glucose did not influence the NGF-stimulated PC12 cell growth 
and protein level, suggesting no net cell death is involved at this stage of high 
glucose exposure, which is consistent with the previous cell viability results. In 
fact, as mentioned before, NGF-treated PC12 cells cease to multiply and start 
growing neurites once attached to poly-L-lysine/collagen treated plates, which 
are highly similar to adult neurons. These findings support PC12 as a useful 
neuronal model in studying adult diabetic neuropathy.
Based on the dual role of the neuropoietic cytokines IL-6 in the nervous system, 
we measured the level of IL-6 in differentiated PC12 cells in the presence of 
high glucose. The results revealed a glucose concentration-dependent increase 
in IL-6 production, although the values did not reach statistical significance. 
Restricted to the nervous system, IL-6 rapidly accumulates following nerve 
injury, which is suggested to improve functional nerve regeneration (Marz et al., 
1999). In fact, two recent studies have shown that the administration of low 
dose IL-6 improved nerve function and attenuated the development of 
neuropathy in STZ-diabetic rats (Andriambeloson et al., 2006; Cameron and 
Cotter, 2007). The dose-dependent increase in IL-6 level in the current study
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may due to the stimulation of a ‘self-rescue’ mechanism in response to high 
glucose.
Collectively, in this chapter PC12 cells were validated as a cell culture model of 
diabetic neuropathy. On the optimum time length of 6 days in culture, elevated 
glucose levels significantly attenuate NGF induced neurite outgrowth, and are 
associated with increased levels of oxidative stress and IL-6 production in 
PC12 cells, thus reproducing some of the phenomena of diabetic neuropathy.
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CHAPTER 4
AN INVESTIGATION OF THE CANNABINOID C B , RECEPTOR 




Cannabinoid CBi receptors are G-protein coupled receptors, which are 
expressed abundantly in central and peripheral nervous system. Activation of 
CBi receptors regulates Ca2+ channels, suppressing neurotransmitter and 
neuropeptide release. It has been found that the declined CBi receptor 
expression contributes to central neurodegenerative process in Huntingson’s 
diseases (Glass et al., 2000; Glass et al., 2004). TRPV1 receptors are non- 
selective cation channels, whch highly co-express with CBi receptors on 
nociceptive afferents. They are activated endogenously by noxious heat 
(>42°C), acidic pH (<6.0) and the endocannabinoid, anandamide (Zygmunt et 
al., 1999; Smith & McQueen, 2001), causing central and peripheral release of 
substance P and calcitonin gene-related peptide (CGRP). Some evidence 
showing that, upregulated function and expression of TRPV1 receptors occur in 
the model of diabetic neuropathy (Rashid et al., 2003; Hong and Wiley, 2005), 
may indicate the balance of CB-i- versus TRPV1-mediated responses is tipped 
unfavourably towards TRPV1 in diabetes.
We hypothesize that a decline in CBi receptor expression contributes to the 
neurodegenerative process observed in diabetic neuropathy. The aim of this 
chapter was to investigate whether the neuronal CBi receptor expression is 
down-regulated in hyperglycaemic conditions by using in vitro and in vivo 
models of diabetic neuropathy. We have previously found that the NGF- 
induced neurite outgrowth was reduced by high glucose in PC12 cells. In this 
chapter, the CBi receptor expression at gene and protein levels was then 
studied in PC12 cells in order to examine whether the impaired neurite 
outgrowth was associated with the decreased CBi expression. The in vitro
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finding was further investigated in primary DRG neurons from diabetic rats to 
test the consistency.
4.2 CBi mRNA down-regulation induced by high concentration of KCI
A high concentration of potassium chloride (KCI, 25mM) was reported to 
downregulate CBi receptor expression in cerebellar granule neurons compared 
with the control concentration of KCI (5mM) by Vallano and colleagues in 2006 
(Vallano et a!., 2006). In the current experiment, the high concentration of KCI 
treatment was employed in use of PC12 cells in order to ensure PC12 is a 
suitable neuronal cell line to study the regulation of CBi receptors.
The effect of KCI (25mM) on the expression of CBi mRNA and GAPDH in 
PC12 cells was investigated, and gel electrophoresis with EtBr staining was 
employed to determine the amount of gene expression in terms of the intensity 
of fluorescence signal (Figure 4.1). As seen in Figure 4.1 (B), the upper image 
shows the fluorescence signal of GAPDH, which were bright bands in both 
cases, suggesting the increase of KCI concentration in the medium had no 
great impact on the expression of GAPDH in PC12 cells. However, the 
fluorescence signal of CBi (the lower image) was noticeably decreased in the 
concentration of 25mM compared to that in the concentration of 5mM, 
indicating the gene expression of CBi mRNA in PC12 cells was considerably 
diminished as the concentration of KCI was augmented from 5mM to 25mM.
The intensities of CBi mRNA signal bands at 5mM and 25mM were quantified 
and normalized by those of GAPDH expressed at the same concentration of 
KCI respectively (Figure 4.1 A). Taking the normalised CBi band intensity with
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KCI 5mM as 100%, the high concentration of KCI (25mM) significantly 
decrease the CBi mRNA expression by 60%. This result suggests that 
membrane depolarisation down regulates the expression of CBi receptors in 
















Figure 4.1 Reverse transcription-PCR analysis of the effect of potassium choride on 
CB, cannabinoid receptor mRNA expression in PC12 cells. RT-PCR was performed 
on total RNA (2 pg) extracted from cells cultured for 6 days in the presence of 50 
ng/ml nerve growth factor and 5 or 25mM KCI. (A) After gel electrophoresis and 
ethidium bromide staining, the intensity of the CBt bands was quantified by 
densitometry, and normalised relative to GAPDH and the positive control of KCI 
5mM. Data is expressed as individual value from three independent experiments (*, 
P < 0.05, unpaired Student’s f-test). (B) Representative gel of RT-PCR reactions: 
marker, <t>X174 RF DNA/Haelll fragments.
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4.3 The effect of glucose on CBi gene expression in an in vitro cell
model
4.3.1 Conventional RT-PCR
Figure 4.2 shows the gene expression of CBimRNA in PC12 cells cultured in 
varying concentration of glucose and its statistical analysis. The representative 
gel result is displayed in Figure 4.2 (B), showing that the strongest band of 
CBimRNA was observed in the positive control, rat brain. A strong 
enhancement in CBimRNA signal was observed when the glucose 
concentration was raised from 5.5mM (physiological glucose level) to 10mM. 
When the concentration of glucose was further increased to 20mM and 30mM, 
the gene expression of CBi appeared similar strength but had a reduction in 
comparison with that expressed in culture medium with 10mM glucose. The 
reduction of gene expression would be enhanced as the increase of glucose in 
the culture medium. The florescence signal attributed to the gene expression 
in 40mM and 50mM glucose levels dramatically declined in contrast with those 
expressed in 10mM glucose levels.
The GAPDH was employed as the reference gene due to its stable expression
in cells cultured at any concentration of glucose. GeneSnap were used to
quantify the density of the bands of both CBi mRNA and GAPDH. The data of
signal density of CBimRNA normalized by that of GAPDH were plotted (Figure
4.2 A), and the means were then statistically explored (n=5). For the gene
expression in any individual treatment where the concentration of glucose was
constant, it was clearly shown that there was a wide range of data distribution
in the similar range, and there was no significant difference of the expressed
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CBimRNA in PC12 cells cultured with a wide range of glucose concentration. 
The reason causing variable results may due to the considerable amount of 
undifferentiated cell samples.
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Figure 4.2 Reverse transcription-PCR analysis of the effect of glucose on CBt 
cannabinoid receptor mRNA expression in PC12 cells. RT-PCR was performed on total 
RNA (2 pg) extracted from cells cultured for 6 days in the presence of 50ng/ml nerve 
growth factor, 5.5-50mM glucose and 30 or 50mM Mannitol. (A) After gel 
electrophoresis and ethidium bromide staining, the intensity of the CBi bands was 
quantified by densitometry, and normalised relative to GAPDH. Mannitol (30 and 50 
mM) was used to exclude potential effects of increased osmolality (M30, M50). Data 
expressed as individual values from five independent experiments (P > 0.05one-way 
ANOVA-Fisher’s post-hoc analysis). (B) Representative gel of RT-PCR reactions: -ve, 
the negative control (i.e. minus template); +ve, the positive control (mRNA extracted 
from rat brain); marker, 0X174 RF DNA/Haelll fragments.
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The RT-PCR detecting the CBi expression in 5.5 or 50mM glucose and 50mM 
mannitol was conducted again after optimising the plating method and 
purchasing new batch of NGF. The RNA was extracted from PC12 cells on 6 
days of culture when a full differentiation was observed.
As shown in the representative image of gel results (Figure 4.3 B), it was 
observed that the density of CBi band at glucose 50mM was weaker than 
those at glucose 5.5mM and mannitol 50mM (the upper image). There was no 
obvious difference observed on the CBi bands at glucose 5.5mM and mannitol 
50mM. Beta-actin was used here to replace GAPDH as the reference gene in 
order to exclude the influence of saturation. The lower image shows that the 
intensity of beta-actin bands was comparable among these three treatments.
The density of bands was measured and the results from four independent 
experiments are shown in Figure 4.3 (A). It was found that 50mM glucose 
significantly decreased CBimRNA expression (P<0.05) to 57% of the control 
level. The CBimRNA expression in mannitol 50mM was 110% of the control 
level, which was also significantly higher than that in glucose 50mM (P<0.05). 
The result excluded the effect of osmolality on the CBi expression, indicating 
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Figure 4.3 Reverse transcription-PCR analysis of the effect of glucose on CB  ̂
receptor mRNA expression in PC12 cells. RT-PCR was performed on total RNA (2 pg) 
extracted from cells cultured for 6 days in the presence of 50 ng/ml nerve growth 
factor, 5.5 or 50 mM glucose and 50mM Mannitol. (A) After gel electrophoresis and 
ethidium bromide staining, the intensity of the cDNA for CB, (320bp) was quantified by 
densitometry, and normalised relative to P-actin (302bp). Data expressed as individual 
values from four independent experiments (*, P < 0.05: one-way ANOVA-Fisher’s 
post-hoc analysis). The amount of CBi products was normalised to the corresponding 
beta actin and the control level of 5.5mM. (B) Representative gels of RT-PCR 
products. M = marker, <t>X174 RF DNA/Haelll fragments.
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4.3.2 Real time-PCR
The fluorescence dye, SYBR GREEN, binds to only double strand DNA, so that, 
more DNA template exists, greater fluorescence is generated. Therefore, the 
cDNA with most target products reaches the exponential phase first with lowest 
threshold cycles (CTso)-
As CBi receptors express abundantly in brain, rat brain RNA was used here to 
validate the real-time PCR conditions by applying a serial concentration of rat 
brain RNA template (0.04-0.68pg). The real time-PCR result (Figure 4.4 A) 
showed that the threshold cycles for the reactions were on a reverse-manner of 
the amount of RNA applied. The reaction with biggest amount of RNA (0.63pg) 
reached the exponential stage first with a lowest CT50 and the reaction with 
lowest amount of RNA (0.04pg) reached exponential stage last with a highest 
CT50.
The real-time PCR products were run on an agrose gel in order to assure the 
accuracy of SYBR GREEN-dependent CBt detection. The gel result (Figure 4.4 
B) showed the intensities of CB1 bands were on a template concentration- 
dependent manner, indicating the amount of final CB1 products was on 
proportion to the amount of RNA templates. The gel result was consistent with 
the real-time result, suggesting the real-time conditions are optimised for 
detecting CB1 expression in samples.
Figure 4.5 (A) shows representative traces of CB1 expression in PC12 cells 
cultured in glucose 5.5, 50mM and mannitol 50mM with (3-actin as the 
reference gene. It can be seen that the threshold cycle of CB1 from glucose 
50mM is much later than those of CB1 from glucose 5.5mM and mannitol
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50mM. In comparison, the traces of (3-actin from all treatment stay very close. 
This result suggests less CBi target fragments in glucose 50mM. The melting 
curve of both CBi and p-actin (Figure 4.5 B) shows clean products above 80°C.
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Figure 4.4 Real time-PCR analysis of the CB! receptor mRNA expression in rat brain. 
(A) The fluorescence traces representing CB, amplification from rat brain 0.04, 0.08, 
0.16, 0.32 and 0.64 pg. (B) The agrose gel result of real time-PCR products. Maker, 





















Figure 4.5 Representative real time-PCR analysis of the CB! receptor mRNA 
expression in PC12 cells. (A) The fluorescence traces representing CBi/p-actin 
amplification from PC12 cells cultured in glucose 5.5 and 50mM and mannitol 50mM. 
(B) The melting curves of real time-PCR products.
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4.4 The cannabinoid CBi protein expression in hyperglycaemic PC12 
cells and DRG neurons from diabetic rats
4.4.1 In  v itro  cell model
4.4.1.1 Immunocytochemistry
The PC12 cells on day 6 of culture in 5.5mM and 50mM glucose conditions 
were stained by using CBi (red) and TRPVR1 (green) antibodies, and 
monitored by using confocal microscopy to investigate the expression level of 
CBi receptors. Figure 4.6 (A) shows a representative image displaying a fully 
differentiated cell cultured in 5.5mM glucose on day 6. As seen in Figure 4.6 (B 
and C), it was observed that the soma and neurite outgrowths of PC12 cells 
expressed CBi receptors, with immunofluorescence associated predominantly 
on the neurite tips and cell body membrane. The decreased 
immunofluoresence of CBt (red) was observed in cells cultured in 30mM and 
50mM glucose levels (Figure 4.6 E and F) compared with the fluorescence in 
cells cultured in 5.5mM glucose levels (Figure 4.6 D), indicating downregulation 
of CBi protein in cells treated with high glucose (30 and 50mM). Meanwhile, 
the co-staining revealed TRPV1-postive immnofluoresence (green) in cells 
cultured in all of three conditions, suggesting the TRPV1 protein is not 
degraded in response to high glucose (30 and 50mM).
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Figure 4.6 Confocal and Western analysis of CB! receptor expression in differentiated 
PC12 cells cultured in variable glucose concentrations. Immunoreactivity 
(fluorescence) is associated with the soma and neurites: red corresponds to CBt 
receptor label (rhodamine) and green to TRPV1 receptor label (FITC). (A), (B) and (C) 
reveal highly differentiated PC12 cells, and the cellular location of CBt expression 
when cultured in 5.5 mM physiological glucose concentration (single staining for CB^. 
(D), (E) and (F) represent the graded reduction of CB, receptor protein (red) 
expressed in PC12 cells cultured in glucose 5.5, 30, and 50 mM, respectively (dual- 
staining for CB! and TRPV,). Representative images of six independent cultures. 
Scale bar = 10 pm. x40 magnification.
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4.4.1.2 Western blotting and immunoprécipitation
The CBi receptor expression was further confirmed by using Western blot and 
immunoprécipitation. The western blot result (Figure 4.7 A) showed there was a 
reduction of CBi protein in cells cultured in 50mM glucose compared with that 
in cells cultured in 5.5mM glucose although double bands appeared in each 
condition. In order to obtain highly specific bands and improve the initial protein 
concentration loaded into SDS gels, immunoprécipitation was adopted to detect 
CBi protein. The result (Figure 4.7 B) showed a very clear single band of CBi 
protein at 60kDa and a reduced density of CBi band in the lane of 50mM 
glucose compared to that in the lane of 5.5mM glucose, whilst the reference 
protein, beta-actin, remained unchanged.
The CBi bands from four independent experiments were measured by 
densitometry and analyzed as shown in Figure 4.7 (C). Taking CB-i protein 
levels in 5.5mM conditions as 100%, the CBi receptor was significantly 
reduced in 50mM conditions by 40%. This indicates a downregulation of CBt 
protein expression in PC12 cells cultured in high glucose conditions (50mM).
As protein kinases disrupt CBi protein activities by phosphorylating CBrserine, 
the phosphorylation of CBi receptor was also studied by applying anti- 
phosphorylated serine antibody to the precipitated CBi protein. The result 
(Figure 4.8 A) showed that the phosphorylation level of CB-\ receptors was less 
in cells cultured in 50mM glucose than in cells culture in 5.5mM glucose (left 
panels). The CBi protein from same samples was conducted as controls (right 
panels). The bands were measured and normalised to control CBi protein 
levels from 5.5mM and 50mM glucose correspondingly. The result (Figure 4.8
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B) showed phosphorylated CBi protein levels were relatively equal in 5.5mM 
and 50mM glucose conditions without significant differences.
A Western blot Immunoprecipitate
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Figure 4.7 Western blot analysis confirmed the reduction of CÊ  receptor protein in 
cells cultured in high glucose. (A) Representative image of western blot of CBt protein 
(60 kDa) in 5.5 or 50mM glucose levels. (B) Representative image of 
immunoprecipitate of CBi protein (60 kDa) in 5.5 or 50mM glucose levies. (C) The 
intensity of the band for CBt was quantified by densitometry and normalised to (3-actin 
band intensity, and is expressed a percentage of the control level (5.5 vs. 50 mM 








Figure 4.8 Immunoprecipitate analysis of phosphorylation of CB! receptors in PC12 
cells cultured in 50mM glucose versus controls (5.5mM). (A) Representative images of 
phosphorylation levels of CBï receptors (left panel) and CBi protein (right panel) in 
PC12 cells cultured in the control (5.5mM) and 50mM glucose. (B) The intensity of the 
bands for phosphorylated CB! receptors were quantified by densitometry and 
normalised to CB-i band intensity, and is expressed a percentage of the control level 
(5.5 vs. 50mM glucose, P > 0.05, unpaired Student’s t-test, n = 4 independent 
cultures).
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4.4.2 In  v ivo  model
4.4.2.1 Optimisation of immunohistochemistry on formalin fixed paraffin 
embedded tissue samples
Paraffin fixation masks the antigenicity of tissue samples, so that an 
appropriate antigen retrieval procedure prior to immunostaining is very 
important to improve the signal of immunofluoresence by unmasking antigen. In 
the current experiment, human mid-brain tissue sections were employed as the 
abundant expression of CBi receptors and rich existence of A and C fibres.
A dual staining of CBi plus A/C fibres or A plus C fibres was conducted in order 
to examine the efficiency of antibodies, dual staining protocols as well as 
antigen retrieval techniques (stated in methods). The immunofluorescence of 
CBi protein, A and C fibres detected by the antibodies was all observed in the 
brain samples (Figure 4.9). Figure 4.9 (A) shows that CBi receptor was highly 
co-localised with C fibres, in contrast, there was only a partial co-localisation 
observed between CBi and A fibres (Figure 4.9 B). The dual staining of A and 
C fibres showed an interlocked distribution of these two type of fibres in human 
brain samples. The sensitive immunofluoresence and accurate detection 
indicates the antibodies, dual staining protocols and antigen retreiveal 
techniques are efficient to detect the expression and location of CBi receptors.
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Figure 4.9 Confocal detection of the colocalisation of cannabinoid CBt receptors, and 
A or C fibres in human mid-brain. (A) represents the colocalisation of CBi receptors 
and C fibres, red corresponds to C fibres and green to CBi receptors. (B) represents 
the colocalisation of CBi receptors and A fibres, red to A fibres and green to CB, 
receptors. (C and D) represent the colocalisation of A and C fibres, red to C fibres and 
green to A fibres.
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A single CBi staining was conducted in order to investigate the CBi expression 
in DRG neuron samples from control or diabetic rats. Figure 4.10 shows that 
the immunofluorescence of CBi protein (red) was mainly located on small and 
intermediate neurons, indicating CBi receptors predominately expressed on 
small and intermediate sized DRG neurons. The results revealed that a lower 
level of CBi receptors existed in DRG neurons from diabetic rats (Figure 4.10 B 
and D) when compared with those expressed in control DRG neurons (Figure 
4.10 A and C). The positive CBi immunofluoresence was further confirmed by 
the negative control showing no clear immunofluoresence detected when 
omitting the first CBi antibody.
CBi positive neurons in each section were quantified as shown in Figure 4.10 
(F). It was found that CBi positive neurons were 49% of total neurons from 
control rats and 26% of total neurons from diabetic rats. There was a significant 
reduction on CBi expression in DRG neurons from diabetic rats compared with 
controls.
The result was further confirmed by using Western blot. Figure 4.11 (A) shows
that the intensity of CBi bands was observed to be decreased in the lane of
diabetic rats compared to the intensity of CBi bands in the lane of control rats.
The reference protein of beta-actin was detected to be unchanged in the same
samples. The intensity of CBi bands were quantified and normalised to beta-
actin. The results (Figure 4.11 B) showed that the CBi expression in diabetic
DRG neurons was 38% of the control levels. This was a more than 2-fold
reduction with significant difference (P<0.01) on CB-i protein levels.
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4.4.2.2 Immuno-detection of CBi protein expression in DRG neurons
from control and diabetic rats
Figure 4.10 Confocal analysis of CB, protein expressed in rat DRG. Immunoreactivity 
(fluorescence) is associated with the DRG neuron cell bodies: red corresponds to CBt 
receptor label (rhodamine) under x40 magnification. (A and C) represent CB, postive (+) 
and negative (-) DRG neurons in control rats. (B and D) represent CB! postive (+) and 
negative (-) DRG neurons in diabetic rats. (E) represents the negative control of CB! 
staining by omitting the first antibody. Scale bar = 50pm. When expressed as a 
percentage of total neuron count per section, (F) shows that experimental diabetes 
significantly decreased the number of CBr positive neurons (approximately twofold) in 
the 4-8 week diabetic animals compared to controls. Data shown are the mean ±29 
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Figure 4.11 Western blot analysis of CBt receptor expression in rat DRG. The 
expression level of CB1 receptor protein markedly decreased on plasma membranes 
of DRG neurons from diabetic rats (DM) as compared with the controls (CT). The 
intensity of the band for CBi (60 kDa) was quantified by densitometry and normalised 
to p-actin band intensity, and is expressed a percentage of the control level (**, P < 
0.01: unpaired Student’s f-test, n = 3 per group).
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The degenerated small neuron fibres are believed to be mainly involved in the 
progression of painful neuropathy occurred in diabetic patients. The current 
experiment examined the CBi protein level in C and A5 fibre-DRG neurons 
from diabetic rats in order to investigate whether loss of CBi receptor occurs on 
small fibre neurons in diabetic conditions.
Figure 4.12 shows the representative confocal images of dual CBi and C fibre 
immunoreacitivity in rat DRG neurons. The result revealed that the co­
localisation (yellow) of CBi receptors (green) and C fibres (red) were less in 
diabetic DRG neurons (Figure 4.12 A and C) than that observed in control 
neurons (Figure 4.12 B and D), indicating a reduction of CBi expression on C 
and A5 fibres in DRG neurons from diabetic rats compared with controls.
4.4.2.3 Immuno-detection of the co-expression of CBi receptors and C
fibres in DRG neurons from control and diabetic rats
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Figure 4.12 Confocal analysis of co-localisation of CBi protein and C fibre in rat 
DRG neurons. Dual-staining for CB-i (green fluorescence) and C- and A5-fibers (red 
fluorescence) associated with DRG cell bodies in (A and C) control and (B and D) 
diabetic rats under low magnification (x20); scale bar = 75pm.
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4.5 Discussion
Based on the observation in the previous chapter, PC12 cells reproduced some 
of the phenomena of diabetic neuropathy when exposed to that chronic of high 
glucose. PC12 cells were chosen as an in vitro model of diabetic neuropathy to 
investigate the effect of glucose on expression of CBi receptors. Furthermore, 
these cells are known to express both CBi receptors (Bisogno et al., 1998) and 
TRPV1 receptors (Someya etal., 2004).
To our knowledage, this is the first study to investigate the role of CBt 
receptors in diabetic neuropathy by using PC12 cell model. We, therefore, 
decided to confirm that this cell line is capable of reflecting changes in CBi 
expression induced by exogenous stimuli. A previous study conducted by 
Vallano et al., (2006) showed that depolarizing the cell membrane by 
increasing the KCI concentration from 5 to 25mM in culture medium down- 
regulates CBt expression in CBi-rich cerebellar granule neurons, which 
subsequently alters down-stream signal transduction (Vallano et al., 2006). By 
adopting the method in PC12 cells, the membrane depolarization was found to 
down-regulate CBi mRNA level by 60% on day 6 of culture. The consistent 
result strongly suggests PC12 is a valid neuronal cell line to study changes in 
CBi expression in an in vitro model of diabetic neuropathy.
The regulation of CBt gene expression was firstly studied in PC12 cells
cultured in a range of glucose treatments (5.5, 10, 20, 30,40 and 50mM) under
the stimulation of NGF (50ng/ml). It can be seen that the results were highly
variable, although there is a trend towards decreased CBi expression, which
may due to the unequal amount of differentiated cells, based on the
observation that PC12 cells did not fully attach and were poorly differentiated
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during the experiment. To address this issue, we compared the CBi gene 
expression in undifferentiated cells and NGF-induced differentiated cells, both 
cultured in physiological glucose (5.5mM), after optimising the plating method 
by extending the drying time of poly-L-lysine coated-plates and purchasing a 
new batch of NGF. The results show that, in 5.5mM glucose, NGF-induced 
differentiated cells had more CBimRNA than the raw cells, which suggests that 
the undifferentiated cells masked the effect of glucose on CBi expression in 
differentiated cells. The likelihood of NGF regulating CBt expression seems to 
be ruled out by evidence provided by Ahluwalia et al, (2002) showing that the 
number of CBi expressing DRG neurons did not decline without NGF 
supplement in culture (Ahluwalia et al., 2002). However, in that study the 
existence of CBi receptors was only defined in the neuronal cell body by 
immunostaining (Ahluwalia et al., 2002), the lack of quantitative measurement 
(eg. Western blot) and omission of axons and dendrites may have led to an 
inaccurate conclusion of NGF-related CBi expression.
By ensuring PC12 cells were optimally differentiated, high glucose was found to 
decrease the expression of CBi receptors at the RNA level by using both 
conventional RT-PCR (50% decrease) and real time PCR (ACT=4). Based on 
the evidence that CBi receptors are synthesised in the cell body and inserted 
to axonal terminals (Hohmann and Herkenham, 1998, Hohmann and 
Herkenham, 1999), the impaired neurite outgrowth induced by high glucose 
may related to the decreased CBtitiRNA expression.
Subsequently, the effect of high glucose on CBi receptors at the protein level 
was also examined. Immunocytochemical analysis revealed CBi receptors are 
located predominantly on the plasma membrane of the soma and neurite tips,
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which may be related to the existence of CBi receptors on presynaptic 
terminals regulating neurotransmitter release (Domenici et at., 2006). From the 
immunostaining images, an overt reduction in CBi receptor protein expression 
was seen with high glucose, whilst TRPV1 receptors, a nociceptive neuronal 
maker, were strongly expressed in PC12 cells at both glucose concentrations, 
which supports the hypothesis that the decreased CBi protein expression is 
involved in the pathogenesis of diabetic neuropathy. These results, together 
with the later Western blot analysis showing a 50% loss of CBi receptors in 
PC12 cells cultured in 50mM glucose, suggest that high glucose decreases 
CBi protein expression. It is known that neurotransmitters and neuropeptides 
transduce the cell signals from the painful stimuli to the central nervous system, 
and depletion of CB1 receptors elevates neuropeptide release in mice (Steiner 
et at., 1999). Combined with the findings showing that hyperglycaemia 
enhances neurotransmitter secretion from PC12 cells (Lelkes et at., 2001), the 
results of decreased CB-i expression in the current study may indicate that the 
enhanced neurotransmission induced by hyperglycaemia is due to the loss of 
CBi receptors.
These results were corroborated in DRG from diabetic rats, where the number
of CBi-positive neurons was decreased to approximately half that of control
animals, and the density of CBi receptors was reduced by 60% in diabetic
versus control DRG. Previous studies report 25-57% of DRG neurons are CB-i-
positive in rats (Ahluwalia et al., 2000; Bridges et at., 2003). The decrease in
number of CBi-positive neurons might reflect a cessation of CBi synthesis in
neurons that normally express CBi (a phenotypic switch), or simply that the
level of expression was undetectable due to reduced receptor density. CBi
receptors mediate, in part, the neuroprotectant properties of cannabinoids
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(reviewed by van der Stelt & Di Marzo, 2005), and any decrease in expression 
is expected to contribute to the development and progression of the 
neurodegeneration associated with diabetes. A study recently published by 
Duarte et al. (2007) revealed decreased CBi mRNA expression in the 
hippocampus of diabetic rats, concomitant with an increase in CBi protein 
density. Whilst the mRNA data are in agreement with our findings, differences 
in neuronal CBi protein expression between hippocampus (f Duarte et al., 
2007) and DRG (| present study) from STZ-induced diabetic rats may reflect 
site-specific signalling pathways involved in mRNA translation, e.g. activation of 
the key rate-limiting translational pathway mTOR in hippocampal neurons 
(Duarte et al., 2007).
Abnormal cell signalling induced by increased PKC activity is indicated in the 
pathophysiology of diabetes. PKC was reported to disrupt CBi activity by 
phosphorylating the receptors (Garcia et al., 1998). We, therefore, examined 
the phosphorylation level of CB-i receptors in the cell model of diabetic 
neuropathy. It was found that the phosphorylation level of CBi receptors was 
relatively equal in both glucose concentrations, suggesting the CBi activity is 
preserved. This result may be positively connected to two recent animal studies 
showing anti-nociceptive action of a mixed cannabinoid CB1/CB2 receptor 
agonist is preserved in diabetic mice (Dogrul A, et al., 2004) and rats (Ulugol A, 
et al., 2004). However, a CB-i function study, investigating whether a decreased 
CBi receptor leads to a decreased function in this cell model, was warranted. 
The results of this study are presented in Chapter 5.
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CHAPTER 5




This chapter investigates whether the function of CE  ̂ receptors is altered in 
PC12 cells cultured in high glucose, mimicking hyperglycaemic conditions, 
where we have previously found a decreased CBt expression. TRPV1 
receptors are a non-selective cation channel sensitive to the pungent vanilloid 
capsaicin (Caterina et al., 1997). Capsaicin-evoked CGRP release from 
sensory neurons is inhibited by the endocannabinoid, anandamide (Richardson 
et al., 1998a). This effect is mediated by cannabinoid CBi receptors, which are 
co-expressed with TRPV1 in nociceptive afferents (Ahluwalia et al., 2002; 
Ahluwalia et al., 2003). Activation of CBi receptors suppresses neuropeptide 
release via inhibition of Ca2+ channels and activation of K+ conductance; in vivo 
and in vitro studies have shown that CBi agonists inhibit capsaicin stimulated- 
Ca2+ entry into sensory neurons via a CBrdependent pathway (Kelly and 
Chapman, 2001; Oshita et al., 2005). In the current studies, the CBi agonist, 
HU210, was used to assess CBi-mediated inhibition of capsaicin-evoked Ca2+ 
influx in the neuronal cell line, PC12. In 2005, Hong and Wiley demonstrated a 
greater Ca2+ current in response to capsaicin occurred in sensory neurons from 
diabetic rats (Hong and Wiley, 2005). It is important to know whether a 
decreased CBi receptor expression leads to a decreased function, resulting in 
increased signal transduction towards TRPV1 receptors in the model of 
diabetic neuropathy.
The aims of this chapter were to determine 1) whether TRPV1 receptors were 
sensitised in differentiated PC12 cells cultured in high glucose mimicking 
hyperglycaemic conditions; 2) whether CBi receptors lost their function in 
response to high glucose in PC12 cells. In the experiments of this chapter,
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PC12 cells were cultured in physiological glucose level (5.5mM) and high 
glucose level (50mM) under the stimulation of NGF (50ng/ml) for 6 days. A 
Ca2+ imaging assay was used to assess the CBi receptor function in 
differentiated PC12 cells from both conditions. A considerate number of 
preliminary experiments were conducted to optimize the techniques. The 
optimal concentration of Ca2+ indicator dye, duration of incubation, frequency of 
scanning, and the time point for the stimulation, were all very important to 
ensure the efficient capture of Ca2+ influx by confocal microscopy. A 
concentration- response course was conducted to obtain the optimal 
concentration of capsaicin and HU210 response in differentiated PC12 cells. 
Having established the capsaicin response and inhibitory effect of HU210 on 
Ca2+ influx, the selective CBi receptor antagonist, AM251, and the selective 
CB2 receptor antagonist, AM630, were used to examine whether the inhibition 
of Ca2+ influx was mediated by CBi receptors, and/or CB2 receptors, 
respectively.
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5.2 Optimization of parameters for Ca2+ imaging assay with confocal 
microscopy
The parameters of Ca2+ imaging were optimized in the preliminary studies. In 
these experiments, the applicability and efficacy of the optimized conditions 
was determined by stimulating intracellular Ca2+ increase in PC12 cells by KCI 
(70mM; depolarizes cell membrane) and thapsigargin (10mM; releases Ca2+ 
from intracellular stores), which was monitored by using a confocal microscope. 
PC12 cells were incubated with 5pM of fluo-3 AM, a calcium-sensitive 
fluorescence dye, for 40 minutes at 37°C before the stimulation.
In Figure 5.1, the upper panel of confocal images shows the fluorescence 
increase, indicating intracellular Ca2+ concentration was induced by KCI 
(70mM). The lower panel of confocal images shows that thapsigargin 
stimulated a second rise of fluorescence which was due to release of 
intracellular Ca2+ stores. Representative traces revealed that a rapid increase 
in Ca2+ levels stimulated by KCI and the Ca2+ level is maintained above 
baseline levels for more than 600 seconds, and the second stimulation with 
thapsigargin induced a further rise in intracellular Ca2+, which was more 
transient in nature (Figure 5.1 B).
This result indicates that the concentration of fluo-3 AM and the time scale of 
the incubation with PC12 cells, as well as the continuous scan used in this 




Figure 5.1 Ca2+ influx induced by the addition of KCI and Thapsigargin. (A) Upper 
Box: confocal images (i) before (ii) 300 seconds after (iii) 600 seconds after the 
stimulation of potassium chloride. Lower box: confocal images (iv) before (v) 300 
seconds after (vi) 600 seconds after the stimulation of thapsigargin. (B) A 
representative trace of the intracellular Ca2+ change stimulated by KCI and 
thapsigargin in a single PC12 cell (pointed out by the white arrow). The cell was 
exposed to potassium chloride (70mM) for 600 seconds followed by the addition of 
thapsigargin (10pM).
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5.3 Ca2+ influx triggered by Capsaicin (1pM)
Initial experiments were designed to test multiple treatments of capsaicin and 
HU210 in one sample. PC12 cells cultured in 50mM glucose were loaded with 
fluo-3 AM (5pM) for 40 minutes at 37°C. As shown in Figure 5.2 (A), in control 
levels, the addition of vehicle (HEPES buffer) caused a small amount of 
intracellular Ca2+ fluctuation. The following treatment with capsaicin 1pM 
triggered a large Ca2+ influx in the fluo-3 labelled PC12 cells. After Ca2+ 
returned to baseline, HU210 (1pM) was added prior to capsaicin (1pM) in order 
to study the inhibitory effect of HU210 on Ca2+ entry. This combination of 
HU210 (1pM) and capsaicin (1 pM) also induced a comparable amount of Ca2+ 
influx, which did not show a dramatic decrease compared with the previous 
single exposure to capsaicin. After removing the HU210, the exposure to 
capsaicin again stimulated a large transient Ca2+ influx, which proved the cells 
were not desensitised by the previous repeated application of capsaicin. At the 
end, a larger Ca2+ influx was observed after the addition of the positive control, 
KCI (70mM). Statistically, the inhibitory capacity of HU210 in PC12 cells 
cultured in 50mM glucose is summarized in Figure 5.2 (B). It shows that the 
fluorescence intensity produced by capsaicin was 390.8±39.7 which is 
significantly higher than that produced by the combination of HU210 and 
capsaicin (278.4±53.1) (P<0.05). In other words, HU210 (1pM) inhibits the Ca2+ 
influx triggered by 1 pM of capsaicin by 29.77%.
The most common concentration of capsaicin used for the stimulation of Ca2+
influx in primary neuronal cells, such as DRG cells is no more than 1pM (Dedov
and Roufogalis, 1998, Khasabova et al., 2002, Winter, 1987). However, it is
worth mentioning that in this study, only 5% of tested PC12 cells cultured in
50mM glucose were found to respond to capsaicin at 1pM. In fact, less than
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5% of tested PC12 cells from control (5.5mM glucose) cells were found to have 
a detectable capsaicin response at 1pM. Therefore, a capsaicin concentration- 
response curve was needed to be conducted in order to find an appropriate 








Figure 5.2 Inhibition of the response of Ca2+ influx to capsaicin in the presence of 
HU210 in PC12 cells cultured in 50mM glucose for 6 days. (A) is a representative 
trace monitoring fluorescence change in PC12 cells during treatments indicated. 
Firstly, cells were treated with vehicle and capsaicin (1 pM) without any inhibitor; then 
pre-incubated with HU210 (1 pM) for 3 min before addition of capsaicin; then, a third 
dose of capsaicin alone followed by KCI after the washout of capsaicin is the end. (B) 
shows the values which are expressed as the mean ± S.E. of the increased 
fluorescence above the basal fluorescence. The increase of fluorescence intensity in 
the PC12 cells treated with capsaicin (1 pM) was significantly different from HU210 
1pM (pre-treatment for 3 min) plus capsaicin (n=8). (*, P<0.05 Student’s paired f-test).
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5.4 Capsaicin concentration-response curve
In these experiments, the Ca2+ indicator, fluo-3 AM was replaced by its 
analogue, fluo-4 AM, since fluo-4 AM emits fluorescence brighter under the 
same wavelength. All the other preparation remained unchanged. In addition, a 
single treatment of capsaicin followed by KCI (70mM) was adopted in order to 
improve the applicability and remove the concern of TRPV1 desensitisation. 
Therefore, the capsaicin response was normalized to KCI response to exclude 
the influence of variable fluorescence baseline and response capacity from 
each individual cell.
In the capsaicin concentration-response study, a range of capsaicin 
concentrations (1- 700pM) were used to generate a Ca2+ influx in differentiated 
PC12 cells. As shown in Figure 5.3, capsaicin above 50pM was able to 
stimulate Ca2+ entry in PC12 cells, and the capsaicin response followed a 
concentration-dependent manner up to 700pM. The representative images in 
Figure 5.3 show the rapid Ca2+ entry evoked by capsaicin. An application of 
KCI 70mM was used at 197 seconds after the recovered Ca2+ level, which 
generated a second peak of Ca2+ entry by depolarizing the cell membrane, and 
then allowed to return to baseline (images not shown). By the different 
mechanism of generation of Ca2+ influx, only the cells responsive to KCI were 
included for analysis to ensure the viability of cells.
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Capsaicin Concentrations (pM)
Figure 5.3 Concentration-response curve to the TRPV1 receptor agonist capsaicin, 
expressed as the change in fluo-4 fluorescence (=[Ca2+]i) as a percentage of the 
response to potassium chloride (70 mM); box: confocal images of fluo-4-loaded PC12 
cells (i) before, (ii) 120 seconds after (peak), and (iii) 200 seconds after stimulation 
with 300pM capsaicin.
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5.5 Ca2+ influx triggered by capsaicin (300pM)
From the capsaicin concentration-response curve, a single concentration of 
300pM capsaicin was adopted to compare the Ca2+ influx in PC12 cells 
cultured in control and hyperglycaemic conditions. The representative traces in 
Figure 5.4 show that capsaicin evoked an overt Ca2+ influx both in 5.5mM (A) 
and 50mM (B) conditions, followed by the second Ca2+ peak induced by the 
addition of KCI 70mM. The vehicle of capsaicin (DMSO 0.6%) did not stimulate 
Ca2+ increase in PC12 cells (C), which excluded the impact of DMSO on 
intracellular Ca2+ increase. To confirm the increased intracellular Ca2+ was 
caused by an influx from extracellular space rather than a release from 
intracellular Ca2+ stores, Ca2+-free buffer was adopted to replace normal buffer. 
As shown in Figure 5.4 (D), both capsaicin and KCI did not cause any 
intracellular Ca2+ increase in PC12 cells present in Ca2+- free buffer, suggesting 
that, in the previous experiments, the intracellular Ca2+ increase caused by 
capsaicin and KCI was indeed from extracelluar space. As summarized in 
Figure 5.4 (E), after normalizing the capsaicin-evoked fluorescence (~ [Ca2+]i) 
increase to the response to KCI, the maximal intracellular Ca2+ level after the 
stimulation of capsaicin (300pM) in PC12 cells cultured in 50mM glucose was 
significantly greater than that in PC12 cells cultured in 5.5mM glucose (P<0.05). 
The magnitude of Ca2+ influx in 50mM cells was 40% greater than in control 
cells. Considering that capsaicin is a TRPV1-receptor agonist (confirmed in the 
following experiment), the results suggest that the TRPV1 receptor was 
sensitized in PC12 cells cultured in hyperglycaemic conditions.
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Figure 5.4 Representative traces showing changes in fluo-4 fluorescence induced by 
capsaicin (Cap, 300 pM) and potassium chloride (KCI, 70mM). (A) represents the 
control (5.5mM glucose), (B) represents the high glucose condition (50mM glucose), 
(C) represents the fluorescence changes induced by vehicle (0.6% DMSO) and KCI 
(70mM), (D) represents the fluorescence changes in Calcium-free buffer. (E) shows 
that the magnitude of capsaicin-evoked fluorescence increase is significantly larger in 
50mM cells than in 5.5mM cells (n=33-35). (*, P< 0.05 Student’s unpaired f-test).
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5.6 The inhibitory effect of capsazepine on Ca2+ influx induced by 
capsaicin
To confirm that the capsaicin-evoked Ca2+ influx was mediated by TRPV1 
receptors, capsazepine (CPZ), a TRPV1 receptor antagonist, was used to 
block the capsaicin-evoked Ca2+ influx. The representative traces in Figure 5.5 
showed that the co-application of CPZ with capsaicin prevented Ca2+ influx; 
however, KCI was still able to induce Ca2+ influx in PC12 cells cultured in either 
5.5mM (A) or 50mM (B) glucose condition. As summarized in Figure 5.5 (C), 
compared with the Ca2+ influx caused by capsaicin alone, the co-application of 
CPZ with capsaicin attenuated the effect of capsaicin on Ca2+ influx by 90% in 
5.5mM condition (P<0.01) and 85% in 50mM condition (P<0.01). The inhibition 
of capsaicin-evoked Ca2+ influx by CPZ indicates that capsaicin stimulates Ca2+ 
influx in PC12 cells via TRPV1 receptors.
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Figure 5.5 Capsazepine blocks capsaicin evoked Ca2+entry in PC12 cells. (A) and 
(B) Representative traces showing the change in fluo-4 fluorescence induced by 
capsaicin (300pM) and potassium chloride (KCI 70mM) with co-application of 
capsazepine for 5.5mM (A) and 50mM (B) glucose conditions. (C) With the co­
application of capsazepine, capsaicin response was reduced to 10% of control values 
in cells cultured in 5.5mM glucose (n= 18), and similarly to 15% of control values in 
cells cultured in 50mM glucose (n= 20). (**, P<0.001 Student’s unpaired f-test).
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5.7 Inhibitory effect of cannabinoid agonist HU210 on calcium influx 
is mediated by CB-i receptors, not by CB2 receptors
5.7.1 Concentration-response curve of inhibitory effect of HU210 on 
Ca2+ influx
A wide range of HU210 concentrations from 0.03-30pM was used to study its 
inhibitory effect on capsaicin-evoked Ca2+ influx. As shown in Figure 5.6, in 
PC12 cells cultured in 5.5mM glucose, HU210 showed a concentration- 
dependent inhibition (solid line), whereby, 0.03pM of HU210 did not inhibit 
capsaicin-evoked Ca2+ influx, and seen as 0%; 30pM of HU210 gave maximal 
85% inhibition.
HU210 concentration (pM)
0.03 0.3 3 30
Figure 5.6 Concentration-response curves of the inhibitory effect of HU210 on 
capsaicin evoked Ca2+ influx in PC12 cells. HU210 (0.03-30 pM) was incubated with 
PC12 cells for 5-10min before the addition of capsaicin (300 pM). The solid line 
represents the % inhibition in control PC 12 cells and the dashed line represents the 
% inhibition in PC12 cells cultured in hyperglycaemic conditions. The mean 
fluorescence increase from Ca2+ influx induced by capsaicin 300 pM in the absence 
of HU210 is considered as 100%. The % inhibition of HU210 on capsaicin induced 
Ca2+ influx is expressed as 100%-% Ca2+ influx induced by capsaicin in the 
presence of HU210. n=15-31 cells.
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In contrast, the HU210 concentration-response curve (shown in dashed line) in 
PC12 cells cultured in 50mM glucose is shifted to the right of the curve of 
5.5mM conditions. It shows that neither 0.03 nor 0.3pM of HU210 inhibited the 
Ca2+influx and was thus seen as 0% of inhibition. However, 30pM of HU210 
showed a similar maximal 84% inhibition to that in 5.5mM condition. At 3pM, 
HU210 blocked the Ca2+ influx by 44% in 50mM glucose condition, compared 
to 51% in 5.5mM glucose condition.
5.7.2 The effect of a selective CBi receptor antagonist on HU210 
responses
To examine whether the inhibitory effect of HU210 on Ca2+ influx is mediated 
by CBi receptors, the selective CBi antagonist, AM251, was employed. HU210 
(30pM) was chosen to give a maximal inhibition of capsaicin (300pM)-evoked 
Ca2+ influx. Responses to capsaicin and KCI were tested in PC12 cells cultured 
in both 5.5mM and 50mM glucose in the presence of HU210 30pM only, or 
HU210 30pM+ AM251 .
In Figure 5.7, (A) represents that Ca2+ influx in PC12 cells cultured in 5.5mM 
glucose. The trace on the left showed that capsaicin 300pM did not stimulate 
Ca2+ influx in the presence of HU210 30pM, however, KCI 70mM did induce a 
rapid Ca2+ entry in the same cells. In contrast, there was a small peak of Ca2+ 
influx stimulated by capsaicin only when the combination of HU210 30pM and 
AM251 30pM was present. Similarly, in PC12 cells cultured in 50mM glucose 
(B), the trace on the left showed that capsaicin (300pM) was unable to induce a 
overt Ca2+ influx in the presence of HU210 30pM and the trace on the right 
showed that capsaicin-evoked Ca2+ influx was recovered in the presence of 
HU210 30pM and AM251 30pM. KCI-induced Ca2+ entry were showed in both
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of the traces. The effect of vehicle of HU210 and AM251 was also tested. As 
shown in trace C, in the presence of vehicle only, capsaicin did stimulate a 
considerable level of Ca2+ entry.
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Figure 5.7 Representative traces showing changes in fluo-4 fluorescence induced by 
capsaicin (Cap, 300pM) and potassium chloride (KCI, 70mM), in the presence (left panels) 
of HU210 (30 pM) or with the co-application of AM251 (30 pM) (right panels), in 5.5 mM 
glucose (A) and 50 mM glucose (B). (C) shows the change in fluo-4 fluorescence induced 
by capsaicin and KCI in the presence of vehicle. Scale bar =120 seconds.
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Capsaicin (300pM)
HU210 (30pM) + Capsaicin (300pM)
AM251 (30pM) +HU210 (30pM) + Capsaicin (300pM)
5.5mM 50mM
Glucose concentration
Figure 5.8 HU210 inhibits capsaicin-evoked responses in PC12 cells In the presence 
of HU210 (30pM) the capsaicin response was reduced to 20% of control values in 
cells cultured in 5.5mM glucose, similarly to 23% of control in cells cultured in 50mM 
glucose (n = 29-42 cells per condition). The CBi receptor antagonist AM251 (30pM) 
was able to reverse the inhibitory response to HU210, confirming its effect was 
mediated via CB-i receptors (n = 33-50 cells per condition). Data shown are the mean 
± s.e.mean (*, P<0.05, unpaired Student’s f-test).
As summarized in Figure 5.8 , in the presence of HU210 30pM, the capsaicin 
response was significantly reduced to 20% of control values in 5.5mM glucose 
condition and 23% of control values in 50mM glucose condition which means 
that HU210 30pM gave 80% and 77% of inhibition of Ca2+ influx respectively. 
Meanwhile, AM251 (30pM) significantly reversed the inhibitory effect of HU210 
(30pM) in both 5.5mM and 50mM glucose conditions by recovering the Ca2+ 
peak back to 63% of control values and 69% of control values, respectively.
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In the previous experiments, a high concentration of HU210 had been used. It 
is possible, at 30pM, HU210 may have been acting non-specifically, therefore, 
in further studies, we decided to examine lower concentrations. From the 
HU210 concentration- response curve shown above, a concentration of 1pM 
was adopted to study the inhibitory effect on capsaicin-evoked Ca2+ influx. The 
selective CBi receptor antagonist, AM251 (1pM), was again used in order to 
confirm the inhibitory effect of HU210 was mediated by the CB1 receptor. 
Representative traces are shown in Figure 5.9. Similar to earlier findings, in 
PC12 cells cultured in 5.5mM glucose, capsaicin stimulated a visible Ca2+ influx 
in the presence of HU210, however, compared with the application of capsaicin 
alone, the Ca2+ peak was much smaller. The co-application of AM251 and 
HU210 reversed the inhibitory effect of HU210 on Ca2+ influx. The magnitude of 
Ca2+ peak was comparable to the Ca2+ peak induced by capsaicin alone. A 
second peak of Ca2+ induced by KCI confirmed the cell viability in both traces.
In PC12 cells cultured in 50mM glucose (Figure 5.9 B), the traces showed a 
very similar trend to those from the control PC12 cells; HU210 showed an 
inhibition of capsaicin-evoked Ca2+ influx, and co-application of AM251 
reversed the HU210 inhibition. As a control, a single application of AM251 
(1pM) was used to treat PC12 cells as shown in Figure 5.7 C demonstrating 
that AM251 itself did not induce any intracellular Ca2+ change (via possible 
inverse agonist actions).
The Ca2+ influx was quantified and is summarized in Figure 5.10. In PC12 cells 
cultured in 5.5mM glucose, HU210 (1pM) significantly inhibited the capsaicin- 
induced Ca2+ by 43%, and the co-application of AM251 (1pM) reversed the
5.7.3 The inhibition of Ca2+ influx by HU210 (1pM)
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HU210 inhibition, bringing the Ca2+ influx back to 100% when stimulated with 
capsaicin (300pM). In high glucose conditions, HU210 (1pM) also significantly 
attenuated the capsaicin-evoked Ca2+ influx by 40%, and in the presence of 
AM251 (1pM)+HU210 (1pM), the Ca2+ peak returned to 95% of the magnitude 


















Figure 5.9 Representative traces showing changes in fluo-4 fluorescence induced by 
capsaicin (Cap, 300pM) and potassium chloride (KCI, 70mM), in the presence (left panels) 
of HU210 (1pM) or with the co-application of AM251 (1pM) (right panels), for 5.5mM 
glucose (A) and 50mM glucose (B). The representative trace (C) showing changes in fluo- 
4 fluorescence induced by AM251 (1pM) or HU210 (1pM) alone followed by potassium 
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Figure 5.10 HU210 inhibits capsaicin-evoked responses in PC12 cells. In the 
presence of HU210 (1pM) the capsaicin response was reduced to 57% of control 
values in cells cultured in 5.5.mM glucose, similarly to 60% of control in cells cultured 
in 50mM glucose (n = 29-42 cells per condition). The CB! receptor antagonist AM251 
(1pM) was able to reverse the inhibitory response to HU210, confirming its effect was 
mediated via CB1 receptors (n = 33-50 cells per condition). Data shown are the mean 
± s.e.mean (*, P<0.05, **, P<0.01, unpaired Student’s t-test).
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AM630 is a selective CB2 receptor antagonist. An equal concentration of 
AM630 (1pM) was used to replace AM251 in these experiments in order to 
exclude the possibility that HU210 inhibits capsaicin-evoked Ca2+ influx by a 
CB2-mediated mechanism.
The addition of AM630 (1pM) had no significant effect on the inhibitory 
response of HU210 (1pM) in PC12 cells cultured in 5.5 and 50mM glucose 
(Figure 5.11). Compared with the previous study showing that HU210 (1pM) 
produced 43% of inhibition of Ca2+ influx in cells with 5.5mM glucose (Figure 
5.10), HU210 (1pM) +AM630 (1pM) in this study gave a comparable 41% 
inhibition (Figure 5.11 D), At 50mM glucose, levels of HU210-mediated 
inhibition were 40% in the absence (Figure 5.10), versus 39% in the presence 
of AM630 (Figure 5.11 D).
5.7.4 The effect of a selective CB2 antagonist on HU210 responses
154
D □  Capsaicin (300pM)
■ Capsaicin (300pM)+AM630 (1pM)/HU210 (1pM)
Glucose Concentration (mM)
Figure 5.11 The CB2 antagonist AM630 is unable to reverse the inhibitory effect of 
HU210 on Ca2+ influx triggered by capsaicin. (A) and (B) Representative traces 
showing changes in fluo-4 fluorescence induced by capsaicin (Cap, 300pM) and 
potassium chloride (KCI, 70mM), in the presence of HU210 (1pM) and AM630 (1pM), 
for 5.5mM glucose (A) and 50mM glucose (B). (C) Representative trace showing 
changes in fluo-4 fluorescence induced by AM630 (1pM) and potassium chloride (KCI, 
70mM), Scale bar = 120 seconds. (D) In the presence of HU210 (1pM) and AM630 
(1pM), the capsaicin response was reduced to 59% of control values in cells cultured 
in 5.5.mM glucose, similarly to 61% of control in cells cultured in 50mM glucose (n = 
29-42 cells per condition). The CB2 receptor antagonist AM251 (1pM) was unable to 
reverse the inhibitory response to HU210, confirming its effect was mediated via CBi 
receptors (n = 33-50 cells per condition). Data shown are the mean ± s.e.mean (**, 
P<0.01: unpaired Student’s t-fest).
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5.8 Discussion
CBi receptor stimulation suppresses TRPV1 -mediated calcium influx and 
neurotransmitter release (Millns et a/., 2001; Oshita et al., 2005). We therefore 
assessed CBi receptor function by measuring the inhibitory effect of HU210 on 
capsaicin-induced calcium influx in PC12 cells cultured in physiological and 
high glucose conditions.
Initial Ca2+ imaging experiments using fluo-4 AM revealed that intracellular 
fluorescence could be stimulated by KCI (70mM) and thapsigargin (10pM) in 
PC12 cells. The intracellular Ca2+ change caused by the two stimuli were 
through different mechanisms, indicating that the preparation procedure (3pM 
of fluo-4 with 0.04% of pluronic acid, 40 minutes loading incubation at 37°C, 
and 2.5mM calcium in HEPES buffer) and scanning frequency (3.93 second 
per scan) were optimal to detect the intracellular Ca2+ change from either 
extracelluar Ca2+ entry or release from intracellular Ca2+ stores.
In DRG and other TRPV1 expressing or recombinant cells, 0.1 to 10pM of 
capsaicin stimulates TRPV1-mediated Ca2+ influx (Oshita et al., 2005; Vriens et 
al., 2004), and the maximal concentration of 20pM gives a saturated response 
in DRG cells (Vellani et al., 2001). To keep the consistence with primary 
neurons, a most commonly used concentration, 1pM of capsaicin, was firstly 
used into PC12 cells. At the outset, the Ca2+ influx induced by capsaicin (1pM) 
and the inhibitory effect of HU210 (1pM) were studied in individual 
differentiated PC12 cell cultured in either control (5.5mM) or high glucose 
(50mM) conditions by applying multiple treatments. It was found that, in PC12 
cells cultured in high glucose, the Ca2+ influx induced by capsaicin (1pM) was 
detected in only 5% cells which responded to KCI (70mM), which was
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significantly inhibited by HU210 (1|jM). However, in PC12 cells cultured in 
control glucose levels, even less than 5% of KCI-responding cells responded to 
capsaicin (1pM). Such a small proportion of responsive cells cannot represent 
the function of TRPV1 or CBi receptors in a whole sample scale. In addition, 
the multiple treatments in one sample were found difficult to operate and the 
repeated exposure to capsaicin was at risk of desensitization of TRPV1 
receptors (Dray et al., 1989; Szolcsanyi, 1977; Piper etal., 1999).
A single application of capsaicin followed by addition of KCI in one sample was
adopted in subsequent studies in order to improve the applicability and
efficiency of experiments. The capsaicin concentration-response study
revealed that capsaicin (50 to 700pM) stimulated a transient Ca2+ influx in a
concentration-dependent manner, and only concentrations above 50pM were
able to stimulate a reproducible Ca2+ influx in the particular cell line. The
concentration of capsaicin (300pM) which evoked half of maximal responses
was applied to the subsequent studies. High glucose facilitated a greater
capsaicin-evoked Ca2+ influx in PC12 cells and the response was significantly
blocked by capsazepine (100pM) in both normal and high glucose conditions,
confirming the response is mediated by TRPV1 receptors. This in vitro result is
positively correlated to the animal study showing the over-sensitised TRPV1
receptor was found in DRG neurons from diabetic rats (Hong and Wiley, 2005).
The concentration of capsaicin required to evoke calcium entry into the cells
was relatively high (300pM) compared to studies involving DRG neurons or
TRPV1-transfected cell lines. However, Someya et al. (2004) have reported
PC12 cells require concentrations above 100pM to evoke an increase in [Ca2+]i,
and equate this to low capsaicin-sensitivity in PC12 cells. Also, the results
showing capsaicin failed to evoke cytosolic calcium increase in the cells when
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calcium was omitted in buffer may reflect the previous expression study 
showing TRPV1 receptor was mainly expressed at cell membrane which is also 
demonstrated in study by Someya et al. (2004).
A wide range of HU210 (0.03, 0.3, 3, 30pM) was used to study the inhibition of 
capsaicin induced-Ca2+ influx. The inhibition (%) curve generated from high 
glucose conditions shifted to the right compared with the control inhibition curve, 
indicating high glucose may slightly decrease CBi function. Focus down to the 
maximal concentration at 30pM used in order to pursue a maximal inhibition of 
calcium entry, HU210 significantly inhibited capsaicin-evoked calcium entry by 
80% and 77% in control and high glucose respectively, which was reversed by 
the CBi antagonist, AM251 (30pM), indicating a CBi-receptor mediated 
inhibition of calcium entry induced by capsaicin. However, the concern about 
the high concentration used is raised from other studies reporting that HU210 
at 1-1 OpM inhibited TRPV1-mediated Ca2+ entry in rat DRG neurons and 
human cells (Fischbach et al., 2007; Wilkinson and Williamson, 2007; Oshita et 
al., 2005), and AM251 at more than 1pM acted as an inverse agonists at CB2 
receptors in human cells (New and Wong, 2003).
Using the more pharmacologically relevant concentration, it was found that 
HU210 at 1pM inhibited capsaicin evoked-Ca2+ influx in PC12 cells cultured in 
both control and high glucose levels by 43% and 40% correspondingly. The 
inhibitory effect was significantly reversed by the CBi antagonist, AM251 (1pM) 
but not by the CB2 antagonist, AM630 (1pM), while HU210/AM251/AM630 did 
not have any effect of their own on PC12 cells. These results strongly suggest 
that the inhibitory effect of TRPV1 -mediated calcium entry is mediated by CBi, 
not CB2 receptors, and there is no inverse agonist effect involved. This is the
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first study to investigate CBi function in PC12 cells. The inhibitory effect of 
HU210 found in the current cell model is consistent with other studies of 
cannabinoid inhibition of capsaicin-induced response (calcium entry, 
neuropeptide release) in DRG neurons (Oshita et al., 2005; Millns et al., 2001), 
spinal cord (Winter et al., 1988; Sarker et al., 2000) and skin (Richardson et al., 
1998; Ellington et al., 2002).
In conclusion, in the cell culture model of diabetic neuropathy, we for the first 
time demonstrate that TRPV1 receptors were over-sensitised in PC12 cells 
cultured in hyperglycaemic conditions. The CBi agonist, HU210, inhibited the 
capsaicin-evoked calcium entry at a similar level in both control and high 
glucose conditions through a CBrdependent pathway, indicating that the CBi 
function is still preserved in hyperglycaemic conditions.
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CHAPTER 6
THE NEUROPROTECTIVE EFFECT OF A CANNABINOID CB! 
RECEPTOR AGONIST IN  V ITR O
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6.1 Introduction
This chapter investigates the neuroprotective effect of the CB1/CB2 (CBi>CB2) 
agonist, HU210, in the cell model of diabetic neuropathy. There is considerable 
evidence showing cannabinoids improve neuron viability and protect neuron 
from insults, such as ischaemia, excitotoxicity, and oxidative stress in vivo and 
in vitro (Hampson etal., 1998; Nagayama et al., 1999; Shen and Thayer, 1998; 
van der Stelt et al., 2001) through CB-i-dependent or CBrindependent 
mechanism. Two recent studies have showed that the antinociceptive action of 
a mixed CB1/CB2 agonist is preserved in diabetic mice (Dogrul et al., 2004) and 
rats (Ulugol et al., 2004), indicating cannabinoids might be appropriate 
therapeutic agents on treating diabetic related-neurodegeneration. In fact, CBi 
activation promotes neurite outgrowth by activating Gi/0 protein-involved kinase 
cascade (He et al., 2005). Considering the previous study showed the CBt 
function was preserved in PC12 cells cultured in hyperglycaemic conditions, we 
speculate CBi agonists may rescue the nerve degeneration caused by high 
glucose.
The aim of this chapter was to investigate whether HU210 can rescue the 
neurite outgrowth in PC12 cells cultured in hyperglycaemic conditions via CBi 
receptor-mediated mechanism. In the studies of this chapter, a dose response 
course of HU210 on cell viability was firstly conducted. A study done by Sarker 
and colleagues showed that exogenous stimulation of anandamide had no any 
effect on cell viability of PC12 cells with the dose no more than 5pM, whilst it 
induced apoptosis with the dose more than 10pM (Sarker et al., 2000). 
Therefore, in order to study whether HU210 can protect neurite outgrowth from 
high glucose, an appropriate range of dose must be carefully determined.
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Subsequently, NGF-induced neurite outgrowth in the presence of HU210 was 
studied in PC12 cells cultured in control or high glucose level. Neuroprotective 
effect of HU210 was assessed by the total length of neurites growing out of 
PC12 cells treated with HU210. The co-treatment of the CBi antagonist, AM251, 
and/or CB2 antagonist, AM630, with HU210 was conducted in parallel in order 
to investigate whether CBi or/and CB2 receptors were involved in the activation 
of HU210. Finally, the study examining the antioxidant property of HU210 in 
PC12 cells cultured in hyperglycaemic conditions was conducted to determine 
whether the neuroprotective effect of HU210 (if any) was independent of CBi 
receptors.
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6.2 The treatment of PC12 cells with a cannabinoid receptor agonist
6.2.1 Concentration response - relationship of HU210 on cell growth
The cell viability of PC12 cells treated with a variety of concentrations of HU210 
in the absence (5.5mM glucose) or presence of high glucose (50mM glucose) 
was determined by using a lactase dehydrogenase (LDH) assay and MTT 
assay. PC12 cells were cultured in DMEM medium supplemented with HU210 
(0, 0.03, 0.3, 3, 30pM) for 6 days under the stimulation of NGF (50ng/ml). The 
supernatant was collected every two days and used to monitor LDH release 
from cytoplasm. The LDH assay determines cell membrane integrity and the 
leakage of LDH from cytoplasm suggests cellular toxicity. Figure 6.1 shows the 
concentration of LDH released from PC12 cells with HU210 treatment on day 2, 
4 and 6, compared to the positive control which was determined from Triton-X 
(0.1%) induced cell lysis. The LDH curves either from 5.5mM or 50mM glucose 
on day 2, 4 and 6 were found to follow a very similar trend, showing a flat line 
from OpM to 3pM of HU210, followed by a dramatic increase at 30pM of HU210 
(Figure 6.1). For each time point studied, it was observed that HU210 up to 
3pM did not induced any significant increase in LDH release from PC12 cells 
cultured in either 5.5mM or 50mM glucose, compared to the control (OpM 
HU210). In contrast, HU210 at 30pM to induced a significant increase in LDH 
release from PC12 cells cultured in both control and high glucose (P<0.01). 
The vehicle (DMSO: 0.6%) was not significantly different from the control. It can 
be seen from Figure 6.1 that the LDH release induced by 30pM HU210 was 
gradually increasing from day 2 to day 6, and at day 6, it was approximately 
equal to the level induced by the positive control (Triton-X: 0.1%).
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Figure 6.1 Mean concentration of lactate dehydrogenase release from PC12 
cells stimulated with NGF (50ng/ml) and in the absence/presence of high 
glucose (50mM) when treated with HU210 (0 -  30pM) on day 2, 4 and 6 of 
culture. V— vehicle (DMSO: 0.6%). +Ve= complete LDH release (from 0.1% 
Triton-treated cells). Values represent meant SEM from 3 independent 
experiments. (**, P<0.01 compared to OpM HU210 concentrations, one-way 
ANOVA-Fisher’s post-hoc analysis).
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Whilst the cell culture supernatants were used for the LDH assay, the actual 
PC12 cells were used as the sample for MTT assay preformed on day 6. The 
MTT assay is based on the mitochondria in living cells being able to convert 
yellow MTT to purple formazan, and the conversion, therefore, is directly 
related to the number of living cells. Figure 6.2 shows the cell viability related to 
the density of purple color detected in PC12 cells treated with HU210 (0.03 to 
30pM). It was found that the treatment of HU210 from 0.03 to 3pM did not 
affect the cell viability of PC12 cells cultured in either 5.5mM or 50mM glucose 
when compared with the corresponding control (OpM HU210). In comparison, a 
10-fold decrease in cell viability was observed in PC12 cells treated with 30pM 
HU210, in both 5.5 and 50mM glucose conditions (P<0.01). The vehicle treated 
cells showed equal cell viability to the control (OpM HU210).
Figure 6.2 Cell viability of PC12 cells treated with HU210 (0 -  3|jM). PC12 cells 
were stimulated with NGF (50ng/ml) and in the absence/presence of high glucose 
(50mM) for 6 days. Values represent mean ± SEM from 3 independent 
experiments. (**, P<0.01 compared to the rest of concentrations, one-way 
ANOVA-Fisher’s post-hoc analysis).
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6.2.2 The effect of HU210 on neurite outgrowth
Neurite length was measured in PC12 cells on day 6 of culture in the presence 
of HU210 (0.03 to 3pM) and expressed as the percentage of cell body diameter. 
Representative photomicrographs of neurite outgrowth in PC12 cells cultured in 
5.5mM and 50mM glucose in the presence of HU210 (0.03, 0.3, 3pM) are 
shown in Figure 6.3. The neurite length with increasing concentrations of 
HU210 did not shown an obvious difference when compared to the control (A) 
and the vehicle (E) in cells cultured in control glucose. However, in cells 
cultured in 50mM glucose, neurite grew longer in the presence of HU210, 
particularly with 0.3 and 3pM, when compared to the control (A) which had 
relatively shorter neurites. Vehicle (E) showed a very similar neurite outgrowth 
to the control.
The effect of HU210 on neurite outgrowth of PC12 cells cultured in control 
(5.5mM) and high glucose (50mM) is summarized in Figure 6.3. As previously 
observed (chapter 3), high glucose attenuate neurite outgrowth by 
approximately 2-fold in PC12 cells (data for OpM HU210). Whilst HU210 had 
little effect on neurite outgrowth in the control glucose condition, at 50mM 
glucose conditions, it rescued neurite outgrowth impaired by high glucose in a 
concentration-dependent manner. The neurite length of PC12 cells in the 
presence of 0.3 and 3pM of HU210 was found to be significantly longer than 
the control (P<0.01). The vehicle from the highest concentration of HU210 did 
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Figure 6.3 CBi agonist treatment promotes neurite outgrowth in PC12 cells: the effect 
of HU210 (0.03-3pM) on neurite length (normalised to cell body diameter) of 
differentiated PC12 cells in control (n=148-220) and high glucose conditions (n=112- 
216). (**, P<0.01 vs. control (OpM HU210). one-way ANOVA-Fisher’s post-hoc 
analysis). The representative photomicrographs A to E show the neurite outgrowth of 
PC12 cells cultured in 5.5 and 50mM glucose in the presence of HU210 (0, 0.03, 0.3, 
3pM) or vehicle (DMSO: 0.6%).
6.2.3 The protective effect of HU210 on oxidative stress caused by high 
glucose
PC12 cells were cultured in DMEM supplemented with a variety of 
concentration of HU210 for 6 days in the absence or presence of high glucose. 
Cell lysates were collected to measure oxidative stress. The ratio of 
GSSG:GSH indicates relative amount of oxidized versus reduced glutathione 
content, and a higher ratio is considered as greater intracellular oxidative stress. 
It has been shown previously, in chapter 3, that higher oxidative stress is found 
in PC12 cells cultured in high glucose (50mM) compared with controls (5.5mM). 
Figure 6.4 shows the impact of HU210 treatment on oxidative stress in PC12
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cells cultured in control and high glucose. In the 5.5mM glucose condition, all 
concentrations of HU210 were not found to have significant effect on oxidative 
stress when compared with the control. In the 50mM glucose condition, it 
appeared that less oxidative stress occurred in PC12 cells cultured in 0.03 and 
0.3pM of HU210, but not in the highest concentration of HU210 (3pM) when 
compared with the control value. Thus, the reduction of oxidative stress by 
HU210 did not follow a concentration-dependent pattern and the difference 
were not statistically significant (P=0.978 for 5.5mM and P=0.346 for 50mM 
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Figure 6.4 A CBi agonist has no significant impact on oxidative stress in 
differentiated PC12 cells. The effect of HU210 treatment (0.03-3pM) on oxidative 
stress in differentiated PC12 cells at control (5.5mM) and high glucose level 
(50mM). Values represent meant SEM from 3 independent experiments (P >0.05, 
one-way ANOVA-Fisher’s post-hoc analysis).
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6.3 The co-application of a selective cannabinoid CBi receptor 
antagonist
6.3.1 Concentration-response relationship of AM251 (3pM) on cell 
growth
The LDH assay and MTT assay were used to determine the cell viability of 
PC12 cells cultured with the co-application of AM251 (3pM) and HU210 (0-3pM) 
in the absence or presence of high glucose. Similar to HU210 treatment alone, 
the LDH release was tested in the supernatant on day 2, 4 and 6 of culture. A 
maximal LDH release by treating cells with Triton-X (100%) was used as the 
positive control. Figure 6.5 shows the LDH level released from PC12 cells with 
the treatment of AM251+ HU210 on day 2, 4 and 6. A similar pattern of a flat 
line was observed in the LDH release from the three time point studies. It was 
observed that the LDH level released from PC12 cells treated with the 
combination of AM251 3pM with each of HU210 concentration: 0, 0.03, 0.3, 3 
was very similar to the control and vehicle values in both of 5.5mM and 50mM 
conditions. Compared to the positive control value of 1800 units/ml, the LDH 




Figure 6.5 Mean concentration of lactase dehydrogenase release from PC12 cells 
stimulated with NGF (50ng/ml) and in the absence/presence of high glucose (50mM) 
when treated with the combination of a CBi antagonist AM251 (3pM) and a selective 
CB! agonist HU210 (0 -  3pM) on day 2, 4 and 6 of culture. Values represent mean ± 
SEM from 3 independent experiments (P>0.05, one-way ANOVA-Fisher’s post-hoc 
analysis).
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The MTT assay was conducted on day 6 of cell culture to test the effect of the 
co-application of AM251 and HU210 on cell viability. Figure 6.6 shows the cell 
viability of PC12 cells cultured in the combination of AM251 (3pM) with each 
concentration of HU210 (0, 0.03, 0.3, 3pM) in the normal or high glucose 
concentrations. It was observed that, at 5.5mM glucose, the treatment of 
AM251 with each concentration of HU210 did not cause a significant change in 
cell viability when compared with the control. A similar result was found at 
50mM glucose, showing constant cell viability in all groups of treatments. Both 
of the vehicle data were found to be comparable to the corresponding control. 
In addition, there was no obvious difference in cell viability with the various 
groups of treatments between 5.5mM and 50mM glucose.
□Control (untreated)
□  HU210 0.03pM+AM251 3|jM 
0HU21O 3(jM+AM251 3pM
■Vehicle
□  HU210 0.3^M+AM251 3|jM 
■  AM251 3pM
Glucose Concentration (mM)
Figure 6.6 Cell viability of PC 12 cells treated with the combination of a selective CBi 
antagonist AM251 (3|jM) with a CB-i agonist HU210 (0 -  3|jM). PC12 cells were 
stimulated with NGF (50ng/ml) and in the absence/presence of high glucose (50mM) 
for 6 days. Values represent mean ± SEM from 3 independent experiments. (P > 0.05, 
one-way ANOVA-Fisher’s post-hoc analysis).
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6.3.2 Neurite outgrowth affected by the co-application of AM251 (3pM) 
and HU210
The representative pictures of the neurite outgrowth of PC12 cells treated with 
the combination of AM251 (3pM) and HU210 (0-3pM) in the presence of high 
glucose are showed in Figure 6.7. It was observed that short neurites extended 
from the cell bodies cultured in control (50mM) and vehicle medium (A and B). 
The presence of AM251 3pM alone was not observed to affect the neurite 
length (C). In contrast, in the presence of the combination of AM251 3pM with 
each HU210 0.03, 0.3 and 3 pM (D, E and F), PC12 cells seemed to bear 
longer neurites, particularly in the co-application of AM251 3pM and HU210 
0.03pM when compared with the control. The same treatments were also 
applied to PC12 cells cultured in control level of glucose. It was observed that 
the neurite outgrowth from each combination treatment appeared to be less 
advanced when compared with the control and vehicle (pictures not shown).
The result from analyzing 82 to 104 cells in each group from both control and 
high glucose conditions is showed in Figure 6.8. In PC12 cells cultured in 
5.5mM glucose, each combination of AM251 3pM with HU210 (0, 0.03, 0.3, 
3pM) was found to reduce neurite outgrowth compared with the control and 
vehicle, however, the reduction did not reach the significant difference 
(P=0.168). In PC12 cells cultured in 50mM glucose, the co-treatment of AM251 
3pM and HU210 0.03pM showed a biggest increase on the neurite length 
reaching 272 (%cell body) among all the treatments compared with the control 
level of 212. This increase is consistent with the previous finding with HU210 
0.03pM treatment only. Although the combination of AM251 3pM and HU210 
0.3 and 3pM did promote a small increase on neurite outgrowth, there was no
dose relation and significant difference (P=0.089) found within those treatments.
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This result is opposite to the previous study with HU210 treatment only showing 
a dose-dependent neurite outgrowth increase in PC12 cells cultured in 50mM 
glucose with the significant increase found in the treatment of HU210 0.3 and 
3pM.
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Figure 6.7 The representative pictures showing the neurite outgrowth in PC12 cells 
cultured in combination of AM251 and HU210 in the presence of high glucose. (A), 
the control (50mM); (B), the vehicle; (C), AM251 3pM only; (D), AM251 3pM+HU210 




H AM251 3̂ IVH-HU210 OpM 
□  AM251 3|jM*-HU210 0.03(jM
□  AM251 3(jM+HU210 0.3|jM 
0AM251 3̂ jM+HU210 3jjM




Figure 6.8 The co-application of AM251 and HU210 affects neurite outgrowth in 
PC12 cells. The effect of AM251 (3pM) plus HU210 (0.03-3mM) on neurite length 
(normalised to cell body diameter) of differentiated PC12 cells in control (n=82-104) 
and high glucose conditions (n=86-104). Values represent mean from 3 
independent experiment ± SEM. (P>0.05, one-way ANOVA-Fisher’s post-hoc 
analysis).
6.3.3 The effect of the co-treatment of AM251 and HU210 on oxidative 
stress induced by high glucose
Oxidative stress was examined in PC12 cells treated with the combination of 
AM251 (3|jM) + HU210 (0, 0.03, 0.3, 3|jM) in the absence or presence of high 
glucose for 6 days as shown in Figure 6.9. In PC12 cells cultured in 5.5mM 
glucose, it was found that the co-application of AM251 with each concentration 
of HU210 did not cause any significant change on oxidative stress level versus 
the control group (P=0.978). In PC12 cells cultured in 50mM glucose, it was 
observed that treatment with AM251+ concentrations of HU210 at 0.03 and 
0.3pM appeared to reduce oxidative stress when compared with the control
value. In comparison, the oxidative stress in PC12 cells cultured with AM251 +
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3pM HU210 was very similar to the level of the control. Thus, the change in 
oxidative stress in PC12 cells cultured in the combination of AM251+ HU210 
did not follow a concentration-dependent pattern, which was similar to the 
previous finding with HU210 treatment alone. It was also observed that the 
oxidative stress level with AM251 alone was less than the control level. 
However, there was no significant difference found between the groups, 
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Figure 6.9 The effect of CB-i antagonists on oxidative stress in differentiated PC12 
cells with/without HU210. Values represent meant SEM from 3 independent 
experiments. (P>0.05, one-way ANOVA-Fisher’s post-hoc analysis).
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6.4 The co-application of a cannabinoid CBi antagonist AM251 (1pM) 
or/and a CB2 antagonist AM630 (1pM)
6.4.1 Cell viability following treatment with AM251 (1pM) and/or AM630 
(1pM) with HU210
PC12 cells were cultured in DMEM supplemented with different combinations 
of HU210, AM251 and AM630 in the presence of high glucose (50mM) for 6 
days under the stimulation of NGF (50ng/ml). The samples were examined by 
MTT assay to assess the cell viability. Figure 6.10 shows the cell viability of 
PC12 cells treated with the co-administration of HU210 (0.3pM), HU210 (0.3pM) 
+ AM251 (1pM), HU210 (0.3pM) +AM630 (1pM) and HU210 (0.3pM) +AM251 
(1pM) +AM630 (1pM) as well as the control and vehicle groups in high glucose. 
No significant change in cell viability between any of the two groups was 
observed compared with the control value (one way ANOVA, P=0.089).









Figure 6.10 Cell viability of PC12 cells treated with the combination of HU210 
(0.3jjM) with AM251 (1|jM) or/and AM630 (1|jM). PC12 cells were stimulated 
with NGF (50ng/ml) in the presence of high glucose (50mM) for 6 days. Values 
represent mean ± SEM from 3 independent experiments (P>0.05, one-way 
ANOVA-Fisher’s post-hoc analysis).
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6.4.2 Neunte outgrowth following the co-application with AM251 (1pM)
and/or AM630 (1pM)
A lower concentration of the selective CBi antagonist, AM251 (1|jM), and a 
selective CB2 antagonist, AM630 (1pM), were both co-applied with HU210 
(0.3pM) in order to examine whether the HU210-induced neurite outgrowth is 
mediated by CBi receptors or CB2 receptors. PC12 cells were cultured in the 
following combinations: HU210 0.3pM only, HU210 0.3pM + AM251 1pM, 
HU210 0.3pM + AM630 1pM and HU210 0.3pM + AM251 1pM + AM630 1pM, 
as well as control and vehicle groups, for 6 days under the stimulation of NGF 
(50ng/ml). A representative photomicrograph of neurite outgrowth in PC12 cells 
cultured in control medium (50mM) is shown in Figure 6.11(A). The addition of 
vehicle to the culture medium had no effect on neurite outgrowth compared to 
the control (Figure 6.11 B). When HU210 (0.3pM) was added to the medium, 
the neurite length of PC12 cells was observed to be longer than in the control 
as shown in (Figure 6.11 C). The co-application of HU210 (0.3pM) + AM251 
(1pM) appeared to reduce the neurite length in PC12 cells compared with the 
HU210 (0.3pM) treatment only (Figure 6.11 D). In contrast, longer neurite 
length was still observed in PC12 cells treated with the combination of HU210 
0.3pM + AM630 1pM compared to the control (Figure 6.11 E). The extent of 
neurite outgrowth was similar to that observed in HU210 (0.3pM) treatment 
alone. Again, in the presence of AM251 (1pM) + HU210 (0.3pM) + AM630 
(1pM), the neurite length in PC12 cells was observed to be shorter than that in 
the co-application of HU210 (0.3pM) + AM630 (1 pM).
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Figure 6.11 The representative photomicrographs show the neurite outgrowth in 
PC12 cells cultured in control medium (A), vehicle medium (B) and the medium 
supplemented with HU210 0.3pM (C), HU210 0.3pM+AM251 1pM (D), HU210 
0.3pM+AM630 1pM (E), and HU210 0.3pM+AM251 1pM+AM630 1pM (F).
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Figure 6.12 shows the total neurite length (expressed as % cell body diameter) 
measured from at least 130 individual cells from each group. In comparison to 
the control group, the addition of HU210 (0.3 pM) alone was found to 
significantly increase neurite outgrowth more than two-fold (P<0.05). The co­
application of AM251 (1pM) but not AM630 (1pM), with HU210 (0.3pM) 
significantly reduced the neurite outgrowth compared to HU210 (0.3pM) 
treatment alone (P<0.05). The neurite length of PC12 cells cultured in AM251 
(1pM) + HU210 (0.3pM) + AM630 (1pM) was significantly reduced compared 
with the neurite length in the HU210 (0.3pM) alone group and the co-treatment 
of HU210 (0.3pM) + AM630 (1pM) (P<0.05).
*
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Figure 6.12 HU210 promotes neurite outgrowth in a CBrdependent manner. It 
shows the total neurite length (expressed as the % of cell body diameter) of PC12 
cells cultured in control media (50mM glucose) or the media supplemented with 
the CB-i agonist, HU210 (0.3pM) +/- selective CBi antagonist, AM251 (1pM), 
and/or selective CB2 antagonist AM630 (1pM) (n=131-208). Values represent





In Chapter 4 and 5, we have demonstrated that CBi receptors remained 
functional although the expression decreased in PC12 cells cultured in high 
glucose. We hypothesized that treatment with cannabinoids may rescue the 
impaired neurite outgrowth through CBi receptors. Cannabinoids are suggested 
to control the survival and death of neurons. Many in vitro and in vivo studies 
have reported that cannabinoids improve neuron viability and protect against 
toxic insults (Mechoulam et a!., 2002; van der Stelt et al., 2002) whilst, in 
contrast, others have shown that cannabinoids can induce apoptosis in cultured 
neurons as well as other non-neuronal cells (Chan et al., 1998; Guzman, 2003). 
The dual effect of cannabinoids may result from various experimental factors, 
such as in vivo or in vitro studies, culture conditions, and the range of doses 
used.
In this chapter, we firstly conducted viability assays in PC12 cells cultured in
the medium supplemented with a range of HU210 concentration in the
presence of control or high glucose, and under the stimulation of NGF for 6
days. Both LDH and MTT assays revealed that, apart from HU210 at 30pM
where cells showed a significant death, the cell viability was not different in
cells among other concentrations (0.03pM-3pM) in both normal and high
glucose conditions compared with control and vehicle groups. This result is in
agreement with the study by Sarker et al, (2000) reporting that the
endocannabinoid, anandamide, dose-dependently caused the loss of cell
viability of PC12 cells (Sarker et al., 2000): no change in cell viability when the
concentration was less than 7.5pM; loss of cell viability when the concentration
reached 10pM. It was also reported in the study conducted by Hart et al., (2004)
that A9-THC and other cannabinoids at nanomolar levels accelerated cell
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proliferation in glioblastoma cells, immune cells, whilst high concentrations of 
cannabinoids induced apoptosis (Hart et at., 2004). The co-treatment with the 
CBi selective antagonist, AM251 (1pM /3pM) + HU210 (0.03pM-3pM) did not 
affect cell viability, indicating that CBi antagonism, at least at these two 
concentrations, had no impact on cell viability.
The neurite outgrowth study showed that the addition of HU210 (0.03pM-3pM)
had no significant effect on the total neurite length in PC12 cells cultured in
5.5mM glucose, while an increased total neurite length was found in PC12 cells
cultured in 50mM glucose in a HU210 concentration-dependent manner when
compared with the controls. HU210 at 0.3pM and 3pM significantly rescued
neurite outgrowth versus control which was reversed by the CBi antagonist,
AM251 (3pM). To exclude the possibility of AM251 and AM630 acting at
additional receptors at higher concentration (>1pM), a lower concentration
(1pM) was chosen for use in subsequent experiments Although AM251 is
described as a CBrselective antagonist, at high concentrations (above 1pM) it
can also have effects on CB2 receptors (New and Wong, 2003). Thus, we
examined whether a lower, selective concentration of AM251 (1pM) had similar
effects on CBi agonist-evoked inhibition of TRPV1 calcium responses. We
found that, the lower concentration, 1pM of AM251, but not the CB2 antagonist
(AM630 1pM), also significantly attenuated the HU210 (0.3pM) mediated-
neurite rescue. This result indicates that HU210 has a therapeutic potential in
neurodegenerativa diseases and it may restore neurite regeneration through
activating CBi receptors. HU210 has been previously found to trigger neurite
outgrowth in cultured Neuro-2A cells (Jordan et at., 2005), where signalling
through Gi/o-coupled CBi receptors causes activation of the small G protein,
Rap1, and neurite outgrowth via a signal transducer and activator of
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transcription (Stat)3-dependent convergent step (He et al., 2005). In PC12 cells, 
activation of Rap1 and extracellular signal-regulated kinase (ERK) plays a 
critical role in neurite outgrowth (Vossler et at., 1997), and CBi can selectively 
activate the ERK pathway in neurons (Derkinderen et a!., 2003, Graham et at., 
2006).
A recent study by Dagon et al., (2007) found that HU210 ameliorates 
hyperglycaemia induced impaired neurite outgrowth in PC12 cells. However, 
they also observed increases in neurite outgrowth in the control 
(“normoglycaemic”) group - we found only significant effects of HU210 in the 
hyperglycaemic group. There are several differences in the experimental 
design of Dagon and colleagues (2007) and our study. Firstly, we measure total 
neurite length of cells whereas Dagon et al. measured percentage of cells with 
neurites. Secondly, the concentrations of glucose used were different between 
each study: for the control/normoglycaemic group we used 5.5mM glucose 
compared to 25mM by Dagon et ai\ for the high glucose/hyperglycaemic group 
we used 50mM compared to 150mM by Dagon et al., (2007). It is possible 
neurite outgrowth was already impaired in their 25mM control group, such that 
HU210 would show an improvement. The higher glucose concentrations could 
also account for the hyperglycaemia-induced apoptotic cell death found by 
Dagon et al., (2007). Finally, the concentrations of HU210 were higher in the 
Dagon study (ranging from 5-20pM) compared to ours (0.03-3pM). At 30pM 
HU210, we observed -100% cell toxicity after 48 hour-exposure, and so for 
chronic (6 day) neuroprotective studies we used a maximum of 3pM. In the in 
vivo arm of the Dagon study, HU210 was shown to alleviate cerebral oxidative 
stress and cognitive impairment in diabetic mice, through a CBi receptor- 
independent mechanism(s) (Dagon et al., 2007).
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Oxidative stress has been implicated in the pathogenesis of neurodegenerative 
diseases, including diabetic neuropathy (Brownlee, 2001, Vincent et al., 2004). 
The phenolic moiety of the Cannabis sativa derivatives, A9- 
tetrahydrocannabinol (A9-THC) and cannabidiol, acts as an electron donor and 
direct free-radical scavenger. This antioxidant property is fully independent of 
CBi activation and confers neuroprotective properties to cannabinoids against 
oxidative stress (Hampson et al., 1998, Marsicano et al., 2002). Reduced 
glutathione (GSH) is one of the major endogenous antioxidants in humans. We 
found that HU210 at 0.03 and 0.3pM reduced the levels of oxidative stress in 
hyperglycemic cells, as shown by a decrease in the ratio of oxidized to reduced 
glutathione (GSSG:GSH) and the addition of AM251 did not change the 
antioxidant property of HU210. Like A9-THC and cannabidiol, this antioxidant 
effect was receptor independent, and likely involves the phenol ring present in 
HU210’s structure.
In summary, we have demonstrated in this chapter, that the synthetic 
cannabinoid HU210 treatment, reversed impaired neurite outgrowth and 
reduced oxidative stress in hyperglycaemic PC12 cells, through CBi receptor- 






The population of people with diabetes is predicted to reach 366 million 
worldwide in 2030 (Wild et al., 2004). Both type 1 and type 2 diabetic patients 
likely develop diabetic neuropathy, which is the most common complication 
associated with diabetes, however, the exact mechanisms remains at least 
understood (Sima, 2003; Vinik et al., 2006). Distal symmetric polyneuropathy, 
the commonest type of diabetic neuropathy, is characterized by the 
degeneration of peripheral nerve endings, resulting in acute pain, sensorimotor 
deficits, and high risk of limb amputation (Vinik et al., 2006). So far, the only 
effective way to prevent and slow diabetic neuropathy is the control of blood 
glucose itself. Failure to do this means that the damage resulting from 
hyperglycaemia is irreversible. The disrupted cellular glucose metabolism in 
hyperglycaemia induces over-production of free radicals and reduces natural 
antioxidant defences, causing oxidation of DNA protein, lipid and abnormal 
signal transductions (McHugh and McHugh, 2004; Vincent et al., 2004). At 
tissue level, hyperglycemia not only reduces the production of NGF and impairs 
NGF transport, but it also slows blood flow and creates ischaemia, resulting in 
neuronal dysfunction (Siemionow and Demir, 2004). However, simply supplying 
antioxidant and NGF, as well as inhibiting other therapeutic targets such as 
protein kinase C or AGEs, have not been found to be successful in human 
clinical trials (Sullivan and Feldman, 2005). The development of a treatment 
that can delay the onset of neuropathy and slow its progression is urgently 
needed to improve the quality of life in patients with diabetes and reduce 
demands on health resources.
Since the revelation that cannabinoids exert their biological functions through
binding to cannabinoid receptors (CB^, which are abundantly expressed in the
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central nervous system and peripheral nerves, cannabinoid signalling has been 
the focus of intensive research. Much of the research thus far has focused on 
cannabinoids’ protective role in the central nervous system in response to 
chronic neurodegenerativo diseases, including Alzheimer’s disease and 
multiple sclerosis, or injury associated with stroke or brain trauma (reviewed by 
Bahr et ai, 2006). These studies demonstrated that both CBi receptor- 
independent (antioxidant) and -dependent mechanisms (inhibition of Ca2+ influx, 
reduced glutamate release and excitotoxicity, vasodilatation, increased NGF 
production and neurotrophic support, hypothermia) are involved in the 
neuroprotectant effect. Peripherally, the activation of CBi receptors has been 
proved to attenuate the release of neurotransmitters and neuropeptides 
(Ralevic, 2003), producing analgesic effects. The loss of CBi receptors has 
been demonstrated in a number of neurodegenerativo diseases, including 
Huntington’s disease (Denovan-Wright & Robertson 2000; Glass et a!., 2004) 
and Parkinson’s disease (Silverdale et at., 2001). Moreover, Denovan-Wright & 
Robertson (2000) found the decrease in CBi mRNA occurred before the onset 
of the motor-related Huntington’s disease-like symptoms in mice and preceded 
neural degeneration, suggesting abnormalities in cannabinoid signalling play a 
significant pathogenetic role. At the outset of this PhD project, no one had 
previously studied the cannabinoid signalling in diabetic neuropathy. To our 
knowledge, this project is the first to investigate the role of CBi receptors in the 
pathogenesis of diabetic neuropathy, and the neuroprotective role of 
cannabinoids in experimental diabetes.
Numerous in vitro models have previously been used to examine the cellular 
mechanisms involved in the pathophysiology of diabetic complications, 
including human SH-SY5Y neuroblastoma cells (Shindo et ai., 1996), and rat
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dorsal root ganglia (DRG) (Russell et al., 1999). In the chapter 1, our initial 
experimental design (Figure 7.1) involved setting up two in vitro cell models of 
diabetic neuropathy: rat PC12 cells and human SH-SY5Y neuroblastoma cells, 
which would be corroborated with animal studies. The results from both in vitro 
and in vivo studies have the potential to lead to a therapeutic indication in 
human clinical trails.
In  v itro
Human neuronal cells 
(SH-SY5Y)
Rat neuronal cells 
(PC12)
In  v iv o C lin ic a l
-> Animal studies -----► Human studies
Figure 7.1 The route of the experimental design.
However, as mentioned in Chapter 3, SH-SY5Y cells remain indefinitely 
dividing, which makes the morphological assessment from a chronic study 
difficult. Most importantly, the lack of TRPV1 receptors in this cell line makes 
the study on inhibitory effect of CB-i receptors on capsaicin (a TRPV1 agonist)- 
induced Ca2+ influx impossible to conduct. Therefore, use of SH-SY5Y cells 
does not fit with the experimental design on the model of small sensory 
neurons which are mainly responsible for painful diabetic neuropathy, based on 
the fact that TRPV1 receptors are present on small sensory neurons and share 
more than 80% of localization with CB1 receptors (Ahluwalia et al., 2000). 
Unlike SH-SY5Y cells, PC12 cells are similar to cultured DRG neurons, in that 
they express both TRPV1 and CBi receptors. Therefore, we discontinued use 
of SH-SY5Y cells, and set up PC12 cells in this study as the in vitro model of
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diabetic neuropathy, after establishment by Lelkes and colleagues (Lelkes et al., 
2001). To validate this cell model, we cultured PC12 cells with increasing 
concentrations of glucose to mimic hyperglycaemic conditions and stimulated 
neurite outgrowth with NGF. This cell model reproduced some of the 
phenomenon of diabetic neuropathy: high glucose attenuated NGF-induced 
neurite outgrowth, which was associated with oxidative stress, and caused 
dose-dependent increase in IL-6 production.
Many animal and in vitro studies have suggested various pathway of glucose 
metabolism in the initiation and progression of diabetic neuropathies. They 
include: increased polyol pathway activity; formation of advanced glycation 
end-products; activation of protein kinase C; and impaired mitochondrial 
electron transfer chain (Yagihashi et al., 2007). These pathways all directly or 
indirectly produce excessive ROS and promote oxidative stress. Indeed, type 1 
diabetics with high serum levels of ROS have more severe peripheral 
neuropathy (Pop-Busui et al., 2004). Oxidative stress is likely to be the unifying 
mechanism triggering the onset of deteriorative processes. Kaur et al, (2005) 
have reported that oxidative stress can disrupt NGF signalling by blocking 
activation of STAT kinase activation which is essential for neurite extension, 
causing neuronal damage observed in neurodegenerative diseases (Kaur et al., 
2005). Oxidative stress-induced mitochondrial dysfunction and apoptosis has 
been widely found in various neuronal cells (Vincent et al., 2002; Schmeichel et 
al., 2003). In the current study, we observed impaired neurite outgrowth caused 
by high glucose occurs before overall cell death. Although not an exact model 
of the “dying-back” axonopathy observed in diabetic neuropathy, it provides a 
basis for examination of neuroprotective agents.
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In parallel with our finding in Chapter 3, high levels of IL-6 have been found in 
plasma and monocytes isolated from diabetic patients, suggesting an 
inflammatory process induced by hyperglycaemic conditions (Giulietti et at., 
2007; Targher et at., 2001; Jain et at., 2003), In the nervous system, IL-6 has 
both physiological and pathophysiological functions. Otten et at., (2000) 
suggests an interaction between cytokines and neurotrophins in normal and 
diseased states, which comes from evidence showing that IL-6 and 
neurotrophinsare co-expressed at the site of nerve injury. Rapid accumulation 
of IL-6 after nerve injury indicates the ‘neuron-rescue’ role of IL-6. The neuron- 
protective action may be achieved through directly or indirectly signalling the 
binding of neurotrophin with TrkA receptors, triggering the pathway of neuronal 
protection (Otten et a/., 2000). On the other hand, sustained high levels of IL-6 
can promote completely opposite on neurons by triggering degeneration of 
neurons after nerve injury. A study from Campbell et at, (1993) reported that 
transgenic mice over-expressing IL-6 in astrocytes showed a marked 
neurodegeneration and the recovery process was hindered by neurotrophin- 
mediated scar formation (Campbell et at., 1993). This study implicates the 
interaction between IL-6 and neurotrophins: sustained high levels of IL-6 may 
promote neurotrophin binding to, the low-affinity receptor , p75, inducing 
neuronal apoptosis (Otten et al., 2000). In addition, numerous clinical studies 
have shown increased synthesis of IL-6 in brain tissue at post-mortem from 
patients with various neurological disorders, including Alzheimer’s, Parkinson’s, 
multiple sclerosis and epilepsy, infection, injury, inflammation and stroke 
(Rothwell and Relton, 1993). However, it is unclear that the increased 
production of IL-6 is directly involved in the pathogenesis of neurodgeneration 
or the increase is only secondary to nerve damage.
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In 2005, Bierhaus and colleagues have reported that loss of pain perception, 
indicative of a long-standing diabetic neuropathy, was remarkably reversed in 
mice lacking the receptor of advanced glycation end products (associated with 
sustained activation of NF-kB), indicating RAGE play a central role in sensory 
neuronal dysfunction. In this study, AGE dysregulated the activation of NF-kB 
and NF-kB-IL-6 expression in peripheral nerves of diabetic mice though binding 
to RAGE (Bierhaus et al., 2005). The association between RAGE and 
activation of NF-kB was further confirmed by the evidence that NF-kB activation 
was blunted in the absence of RAGE. In the view of Bierhaus et al., (2005), the 
initial pulse of NF-kB activation and subsequent IL-6 expression has 
cytoprotective properties in response to oxidative stress. However, more 
sustained NF-kB activation, leading to sustained over-expression of IL-6, might 
have deleterious consequences for neuronal properties. Although AGE-RAGE 
mediated signal transduction involving sustained over-expression of pro- 
inflammatory cytokines is not the only factor inducing neuron damage, it, at 
least partially, contributes to the development and progression of diabetic 
neuropathy (Bierhaus et al., 2004).
Chapter 4 investigated the regulation of CBi expression in in vitro and in vivo
models of diabetic neuropathy. In agreement with our hypothesis, CBi receptor
protein appears to be down-regulated in nerve cells grown in conditions
mimicking hyperglycaemia and in neurons from diabetic rats, which may
contribute to the neurodegenerative process observed in diabetic neuropathy.
Whilst data from in vitro studies involving animal cells cannot be directly
extrapolated to human disease, the fact we also demonstrated reduced CBt
expression in DRG neurons of a rat model of diabetes ex vivo adds credence to
our findings. Of course, due consideration must be made when comparing “in
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vitro high glucose” and “in vivo diabetic” states, since we had a 9-fold difference 
in glucose levels between cell-treatment groups, which remained elevated 
during the culture, whilst the rat diabetic model showed a 5-fold elevation in 
plasma glucose compared to controls, and these levels would fluctuate 
throughout the animals’ lives. Others have reported plasma glucose levels in 
the STZ-diabetic rat range from 25 - 50 mM (mean 34.5 ± 3.05 mM) (Purves et 
a!., 2001), thus making the concentrations used in our in vitro study reasonable.
The pathogenesis of diabetic neuropathy is multifactorial. Extending from our 
findings, Figure 7.2 illustrates the possible downstream mechanisms derived 
from hyperglycaemia-induced oxidative stress, which may be involved in the 
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Figure 7.2 Mechanisms involved in development and progression of 
diabetic neuropathy.
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A major consequence of a decline in CBi expression is likely to be increased 
TRPV1 receptor signalling. Up-regulation of TRPV1 receptors on sensory 
nerves contributes to the thermal hyperalgesia and allodynia observed in 
diabetic mice (Kamei et al., 2001b; Rashid et ai, 2003). In 2005, Hong and 
Wiley published data showing enhanced function of TRPV1 in diabetic rats, 
involving increased receptor phosphorylation via protein kinase C, 
oligomerization to active form, and recruitment to cell surface plasma 
membrane (Hong & Wiley, 2005).
Protein kinase C (PKC) activation in diabetes could result from the enhanced 
release of chemical mediators (e.g. bradykinin) under ischaemic conditions, 
following hyperglycaemia-induced oxidative stress. Indeed, inhibitors of PKC 
have been shown to decrease the hyperalgesia and C-fibre hyperexcitability 
found in diabetic rats (Ahlgren and Levine, 1994). Interestingly, whilst PKC can 
sensitize TRPV1 receptors, it down-regulates the activity of CBi receptors 
(Garcia et al., 1998). Ellington and co-workers (2002) examined anandamide- 
induced inhibition of capsaicin-evoked CGRP release in rat paw skin from 
control and diabetic rats. They found anandamide inhibited CGRP release only 
in skin from control animals, and furthermore, actually stimulated CGRP 
release in skin from diabetic rats when tested at higher concentrations. These 
data suggest anandamide action at TRPV1 receptors overcomes the inhibitory 
actions mediated by CBt receptors in diabetes. Even if TRPV1 activation 
evokes synthesis and release of anandamide, as has been demonstrated in 
cultured rat neurons (Ahluwalia et al., 2003), this will only serve to enhance 
TRPV1 signalling under conditions where CBi receptors are down-regulated. 
Thus, there would appear to be a differential regulation of CBi versus TRPV1 
expression and/or function in diabetes.
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Higher circulating endocannabinoid levels (anandamide and 2-AG) have been 
demonstrated in obese patients with type 2 diabetes (Matias et al., 2006a), and 
the same authors report up-regulation of endocannabinoids in post-mortem eye 
tissues of patients with diabetic retinopathy (Matias et al., 2006b). In obese 
postmenopausal women with fasting hyperinsulinaemia, elevated levels of 
anandamide and 2-AG were found to be associated with decreased CBi 
receptor expression in adipose tissue (Engeli et al., 2005). The mechanistic link 
between glucose concentration and CBi receptors is likely to be oxidative 
stress. Obesity is strongly correlated with increased oxidative stress and, 
because high glucose enhances the production of cellular reactive oxygen 
species (Brownlee, 2001), the oxidative burden is even greater when obesity is 
coupled with insulin resistance (van Guilder et al., 2006). Raised levels of 
endocannabinoids are likely to result from decreased enzymatic degradation, 
since Engeli and co-workers (2005) reported fatty acid amide hydrolase (FAAH) 
gene expression was down-regulated in adipocytes from obese women. In turn, 
the raised ligand concentrations may down-regulate CBi receptor expression 
via a negative feedback loop. As previously mentioned, a decline in CBi 
receptors in the presence of elevated endocannabinoid levels might tip the 
balance towards TRPV1 activation. Furthermore, FAAH can attenuate TRPV1 
activation (Millns et al., 2006), so any reduction in FAAH levels would further 
enhance signalling via TRPV1 receptors.
As mentioned above, low levels of IL-6 are neuroprotective. However,
sustained high levels of IL-6 are neurotoxic. The resources contributing the
high levels of IL-6 production come from not only the hyperglycaemia-induced
oxidative stress (Gumieniczek et al., 2006), but also other aberrant signal
transducers, including activated PKC (Devaraj et al., 2005) and TRPV1
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receptors (Seki et al., 2007, Nicol et al., 1997). Furthermore, the over­
expression of IL-6 may also contribute to the sensitization of TRPV1 receptors. 
Tamura and colleagues have demonstrated that oncostatin M, a member of the 
IL-6 family of cytokines, was expressed in both cell bodies and processes of 
nociceptive neurons in adult mice, which provided anatomical evidences that 
oncostatin M may affect the nociceptive function of the neurons through the 
modulation of TRPV1 receptors (Tamura et al., 2003). Indeed, inflammatory 
cytokines as one of numerous inflammatory mediators can sensitize the 
response of TRPV1 receptors to noxious heat, protons and capsaicin, thus 
augmenting thermal hyperalgesia (Ma and Quirion, 2007).
In consequence, as suggested in Figure 7.2, TRPV1 sensitization could deprive 
sensory nerves of NGF and lead to axonal degeneration. This is based on the 
observation by Taylor and colleagues (1985) that capsaicin prevents retrograde 
axonal transport in rat sensory neurons (Taylor et al., 1985). The tipped CB1 
and TRPV1 expression or signalling towards TRPV1 receptors leads to 
increased Ca2+ signalling, neurotransmitter and neuropeptide release, 
decreased neurotrophic support and blood flow, and sustained inflammation, 
which all contribute the development and progression of diabetic neuropathy.
We demonstrated decreased neuronal expression of CBi receptors in in vitro
and in vivo models of diabetic neuropathy (Chapter 4) (Zhang et al., 2007), and
hypothesized that such a decrease would result in attenuated nerve cell
responses to a CBi agonist under hyperglycaemic conditions. At
concentrations of the CBi agonist HU210 below 1mM we indeed observed a
blunted inhibition of capsaicin-evoked calcium influx in PC12 cells cultured in
high glucose in Chapter 5. However, at concentrations >1mM HU210, the
197
function of the CBi receptor is preserved, as evidenced by a similar degree of 
inhibition of capsaicin-evoked calcium influx in 5.5 and 50mM glucose 
conditions. These data actually draw a parallel with findings that the anti­
nociceptive action of the mixed cannabinoid CB1/CB2 receptor agonist, WIN 
55212-2, is preserved in diabetic mice (Dogrul et al., 2004) and rats (Ulugol et 
al., 2004). However, the results from these in vivo studies may involve non-CB 
receptor mechanisms. In 2006, Patwardhan and colleagues demonstrated that 
WIN 55,212-2 could inhibit capsaicin-evoked calcium currents in rat trigeminal 
neurons, via calcineurin-dependent dephosphorylation of TRPV1. This 
mechanism was independent of G-protein coupled CB receptors (Patwardhan 
et al., 2006). We found that the inhibitory effect of HU210 on capsaicin-induced 
calcium influx could be blocked by the CBi antagonist AM251, as have others 
in rat DRG neurons (Millns et al., 2001; Oshita et al., 2005). This suggests the 
response is CB-i-dependent and, therefore, in our in vitro model of diabetic 
neuropathy, the enduring CBi receptors remain functional. The activation of 
PKC is involved in the development of diabetic neuropathy (Hong and Wiley, 
2005; Ohsawa and Kamei, 1999), it may disrupt the cannabinoid neuro- 
protective action by phosphorylation of the CBi receptor (Garcia et al., 1998). 
We, therefore, examined the phosphorylated CBi receptors to assess the 
remaining functional sites in hyperglycaemic cells. The results revealed that, 
although the active form of CBi receptors was indeed reduced in 
hyperglycaemic condition, the percentage out of the already reduced CBi 
receptor maintained unchanged, which may explain the CBi receptors remain 
functional although the expression is decreased.
Even so, the maintenance of receptor function following activation by 
concentrations of HU210 >1mM may reflect only the ability of exogenous
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cannabinoids to activate the receptors. Critical to the link between decreased 
receptor expression and maintained function is the level of endocannabinoid 
CBi ligands. In obese patients with type 2 diabetes, higher circulating 
endocannabinoid levels (anandamide and 2-AG) have been demonstrated 
(Matias et a/., 2006a). Similarly elevated levels of anandamide and 2-AG were 
found to be associated with decreased CBi receptor expression in adipose 
tissue from obese postmenopausal women with fasting hyperinsulinaemia 
(Engeli et at., 2005). The function of CBi receptors in these patients remains to 
be determined.
Considering CBi function still remains in hyperglycaemic conditions, we have 
investigated, in Chapter 6, the neuroprotective effect of the CBi agonist, H210, 
in the cell culture model of diabetic neuropathy, and whether the protection is 
through CBrdependent or CBr independent mechanism. In the present study, 
we have showed HU210 rescued neurite outgrowth in a concentration- 
dependent manner, and HU210 at the concentration 0.3-3pM fully restored the 
neurite outgrowth in hyperglycaemic cells to the degree comparable with the 
control cells. The rescue by HU210 is inhibited by the CBi agonist, but not the 
CB2 agonist, suggesting that HU210 promotion of neurite outgrowth is 
mediated by the CBi receptor whilst the subsequent oxidative stress study 
suggests that the antioxidant effect of HU210 is largely independent of the CBi 
receptor. As already discussed in the chapter 6, the mechanism of HU210 
regulating neurite outgrowth may involve the CBi receptor mediated Rap 1 
activation via a convergent signal transducer and activator of (stat 3) 
dependent transcription process (He et at., 2005; Vossler et at., 1997). In 
addition, the antioxidant property of HU210 also plays an important part in 
facilitating neurite outgrowth in hyperglycaemic condition. It is well known that
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oxidative stress is largely generated under diabetic states and it negatively 
affects mitochondrial function, endoneurial blood flow and neurotrophic support, 
all key elements influencing neuron function and survival. In PC12 cells, Rap1- 
STAT kinase activation is required for NGF signalling (Obara et al., 2004), and 
it can be disrupted by oxidative stress (Kaur et al., 2005). Therefore, like many 
other cannabinoids, HU210 acting as an antioxidant displays the 
neuroprotective property through a fully CBrindependent mechanism 
(Hampson et al., 1998; Marsicano et al., 2002).
Further work must be conducted to determine the relative importance of CBi 
receptor mediated versus receptor-independent neuroprotective actions of 
natural and synthetic cannabinoids. A potential caveat in using CBt receptor 
agonists to prevent neurodegeneration in diabetes comes from a recent report 
revealing that administration of anandamide causes glucose intolerance in rats 
(Bermudez-Siva et al., 2006). This appears to result from a reduction of 
glucose-dependent insulin secretion from the pancreas, which has implications 
in type 2 diabetes. Conversely, one must also consider the potential adverse 
effects on the nervous system if obese type 2 diabetics are prescribed the 
selective CBi antagonist SR141716 (rimonabant).
This is especially timely given the use of the selective CBi antagonist
SR141716 (rimonabant) in patients with type 2 diabetes (Scheen et al., 2006).
Whilst Scheen and co-workers (2006) reported a reduction in bodyweight and
improved metabolic risk factors in the treatment group, no data have yet been
presented on nerve function in clinical trials of rimonabant. Considering the
neuroprotective role cannabinoids play, there is potential for adverse effects on
the nervous system in diabetics prescribed CB-i antagonists. Early indications
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from animal studies were that rimonabant administration caused hyperalgesia 
(Richardson et al., 1997). This was attributed to tonic endocannabinoid 
production and activity on sensory neurons, a concept that has not been upheld 
(Beaulieu et al., 2000). An alternative explanation is a possible inverse agonist 
action of SR141716 (Landsman et al., 1997). More recently, researchers have 
found rimonabant confers analgesic and anti-inflammatory effects in lean and 
diet-induced obese arthritic female rats (Croci and Zarini, 2007). These 
apparently conflicting outcomes may be related to the timescale and conditions 
of the rodents used in the studies: acute versus chronic, healthy animals versus 
disease models. Clearly, the presence of excessive inflammation is significant, 
with analgesic actions of rimonabant being observed in models of neurogenic 
inflammatory pain (Costa et al., 2005; Croci and Zarini, 2007). In their paper, 
Croci and Zarini (2007) state analgesia may not be due to CB-i-blockade per se, 
but rather a desensitization of TRPV1 receptors, or super-stimulation by 
endocannabinoids of CB2 receptors which have potent anti-inflammatory 
actions, and have recently been shown to be present on neurons (Gong et al., 
2006) as well as immune cells. However, in 17 conditions such as diabetes, 
where TRPV1 receptors are up-regulated and sensitized, it is not clear whether 
anandamide -  also being an endovanilloid (Zygmunt et al., 1999) - would 
merely activate or desensitize the nociceptive pathway. We await the results of 
further clinical trials of rimonabant with interest.
In conclusion, in this project, we have demonstrated that the expression of CBi
receptors is decreased in hyperglycaemic nerve cells and DRG neurons from
diabetic rats. The loss of CBi receptors may contribute to the development of
progression of diabetic neuropathy. However, the function of CBi receptors is
still preserved in nerve cells when stimulated by high concentrations (>1pM) of
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exogenous agonists under conditions mimicking hyperglycaemia. High glucose 
impaired neurite outgrowth and produced oxidative stress in the cell culture 
model, which was counteracted by HU210 treatment through CBrdependent 
and CBi-independent pathways, respectively. There is currently no single 
treatment for neuropathy that is effective in all diabetic patients. By virtue of 
their receptor-dependent and -independent neuroprotective actions, 
cannabinoids may be appropriate therapeutic agents in preventing the 
neurodegenerative process in diabetes.
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7.2 Conclusions
In this thesis, we have investigated the expression of CBi receptors in an in 
vitro and in vivo model of diabetic neuropathy, and also an altered nerve cell 
response to CBi agonists resulting from the decreased CBi expression in 
hyperglycaemic conditions.
Firstly, we have validated PC12 cells being an in vitro cell model of diabetic 
neuropathy. PC12 cells were stimulated with NGF (50ng/ml) in the presence of 
increasing concentrations of glucose (5.5,10,20,30,40,50mM) to mimic 
hyperglycaemic conditions in vivo. The optimum length of time, 6 days, was 
determined by the observation of a maximal neurite outgrowth and difference 
between high glucose treatments and controls. On day 6 of culture, the result of 
total neurite length showed that high glucose (20-50mM) significantly 
attenuated the neurite outgrowth in PC12 cells. This inhibitory effect was due to 
high glucose as the osmotic control, mannitol (30 and 50mM), showed a similar 
level of neurite outgrowth to the control (glucose 5.5mM). Furthermore, the 
impaired neurite outgrowth in the presence of high glucose is associated with 
increased levels of oxidative stress and a glucose concentration-dependent 
increase in IL-6 production, thus producing some of the phenomena of diabetic 
neuropathy.
Secondly, we have examined the expression of CBi expression in PC12 cells 
cultured in high glucose. Increasing concentrations of glucose were found to 
decrease CBi expression at RNA and protein levels in PC12 cells. This result 
was corroborated in DRG neurons from diabetic rats, where the number of 
CBrpositive neurons was decreased to approximately half that of control
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animals, and the density of CBi receptors was reduced by 60% in diabetic 
versus control DRG.
Thirdly, we investigated whether the decreased expression of CBi receptors 
resulted in decreased function. Contrary to our hypothesis, we have found that 
CBi function is preserved at some agonist concentrations in PC12 cells 
cultured in high glucose. The capsaicin response study showed that capsaicin 
(50-700pM) stimulated a transient Ca2+ influx in a concentration-dependent 
manner with the C50 value of 300pM. The application of capsaicin (300pM) 
evoked greater Ca2+ influx in PC12 cells cultured in high glucose compared to 
the control and this response was significantly blocked by capsazepine (100pM) 
in both normal and high glucose conditions, confirming the response is 
mediated by TRPV1 receptors. The HU210 concentration-dependent (0.03, 0.3, 
3, 30pM) inhibitory studies showed that the inhibition (%) curve generated from 
high glucose conditions shifted to the right compared with the control inhibition 
curve, indicating high glucose may slightly decrease CBi function. At higher 
concentration of 30pM, HU210 significantly inhibited capsaicin-evoked calcium 
entry by 80% and 77% in control and high glucose respectively. The lower 
HU210 (1pM) concentration showed a similar inhibitory effect by 43% and 40% 
correspondingly. The use of the CBi antagonist, AM251, and the CB2 
antagonist, AM630, strongly suggest that the inhibitory effect of TRPV1- 
mediated calcium entry is mediated by CB-i, not CB2 receptors.
Finally, we have demonstrated that the CBi agonist, HU210 has 
neuroprotective effect in hyperglycaemic cells. The cell viability assay revealed 
that, on the day 6 of culture, apart from HU210 at 30pM where cells showed a
significant death, the cell viability was not different in cells among other
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concentrations (0.03pM-3pM) in both normal and high glucose conditions 
compared to controls. HU210 was found to rescue neurite outgrowth in PC12 
cells cultured in 50mM glucose in a concentration-dependent manner (0.03pM- 
3pM) while there was no effect in the cells cultured in 5.5mM glucose. The CBi 
antagonist (AM251 1pM), but not the CB2 antagonist (AM630 1pM), 
significantly attenuated the HU210 (0.3pM) mediated-neurite rescue, indicating 
a CBr mediated neuroprotective mechanism. In addition, HU210 at 0.03 and 
0.3pM reduced the levels of oxidative stress in hyperglycaemic cells, which 
was not reversed by AM251. These results suggest that HU210 rescue neurite 
outgrowth via CBrdependent and CBrindependent mechanisms.
In conclusion, we have demonstrated that despite a decrease in receptor 
expression, the function of the CBi receptor is preserved in nerve cells when 
stimulated by an exogenous agonist under conditions mimicking 
hyperglycaemia. High glucose impaired neurite outgrowth and enhanced 
oxidative stress was counteracted by HU210 treatment through CBrdependent 
and -independent pathways, respectively. Diabetic neuropathy affects at least 
50% of diabetic patients and occurs with the same frequency in type 1 and type 
2 diabetes; this number approaches 100% if subclinical non-symptomatic 
neuropathy is included (Vinik et al., 2006). There is currently no single 
treatment for neuropathy that is effective in all diabetic patients. By virtue of 
their receptor-dependent and -independent neuroprotective actions, 
cannabinoids may be appropriate therapeutic agents in preventing the 
neurodegenerative process in diabetes.
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7.3 Future studies
In the future, whether the CBi function is still preserved in hyperglycaemic 
conditions will be investigated in DRG neurons from diabetic rats using patch 
clamp technique. The example traces are showed in Figure 7.3. The capsaicin- 
evoked increased action potential from DRG neurons can be similarly 
conducted as displayed in Figure 7.3. The co-application of CBi agonists and 
antagonists with capsaicin will provide a clear answer whether the activation of 
CBi receptors can attenuate capsaicin-mediated response in hyperglycaemic 
neurons compared to controls.
Figure 7.3 Representative traces showing the increase in sensory discharge from 
perivascular nerves in response to capsaicin (c; 0.3 nmoles i.a.) in an anaesthetised 
rat. Top and middle traces = recorded action potentials (microvolts), unfiltered and 
filtered, respectively, and bottom trace = pooled discharge of individual action 
potentials recorded from the surface of the femoral artery (imp s-1). Inset = individual 
unit. (From supervisor: Dr Paula Smith, adapted from Smith & McQueen, 2001)
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The level of endogenous cannablnoids can be measured in diabetic rats. If 
endogenous cannabinoids increase in response to hyperglycaemia, it may 
explain why the CBi function is still preserved whilst the expression is reduced.
Finally, the neuroprotective role of CBi agonists (HU210) can be studied in ex 
in vivo model, DRG neurons from diabetic rats. Also, the level of CBi receptors 
could be investigated after the treatment of CBi agonists. As the CBi receptor 
is a G protein-coupled receptor, an application of a Gi/0 protein inhibitor, or 
kinase pathway inhibitors, may be used to study the mechanism involved in the 
‘neurite rescue’ by CBt agonists.
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